[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foJT-NRcmRE4aLIRxntW2gE-72AiL8j5p2cb6Aacfot8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":36,"phaseBuckets":83,"rows":90},"University of Miami",[4,6],"University of Miami Sylvester Comprehensive Cancer Center",820,false,194,27,275049,111,563,[15,18,21,24,26,28,31,34],{"name":16,"count":17},"Depression",22,{"name":19,"count":20},"Prostate Cancer",20,{"name":22,"count":23},"Spinal Cord Injury",18,{"name":25,"count":23},"Breast Cancer",{"name":27,"count":23},"Obesity",{"name":29,"count":30},"Spinal Cord Injuries",17,{"name":32,"count":33},"Cancer",12,{"name":35,"count":33},"Head and Neck Cancer",[37,42,47,51,55,60,65,70,74,78],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06751290","The Use of Cyproheptadine in Pediatric Feeding Disorders","2026-04-30","Cyproheptadine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05607719","Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD","2026-06-30","Bevespi",{"nctId":48,"briefTitle":49,"date":45,"intervention":50},"NCT04487041","Tfh Dysfunction in HIV and Aging","Standard dose influenza vaccination",{"nctId":52,"briefTitle":53,"date":45,"intervention":54},"NCT05630235","Effects of CBD\u002FCBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI","CBD\u002FCBD-A",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06902285","Magnesium-L-Threonate for Sleep Quality Post-Arthroplasty","2026-07-01","Magnesium Threonate",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05826964","Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","2026-07-31","AI+CDK4\u002F6i",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05842044","NSAID Use After Robotic Partial Nephrectomy","2026-09-30","Ketorolac",{"nctId":71,"briefTitle":72,"date":68,"intervention":73},"NCT05812924","A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause","Platelet-rich plasma",{"nctId":75,"briefTitle":76,"date":68,"intervention":77},"NCT06293300","Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)","BoNT A",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05412082","SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","2026-10-31","5-fluorouracil",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,145,163,192,215,233,260,286,312,338,364,382,407,434,460,491,509,527,545,563,581,602,626,653,679,697,724,746,772,790,816,859,877,904,922,1008,1064,1178,1239,1265,1299,1321,1343,1430,1456,1493,1523,1593,1633,1664,1703,1721,1739,1757,1783,1801,1828,1846,1879,1897,1915,1933,1951,1969,1987,2005,2023,2041,2059,2080,2098,2124,2142,2160,2178,2196,2214,2232,2257,2275,2299,2319,2347,2373,2391,2416,2434,2458,2476,2494,2526,2552,2570,2595,2613,2633,2654,2682,2700,2718,2814,2874,2907,2938,2975,2999,3017,3035,3053,3078,3111,3136,3180,3206,3235,3257,3279,3313,3349,3386,3408,3435,3460,3483,3501,3519,3544,3562,3588,3606,3624,3648,3666,3684,3709,3733,3760,3778,3796,3821,3839,3862,3887,3912,3930,3954,3972,3998,4023,4049,4074,4098,4116,4142,4160,4186,4204,4228,4252,4277,4301,4326,4350,4377,4395,4419,4437,4463,4481,4507,4525,4549,4567,4592,4610,4635,4653,4679,4697,4721,4747,4771,4798,4816,4834,4880,4919,4948,4970,4994,5019,5037,5062,5085,5103,5129,5147,5165,5183,5201,5219,5237,5255,5273,5300,5325,5350,5368,5386,5410,5436,5454,5472,5495,5513,5563,5589,5628,5665,5691,5717,5739,5767,5791,5819,5841,5863,5885,5922,5954,5972,5994,6017,6042,6060,6083,6108,6130,6151,6173,6191,6209,6227,6245,6268,6292,6313,6342,6360,6378,6396,6419,6437,6461,6479,6497,6515,6533,6554,6578,6606,6628,6646,6664,6688,6706,6730,6748,6772,6795,6818,6843,6861,6879,6897,6922,6946,6967,6989,7007,7034,7060,7085,7103,7121,7146,7172,7190,7208,7232,7256,7284,7302,7320,7338,7356,7374,7396,7419,7437,7461,7483,7507,7531,7553,7571,7595,7613,7636,7660,7686,7704,7728,7751,7773,7798,7816,7834,7858,7876,7898,7959,8005,8043,8073,8103,8133,8163,8196,8222,8256,8278,8300,8322,8344,8373,8391,8415,8433,8451,8469,8495,8513,8535,8553,8571,8589,8607,8625,8647,8665,8687,8708,8726,8744,8762,8780,8803,8825,8848,8871,8889,8911,8938,8956,8982,9005,9028,9055,9078,9096],{"intervention":92,"totalTrials":93,"cells":94},"Liraglutide",3,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":143},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":142,"soonestReadout":111},[106,118,130],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT03856632","Liraglutide Effect in Atrial Fibrillation","ACTIVE_NOT_RECRUITING",[88],"2026-12-31","2019-03-18",60,[115],"Atrial Fibrillation",[92,117],"Anti Arrhythmics",{"nctId":119,"briefTitle":120,"status":121,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":97,"conditions":126,"interventions":129},"NCT02920190","Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat","WITHDRAWN",[88],"2021-09-01","2021-12-31","2020-09-01",[127,128,27],"Monoclonal Gammopathies","Overweight",[92],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT02014740","Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes","COMPLETED",[88],"2017-03","2014-03",100,[139,128,27],"Type 2 Diabetes",[92,141],"Metformin",1,{"trials":144,"activeCount":97},[],{"intervention":117,"totalTrials":142,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":161},{"trials":148,"activeCount":97},[],{"trials":150,"activeCount":97},[],{"trials":152,"activeCount":97},[],{"trials":154,"activeCount":97},[],{"trials":156,"activeCount":142,"soonestReadout":111},[157],{"nctId":107,"briefTitle":108,"status":109,"phases":158,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":159,"interventions":160},[88],[115],[92,117],{"trials":162,"activeCount":97},[],{"intervention":164,"totalTrials":142,"cells":165},"Bactrim",{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":190},{"trials":167,"activeCount":97},[],{"trials":169,"activeCount":97},[],{"trials":171,"activeCount":97},[],{"trials":173,"activeCount":97},[],{"trials":175,"activeCount":142,"soonestReadout":181},[176],{"nctId":177,"briefTitle":178,"status":179,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":189},"NCT07501065","Prophylactic Antibiotics for Outpatient Urethral Bulking","NOT_YET_RECRUITING",[88],"2028-06","2028-12","2026-06",150,[186,187,188],"Urinary Tract Infections","Stress Urinary Incontinence","Urinary Incontinence",[164],{"trials":191,"activeCount":97},[],{"intervention":50,"totalTrials":142,"cells":193},{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":213},{"trials":195,"activeCount":97},[],{"trials":197,"activeCount":97},[],{"trials":199,"activeCount":97},[],{"trials":201,"activeCount":97},[],{"trials":203,"activeCount":142,"soonestReadout":45},[204],{"nctId":48,"briefTitle":49,"status":109,"phases":205,"primaryCompletion":45,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},[88],"2026-12-30","2020-10-30",400,[210],"Human Influenza",[50,212],"High dose influenza vaccination",{"trials":214,"activeCount":97},[],{"intervention":212,"totalTrials":142,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":218,"activeCount":97},[],{"trials":220,"activeCount":97},[],{"trials":222,"activeCount":97},[],{"trials":224,"activeCount":97},[],{"trials":226,"activeCount":142,"soonestReadout":45},[227],{"nctId":48,"briefTitle":49,"status":109,"phases":228,"primaryCompletion":45,"completion":206,"start":207,"enrollment":208,"conditions":229,"interventions":230},[88],[210],[50,212],{"trials":232,"activeCount":97},[],{"intervention":234,"totalTrials":142,"cells":235},"PYTEST® 14C-Urea Capsule Breath Test",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":258},{"trials":237,"activeCount":97},[],{"trials":239,"activeCount":97},[],{"trials":241,"activeCount":97},[],{"trials":243,"activeCount":97},[],{"trials":245,"activeCount":142,"soonestReadout":250},[246],{"nctId":247,"briefTitle":248,"status":109,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":257},"NCT07224048","Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2",[88],"2027-11-06","2024-11-06",75,[254,255,256],"H. Pylori Infection","Gastric Cancer","Gastritis H Pylori",[234,234],{"trials":259,"activeCount":97},[],{"intervention":261,"totalTrials":142,"cells":262},"Testosterone cypionate",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":284},{"trials":264,"activeCount":97},[],{"trials":266,"activeCount":97},[],{"trials":268,"activeCount":97},[],{"trials":270,"activeCount":97},[],{"trials":272,"activeCount":142,"soonestReadout":277},[273],{"nctId":274,"briefTitle":275,"status":179,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},"NCT07278362","Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance",[88],"2031-05-31","2032-05-31","2026-05-31",35,[19,282],"Hypogonadism, Male",[261],{"trials":285,"activeCount":97},[],{"intervention":287,"totalTrials":142,"cells":288},"Tirzepatide",{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":310},{"trials":290,"activeCount":97},[],{"trials":292,"activeCount":97},[],{"trials":294,"activeCount":97},[],{"trials":296,"activeCount":97},[],{"trials":298,"activeCount":142,"soonestReadout":304},[299],{"nctId":300,"briefTitle":301,"status":302,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT06774079","Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients","RECRUITING",[88],"2027-03-05","2025-03-05",24,[308],"Crohn Disease",[287],{"trials":311,"activeCount":97},[],{"intervention":313,"totalTrials":142,"cells":314},"Niraparib",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":336},{"trials":316,"activeCount":97},[],{"trials":318,"activeCount":97},[],{"trials":320,"activeCount":97},[],{"trials":322,"activeCount":97},[],{"trials":324,"activeCount":142,"soonestReadout":329},[325],{"nctId":326,"briefTitle":327,"status":302,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT06412120","Study Evaluating Safety, Tolerability, and Metabolism of Niraparib",[88],"2029-06-01","2031-06-01","2026-06-01",70,[334],"Ovarian Cancer",[313],{"trials":337,"activeCount":97},[],{"intervention":339,"totalTrials":142,"cells":340},"ZYNRELEF 400Mg-12Mg Extended-Release Solution",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":362},{"trials":342,"activeCount":97},[],{"trials":344,"activeCount":97},[],{"trials":346,"activeCount":97},[],{"trials":348,"activeCount":97},[],{"trials":350,"activeCount":142,"soonestReadout":355},[351],{"nctId":352,"briefTitle":353,"status":179,"phases":354,"primaryCompletion":355,"completion":355,"start":183,"enrollment":356,"conditions":357,"interventions":360},"NCT07216586","Zynrelef Versus Adductor Canal Block",[88],"2028-01",120,[358,359],"Knee Osteoarthritis","Arthritis Knee",[339,361],"Ropivacaine 0.5% Injectable Solution",{"trials":363,"activeCount":97},[],{"intervention":361,"totalTrials":142,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":380},{"trials":367,"activeCount":97},[],{"trials":369,"activeCount":97},[],{"trials":371,"activeCount":97},[],{"trials":373,"activeCount":97},[],{"trials":375,"activeCount":142,"soonestReadout":355},[376],{"nctId":352,"briefTitle":353,"status":179,"phases":377,"primaryCompletion":355,"completion":355,"start":183,"enrollment":356,"conditions":378,"interventions":379},[88],[358,359],[339,361],{"trials":381,"activeCount":97},[],{"intervention":383,"totalTrials":142,"cells":384},"Fluzone Quadrivalent",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":405},{"trials":386,"activeCount":97},[],{"trials":388,"activeCount":97},[],{"trials":390,"activeCount":97},[],{"trials":392,"activeCount":97},[],{"trials":394,"activeCount":142,"soonestReadout":399},[395],{"nctId":396,"briefTitle":397,"status":109,"phases":398,"primaryCompletion":399,"completion":400,"start":401,"enrollment":208,"conditions":402,"interventions":404},"NCT04304768","Opioid, HIV and Immune System",[88],"2027-01-31","2027-12-31","2020-11-18",[403],"Immune Defect",[383],{"trials":406,"activeCount":97},[],{"intervention":408,"totalTrials":142,"cells":409},"Perineal ice packs, medicated witch-hazel pads, and topical benzocaine spray",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":432},{"trials":411,"activeCount":97},[],{"trials":413,"activeCount":97},[],{"trials":415,"activeCount":97},[],{"trials":417,"activeCount":97},[],{"trials":419,"activeCount":142,"soonestReadout":424},[420],{"nctId":421,"briefTitle":422,"status":302,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":332,"conditions":427,"interventions":431},"NCT07401134","Improving Postoperative Recovery: A Study of Multimodal Perineal Analgesia Protocol (MPAP) After Vaginal Surgery",[88],"2027-01","2027-02","2026-02-18",[428,429,430],"Perineal Injury","Pain Vulva","Perineum; Injury",[408],{"trials":433,"activeCount":97},[],{"intervention":435,"totalTrials":142,"cells":436},"Vitamin D3",{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":458},{"trials":438,"activeCount":97},[],{"trials":440,"activeCount":97},[],{"trials":442,"activeCount":97},[],{"trials":444,"activeCount":97},[],{"trials":446,"activeCount":142,"soonestReadout":451},[447],{"nctId":448,"briefTitle":449,"status":109,"phases":450,"primaryCompletion":451,"completion":451,"start":452,"enrollment":453,"conditions":454,"interventions":457},"NCT07006714","Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA)",[88],"2027-07-01","2025-09-08",200,[455,456],"Osteoarthritis","Vitamin D Deficiency",[435],{"trials":459,"activeCount":97},[],{"intervention":461,"totalTrials":142,"cells":462},"Triamcinolone 10 Mg\u002FmL Injectable Suspension",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":489},{"trials":464,"activeCount":97},[],{"trials":466,"activeCount":97},[],{"trials":468,"activeCount":97},[],{"trials":470,"activeCount":97},[],{"trials":472,"activeCount":142,"soonestReadout":477},[473],{"nctId":474,"briefTitle":475,"status":179,"phases":476,"primaryCompletion":477,"completion":477,"start":478,"enrollment":184,"conditions":479,"interventions":483},"NCT07494136","Dose Dependent Steroid Injections",[88],"2027-05","2026-05",[480,481,482],"Lumbar Radiculopathy","Sciatica","Back Pain With Radiation",[461,484,485,486,487,488],"Triamcinolone 40 Mg\u002FmL Injectable Suspension","Triamcinolone 80 Mg\u002FmL Injectable Suspension","Dexamethasone 2 MG","Dexamethasone 4mg","Dexamethasone 8 MG",{"trials":490,"activeCount":97},[],{"intervention":484,"totalTrials":142,"cells":492},{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":507},{"trials":494,"activeCount":97},[],{"trials":496,"activeCount":97},[],{"trials":498,"activeCount":97},[],{"trials":500,"activeCount":97},[],{"trials":502,"activeCount":142,"soonestReadout":477},[503],{"nctId":474,"briefTitle":475,"status":179,"phases":504,"primaryCompletion":477,"completion":477,"start":478,"enrollment":184,"conditions":505,"interventions":506},[88],[480,481,482],[461,484,485,486,487,488],{"trials":508,"activeCount":97},[],{"intervention":485,"totalTrials":142,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":525},{"trials":512,"activeCount":97},[],{"trials":514,"activeCount":97},[],{"trials":516,"activeCount":97},[],{"trials":518,"activeCount":97},[],{"trials":520,"activeCount":142,"soonestReadout":477},[521],{"nctId":474,"briefTitle":475,"status":179,"phases":522,"primaryCompletion":477,"completion":477,"start":478,"enrollment":184,"conditions":523,"interventions":524},[88],[480,481,482],[461,484,485,486,487,488],{"trials":526,"activeCount":97},[],{"intervention":486,"totalTrials":142,"cells":528},{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":543},{"trials":530,"activeCount":97},[],{"trials":532,"activeCount":97},[],{"trials":534,"activeCount":97},[],{"trials":536,"activeCount":97},[],{"trials":538,"activeCount":142,"soonestReadout":477},[539],{"nctId":474,"briefTitle":475,"status":179,"phases":540,"primaryCompletion":477,"completion":477,"start":478,"enrollment":184,"conditions":541,"interventions":542},[88],[480,481,482],[461,484,485,486,487,488],{"trials":544,"activeCount":97},[],{"intervention":487,"totalTrials":142,"cells":546},{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":555,"NA":561},{"trials":548,"activeCount":97},[],{"trials":550,"activeCount":97},[],{"trials":552,"activeCount":97},[],{"trials":554,"activeCount":97},[],{"trials":556,"activeCount":142,"soonestReadout":477},[557],{"nctId":474,"briefTitle":475,"status":179,"phases":558,"primaryCompletion":477,"completion":477,"start":478,"enrollment":184,"conditions":559,"interventions":560},[88],[480,481,482],[461,484,485,486,487,488],{"trials":562,"activeCount":97},[],{"intervention":488,"totalTrials":142,"cells":564},{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":573,"NA":579},{"trials":566,"activeCount":97},[],{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[],{"trials":572,"activeCount":97},[],{"trials":574,"activeCount":142,"soonestReadout":477},[575],{"nctId":474,"briefTitle":475,"status":179,"phases":576,"primaryCompletion":477,"completion":477,"start":478,"enrollment":184,"conditions":577,"interventions":578},[88],[480,481,482],[461,484,485,486,487,488],{"trials":580,"activeCount":97},[],{"intervention":59,"totalTrials":142,"cells":582},{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":591,"NA":600},{"trials":584,"activeCount":97},[],{"trials":586,"activeCount":97},[],{"trials":588,"activeCount":97},[],{"trials":590,"activeCount":97},[],{"trials":592,"activeCount":142,"soonestReadout":58},[593],{"nctId":56,"briefTitle":57,"status":302,"phases":594,"primaryCompletion":58,"completion":58,"start":595,"enrollment":596,"conditions":597,"interventions":599},[88],"2025-04-21",64,[598,358],"Sleep",[59],{"trials":601,"activeCount":97},[],{"intervention":603,"totalTrials":142,"cells":604},"Duloxetine",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":624},{"trials":606,"activeCount":97},[],{"trials":608,"activeCount":97},[],{"trials":610,"activeCount":97},[],{"trials":612,"activeCount":97},[],{"trials":614,"activeCount":142,"soonestReadout":619},[615],{"nctId":616,"briefTitle":617,"status":302,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":596,"conditions":621,"interventions":623},"NCT06807866","Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT",[88],"2026-12-01","2025-03-01",[622],"THA",[603],{"trials":625,"activeCount":97},[],{"intervention":627,"totalTrials":142,"cells":628},"Durysta, Bimatoprost Intracameral Implant 10 µg",{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":635,"PHASE4":637,"NA":651},{"trials":630,"activeCount":97},[],{"trials":632,"activeCount":97},[],{"trials":634,"activeCount":97},[],{"trials":636,"activeCount":97},[],{"trials":638,"activeCount":142,"soonestReadout":643},[639],{"nctId":640,"briefTitle":641,"status":302,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":20,"conditions":645,"interventions":650},"NCT07217678","Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use",[88],"2028-01-31","2026-02-09",[646,647,648,649],"Glaucoma","Open-Angle Glaucoma","Ocular Hypertension","Glaucoma Suspect",[627],{"trials":652,"activeCount":97},[],{"intervention":654,"totalTrials":142,"cells":655},"PYTEST® 14C-Urea Breath Test",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":664,"NA":677},{"trials":657,"activeCount":97},[],{"trials":659,"activeCount":97},[],{"trials":661,"activeCount":97},[],{"trials":663,"activeCount":97},[],{"trials":665,"activeCount":142,"soonestReadout":250},[666],{"nctId":667,"briefTitle":668,"status":109,"phases":669,"primaryCompletion":250,"completion":250,"start":670,"enrollment":671,"conditions":672,"interventions":675},"NCT07224035","Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1",[88],"2022-10-15",500,[673,674,255],"H Pylori Infection","H Pylori Gastritis",[654,676],"VOQUEZNA® Triple Pak®",{"trials":678,"activeCount":97},[],{"intervention":676,"totalTrials":142,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":689,"NA":695},{"trials":682,"activeCount":97},[],{"trials":684,"activeCount":97},[],{"trials":686,"activeCount":97},[],{"trials":688,"activeCount":97},[],{"trials":690,"activeCount":142,"soonestReadout":250},[691],{"nctId":667,"briefTitle":668,"status":109,"phases":692,"primaryCompletion":250,"completion":250,"start":670,"enrollment":671,"conditions":693,"interventions":694},[88],[673,674,255],[654,676],{"trials":696,"activeCount":97},[],{"intervention":698,"totalTrials":142,"cells":699},"Nicorette",{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":708,"NA":722},{"trials":701,"activeCount":97},[],{"trials":703,"activeCount":97},[],{"trials":705,"activeCount":97},[],{"trials":707,"activeCount":97},[],{"trials":709,"activeCount":142,"soonestReadout":714},[710],{"nctId":711,"briefTitle":712,"status":302,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":721},"NCT06098144","Smoking Cessation Program in the Construction Sector",[88],"2027-02-28","2024-04-10",608,[718,719,720],"Smoking Cessation","Tobacco Use Cessation","Tobacco Smoking",[698],{"trials":723,"activeCount":97},[],{"intervention":41,"totalTrials":142,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":744},{"trials":727,"activeCount":97},[],{"trials":729,"activeCount":97},[],{"trials":731,"activeCount":97},[],{"trials":733,"activeCount":97},[],{"trials":735,"activeCount":142,"soonestReadout":40},[736],{"nctId":38,"briefTitle":39,"status":109,"phases":737,"primaryCompletion":40,"completion":40,"start":738,"enrollment":739,"conditions":740,"interventions":743},[88],"2024-12-30",50,[741,742],"Pediatric Feeding Disorder, Chronic","Avoidant Restrictive Food Intake Disorder",[41],{"trials":745,"activeCount":97},[],{"intervention":747,"totalTrials":142,"cells":748},"Albuterol Sulfate",{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":755,"PHASE4":757,"NA":770},{"trials":750,"activeCount":97},[],{"trials":752,"activeCount":97},[],{"trials":754,"activeCount":97},[],{"trials":756,"activeCount":97},[],{"trials":758,"activeCount":142,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":302,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":768},"NCT07426458","Ventilation and Perfusion in Asthmatics",[88],"2028-04","2026-04-27",40,[767],"Asthma",[747,769],"Albuterol-Budesonide",{"trials":771,"activeCount":97},[],{"intervention":769,"totalTrials":142,"cells":773},{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":780,"PHASE4":782,"NA":788},{"trials":775,"activeCount":97},[],{"trials":777,"activeCount":97},[],{"trials":779,"activeCount":97},[],{"trials":781,"activeCount":97},[],{"trials":783,"activeCount":142,"soonestReadout":763},[784],{"nctId":760,"briefTitle":761,"status":302,"phases":785,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":786,"interventions":787},[88],[767],[747,769],{"trials":789,"activeCount":97},[],{"intervention":791,"totalTrials":142,"cells":792},"Collagenase Clostridium Histolyticum",{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":799,"PHASE4":801,"NA":814},{"trials":794,"activeCount":97},[],{"trials":796,"activeCount":97},[],{"trials":798,"activeCount":97},[],{"trials":800,"activeCount":97},[],{"trials":802,"activeCount":142,"soonestReadout":807},[803],{"nctId":804,"briefTitle":805,"status":302,"phases":806,"primaryCompletion":807,"completion":807,"start":808,"enrollment":17,"conditions":809,"interventions":813},"NCT05777031","Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease",[88],"2027-01-15","2023-10-02",[810,811,812],"Peyronie Disease","Sexual Dysfunctions, Psychological","Genital Diseases, Male",[791],{"trials":815,"activeCount":97},[],{"intervention":817,"totalTrials":818,"cells":819},"Diphenhydramine",2,{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":844,"PHASE4":855,"NA":857},{"trials":821,"activeCount":97},[],{"trials":823,"activeCount":97},[],{"trials":825,"activeCount":142,"soonestReadout":830},[826],{"nctId":827,"briefTitle":828,"status":109,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":835},"NCT04268498","A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma",[86],"2027-02-01","2020-02-11",310,[834],"Multiple Myeloma",[836,837,838,839,817,840,841,842,843],"Bortezomib","Dexamethasone","Lenalidomide","Acetaminophen","Montelukast","Carfilzomib","Daratumumab","Autologous Stem Cell Transplant",{"trials":845,"activeCount":142,"soonestReadout":850},[846],{"nctId":847,"briefTitle":848,"status":179,"phases":849,"primaryCompletion":850,"completion":850,"start":58,"enrollment":113,"conditions":851,"interventions":853},"NCT07472413","Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project",[87],"2028-07-01",[852],"Multiple Sclerosis",[854,817],"Cetirizine",{"trials":856,"activeCount":97},[],{"trials":858,"activeCount":97},[],{"intervention":854,"totalTrials":142,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":873,"NA":875},{"trials":862,"activeCount":97},[],{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[],{"trials":868,"activeCount":142,"soonestReadout":850},[869],{"nctId":847,"briefTitle":848,"status":179,"phases":870,"primaryCompletion":850,"completion":850,"start":58,"enrollment":113,"conditions":871,"interventions":872},[87],[852],[854,817],{"trials":874,"activeCount":97},[],{"trials":876,"activeCount":97},[],{"intervention":878,"totalTrials":142,"cells":879},"Probenecid 500 Milligrams",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":900,"NA":902},{"trials":881,"activeCount":97},[],{"trials":883,"activeCount":97},[],{"trials":885,"activeCount":97},[],{"trials":887,"activeCount":142,"soonestReadout":892},[888],{"nctId":889,"briefTitle":890,"status":302,"phases":891,"primaryCompletion":892,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":898},"NCT05903859","Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)",[87],"2027-05-31","2028-12-31","2024-01-18",90,[897],"Infertility, Male",[878,899],"probenecid 250 Milligrams",{"trials":901,"activeCount":97},[],{"trials":903,"activeCount":97},[],{"intervention":899,"totalTrials":142,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":918,"NA":920},{"trials":907,"activeCount":97},[],{"trials":909,"activeCount":97},[],{"trials":911,"activeCount":97},[],{"trials":913,"activeCount":142,"soonestReadout":892},[914],{"nctId":889,"briefTitle":890,"status":302,"phases":915,"primaryCompletion":892,"completion":893,"start":894,"enrollment":895,"conditions":916,"interventions":917},[87],[897],[878,899],{"trials":919,"activeCount":97},[],{"trials":921,"activeCount":97},[],{"intervention":837,"totalTrials":923,"cells":924},6,{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":975,"PHASE4":988,"NA":1006},{"trials":926,"activeCount":97},[],{"trials":928,"activeCount":97},[],{"trials":930,"activeCount":974,"soonestReadout":830},[931,947,951,964],{"nctId":932,"briefTitle":933,"status":302,"phases":934,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":938,"interventions":941},"NCT07002216","BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma",[86],"2030-07-15","2025-07-15",48,[939,940],"Hodgkin Lymphoma","Advanced Hodgkin Lymphoma",[942,943,944,945,946,837],"Brentuximab Vedotin","Etoposide","Cyclophosphamide","Doxorubicin","Dacarbazine",{"nctId":827,"briefTitle":828,"status":109,"phases":948,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":949,"interventions":950},[86],[834],[836,837,838,839,817,840,841,842,843],{"nctId":952,"briefTitle":953,"status":302,"phases":954,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":961},"NCT05530421","Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed\u002FRefractory Multiple Myeloma",[86],"2028-03-26","2030-03-26","2023-03-26",33,[960],"Relapsed and Refractory Multiple Myeloma",[962,963,837],"Selinexor","Venetoclax",{"nctId":965,"briefTitle":966,"status":302,"phases":967,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":972},"NCT06997081","ERd Combination Treatment in Newly Diagnosed Multiple Myeloma",[86],"2030-09-30","2025-09-16",104,[834],[838,837,973],"Elranatamab",4,{"trials":976,"activeCount":97},[977],{"nctId":978,"briefTitle":979,"status":133,"phases":980,"primaryCompletion":981,"completion":981,"start":982,"enrollment":983,"conditions":984,"interventions":986},"NCT04655144","Dexamethasone for Post Uterine Artery Embolization Pain",[87],"2024-12-04","2021-01-25",42,[985],"Leiomyoma",[837,987],"Saline",{"trials":989,"activeCount":97},[990],{"nctId":991,"briefTitle":992,"status":133,"phases":993,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":1000},"NCT05974501","Pre vs Post Block in Total Knee Arthroplasty (TKA)",[88],"2024-01-22","2023-09-29",84,[358,998,999],"Arthroplasty Complications","Postoperative Pain",[837,839,1001,1002,1003,1004,1005],"Lyrica","Celebrex","Meloxicam","Oxycodone","Ropivacaine",{"trials":1007,"activeCount":97},[],{"intervention":839,"totalTrials":1009,"cells":1010},5,{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1042,"PHASE4":1056,"NA":1062},{"trials":1012,"activeCount":97},[],{"trials":1014,"activeCount":97},[],{"trials":1016,"activeCount":818,"soonestReadout":68},[1017,1028,1032],{"nctId":66,"briefTitle":67,"status":302,"phases":1018,"primaryCompletion":68,"completion":68,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1025},[86],"2023-09-15",110,[1022,1023,1024],"Kidney Cancer","Renal Cancer","Renal Neoplasm",[69,839,1004,1026,1027],"Hydromorphone","Ibuprofen",{"nctId":827,"briefTitle":828,"status":109,"phases":1029,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":1030,"interventions":1031},[86],[834],[836,837,838,839,817,840,841,842,843],{"nctId":1033,"briefTitle":1034,"status":133,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":30,"conditions":1038,"interventions":1040},"NCT03997851","Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects",[85,86],"2020-03-18","2019-07-22",[1039],"Pruritus",[839,1041],"Carbomer 980",{"trials":1043,"activeCount":97},[1044],{"nctId":1045,"briefTitle":1046,"status":121,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":97,"conditions":1050,"interventions":1052},"NCT05965492","Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery",[87],"2025-06-01","2024-06-01",[1051],"Spinal Disorder",[839,1002,1053,1054,1055,1004],"Gabapentin","Famotidine","Decadron",{"trials":1057,"activeCount":97},[1058],{"nctId":991,"briefTitle":992,"status":133,"phases":1059,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":1060,"interventions":1061},[88],[358,998,999],[837,839,1001,1002,1003,1004,1005],{"trials":1063,"activeCount":97},[],{"intervention":1065,"totalTrials":1066,"cells":1067},"Leucovorin",8,{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1083,"PHASE3":1172,"PHASE4":1174,"NA":1176},{"trials":1069,"activeCount":97},[],{"trials":1071,"activeCount":142,"soonestReadout":81},[1072],{"nctId":79,"briefTitle":80,"status":302,"phases":1073,"primaryCompletion":81,"completion":1074,"start":1075,"enrollment":1076,"conditions":1077,"interventions":1079},[85],"2028-10-31","2022-10-05",25,[1078],"Locally Advanced Rectal Cancer",[82,1065,1080,1081,1082],"Oxaliplatin","Capecitabine","Irinotecan",{"trials":1084,"activeCount":142,"soonestReadout":968},[1085,1097,1109,1127,1140,1151,1160],{"nctId":1086,"briefTitle":1087,"status":1088,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1076,"conditions":1093,"interventions":1094},"NCT00448682","Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery","TERMINATED",[86],"2009-12","2010-03","2005-06",[255],[1095,1096,1065,1080],"Docetaxel","Floxuridine",{"nctId":1098,"briefTitle":1099,"status":133,"phases":1100,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1106},"NCT00448760","Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery",[86],"2010-04","2004-10",29,[1105],"Esophageal Cancer",[1095,1096,1065,1080,1107,1108],"Microarray analysis","reverse transcriptase-polymerase chain reaction",{"nctId":1110,"briefTitle":1111,"status":133,"phases":1112,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":1115,"interventions":1117},"NCT00450801","R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma",[86],"2015-07","2004-04",[1116],"Lymphoma",[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],"Rituximab","Cytarabine","Ifosfamide","Methotrexate","Thalidomide","Vincristine","Mesna","Filgrastim","Granisetron",{"nctId":1128,"briefTitle":1129,"status":1088,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":923,"conditions":1133,"interventions":1137},"NCT01964755","Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma",[86],"2018-06-07","2009-04-21",[1134,1135,1136],"Epstein Barr Virus Associated Non Hodgkin's Lymphoma","Epstein Barr Virus Associated Hodgkin's Lymphoma","Post-Transplant Lymphoproliferative Disease",[945,1121,1065,1138,1139,1118],"Hydroxyurea","Zidovudine",{"nctId":1141,"briefTitle":1142,"status":133,"phases":1143,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":1147,"interventions":1149},"NCT00878254","Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma",[86],"2024-06-28","2025-05-30","2009-03-25",[1148],"Mantle-Cell Lymphoma",[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],"G-CSF",{"nctId":1152,"briefTitle":1153,"status":1088,"phases":1154,"primaryCompletion":1091,"completion":1091,"start":1155,"enrollment":1076,"conditions":1156,"interventions":1158},"NCT00449163","Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer",[86],"2006-03-01",[1157],"Colorectal Cancer",[1159,1096,1082,1065],"Bevacizumab",{"nctId":1161,"briefTitle":1162,"status":302,"phases":1163,"primaryCompletion":968,"completion":968,"start":1164,"enrollment":739,"conditions":1165,"interventions":1168},"NCT07096362","Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma",[86],"2025-09-09",[1166,1167],"Metastatic Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma",[1169,1080,1065,1082,1170,1171],"5-Fluorouracil","Gemcitabine","Nab Paclitaxel",{"trials":1173,"activeCount":97},[],{"trials":1175,"activeCount":97},[],{"trials":1177,"activeCount":97},[],{"intervention":1179,"totalTrials":974,"cells":1180},"Pembrolizumab",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1233,"PHASE4":1235,"NA":1237},{"trials":1182,"activeCount":97},[],{"trials":1184,"activeCount":97},[],{"trials":1186,"activeCount":818,"soonestReadout":1225},[1187,1196,1211,1221],{"nctId":1188,"briefTitle":1189,"status":302,"phases":1190,"primaryCompletion":330,"completion":330,"start":331,"enrollment":1191,"conditions":1192,"interventions":1194},"NCT07594015","Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy",[86],46,[1193],"Recurrent Endometrial Cancer",[1179,1195],"Lenvatinib",{"nctId":1197,"briefTitle":1198,"status":1088,"phases":1199,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1208},"NCT02834975","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",[86],"2022-09-01","2022-12-01","2016-12-22",26,[1205,1206,1207],"Fallopian Tube Cancer","Peritoneum Cancer","Epithelial Ovarian Cancer",[1179,1209,1210],"Paclitaxel","Carboplatin",{"nctId":1212,"briefTitle":1213,"status":1088,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":30,"conditions":1217,"interventions":1219},"NCT03367871","Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer",[86],"2023-01-30","2018-09-06",[1218],"Cervical Cancer",[1179,1209,1220,1210,1159],"Cisplatin",{"nctId":1222,"briefTitle":1223,"status":302,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1231},"NCT06902272","ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer",[86],"2028-06-11","2029-06-11","2025-06-11",30,[1230],"Non Small Cell Lung Cancer",[1179,1232],"Platinum Doublet Chemotherapy",{"trials":1234,"activeCount":97},[],{"trials":1236,"activeCount":97},[],{"trials":1238,"activeCount":97},[],{"intervention":1082,"totalTrials":93,"cells":1240},{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1249,"PHASE3":1259,"PHASE4":1261,"NA":1263},{"trials":1242,"activeCount":97},[],{"trials":1244,"activeCount":142,"soonestReadout":81},[1245],{"nctId":79,"briefTitle":80,"status":302,"phases":1246,"primaryCompletion":81,"completion":1074,"start":1075,"enrollment":1076,"conditions":1247,"interventions":1248},[85],[1078],[82,1065,1080,1081,1082],{"trials":1250,"activeCount":142,"soonestReadout":968},[1251,1255],{"nctId":1152,"briefTitle":1153,"status":1088,"phases":1252,"primaryCompletion":1091,"completion":1091,"start":1155,"enrollment":1076,"conditions":1253,"interventions":1254},[86],[1157],[1159,1096,1082,1065],{"nctId":1161,"briefTitle":1162,"status":302,"phases":1256,"primaryCompletion":968,"completion":968,"start":1164,"enrollment":739,"conditions":1257,"interventions":1258},[86],[1166,1167],[1169,1080,1065,1082,1170,1171],{"trials":1260,"activeCount":97},[],{"trials":1262,"activeCount":97},[],{"trials":1264,"activeCount":97},[],{"intervention":1266,"totalTrials":818,"cells":1267},"Regorafenib",{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1269,"activeCount":97},[],{"trials":1271,"activeCount":97},[],{"trials":1273,"activeCount":818,"soonestReadout":111},[1274,1284],{"nctId":1275,"briefTitle":1276,"status":302,"phases":1277,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1228,"conditions":1280,"interventions":1283},"NCT06902246","Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma",[86],"2031-08-01","2026-08-01",[1281,1282],"Unresectable Hepatocellular Carcinoma","Hepatocellular Carcinoma",[1266],{"nctId":1285,"briefTitle":1286,"status":302,"phases":1287,"primaryCompletion":111,"completion":893,"start":1288,"enrollment":937,"conditions":1289,"interventions":1291},"NCT05366816","ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST",[86],"2023-10-17",[1290],"Gastrointestinal Stromal Tumors",[1292,1266],"Sunitinib",{"trials":1294,"activeCount":97},[],{"trials":1296,"activeCount":97},[],{"trials":1298,"activeCount":97},[],{"intervention":838,"totalTrials":818,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1302,"activeCount":97},[],{"trials":1304,"activeCount":97},[],{"trials":1306,"activeCount":818,"soonestReadout":830},[1307,1311],{"nctId":827,"briefTitle":828,"status":109,"phases":1308,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":1309,"interventions":1310},[86],[834],[836,837,838,839,817,840,841,842,843],{"nctId":965,"briefTitle":966,"status":302,"phases":1312,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":1313,"interventions":1314},[86],[834],[838,837,973],{"trials":1316,"activeCount":97},[],{"trials":1318,"activeCount":97},[],{"trials":1320,"activeCount":97},[],{"intervention":82,"totalTrials":818,"cells":1322},{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1331,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1324,"activeCount":97},[],{"trials":1326,"activeCount":142,"soonestReadout":81},[1327],{"nctId":79,"briefTitle":80,"status":302,"phases":1328,"primaryCompletion":81,"completion":1074,"start":1075,"enrollment":1076,"conditions":1329,"interventions":1330},[85],[1078],[82,1065,1080,1081,1082],{"trials":1332,"activeCount":142,"soonestReadout":968},[1333],{"nctId":1161,"briefTitle":1162,"status":302,"phases":1334,"primaryCompletion":968,"completion":968,"start":1164,"enrollment":739,"conditions":1335,"interventions":1336},[86],[1166,1167],[1169,1080,1065,1082,1170,1171],{"trials":1338,"activeCount":97},[],{"trials":1340,"activeCount":97},[],{"trials":1342,"activeCount":97},[],{"intervention":1080,"totalTrials":1344,"cells":1345},9,{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1354,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1347,"activeCount":97},[],{"trials":1349,"activeCount":142,"soonestReadout":81},[1350],{"nctId":79,"briefTitle":80,"status":302,"phases":1351,"primaryCompletion":81,"completion":1074,"start":1075,"enrollment":1076,"conditions":1352,"interventions":1353},[85],[1078],[82,1065,1080,1081,1082],{"trials":1355,"activeCount":142,"soonestReadout":968},[1356,1367,1371,1382,1392,1396,1408],{"nctId":1357,"briefTitle":1358,"status":133,"phases":1359,"primaryCompletion":1360,"completion":1361,"start":1362,"enrollment":1228,"conditions":1363,"interventions":1364},"NCT00448552","Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer",[86],"2007-04","2008-06","2004-02",[35],[1365,1366],"capecitabine","oxaliplatin",{"nctId":1086,"briefTitle":1087,"status":1088,"phases":1368,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1076,"conditions":1369,"interventions":1370},[86],[255],[1095,1096,1065,1080],{"nctId":1372,"briefTitle":1373,"status":1088,"phases":1374,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":1379,"interventions":1380},"NCT00276861","Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer",[86],"2006-09","2008-05","2005-09",10,[1157],[1381,1366],"gemcitabine hydrochloride",{"nctId":1383,"briefTitle":1384,"status":133,"phases":1385,"primaryCompletion":1386,"completion":1387,"start":1388,"enrollment":1228,"conditions":1389,"interventions":1391},"NCT00305786","Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[86],"2007-12","2010-05","2005-08",[1390],"Lung Cancer",[1381,1366],{"nctId":1098,"briefTitle":1099,"status":133,"phases":1393,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1394,"interventions":1395},[86],[1105],[1095,1096,1065,1080,1107,1108],{"nctId":1397,"briefTitle":1398,"status":1088,"phases":1399,"primaryCompletion":1400,"completion":1400,"start":1401,"enrollment":1344,"conditions":1402,"interventions":1406},"NCT00955721","A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer",[85,86],"2014-07","2009-08",[1403,1404,1405],"Cholangiocarcinoma","Biliary Tract Cancer","Gallbladder Cancer",[1170,1080,1407],"Sorafenib",{"nctId":1161,"briefTitle":1162,"status":302,"phases":1409,"primaryCompletion":968,"completion":968,"start":1164,"enrollment":739,"conditions":1410,"interventions":1411},[86],[1166,1167],[1169,1080,1065,1082,1170,1171],{"trials":1413,"activeCount":97},[],{"trials":1415,"activeCount":97},[],{"trials":1417,"activeCount":97},[1418],{"nctId":1419,"briefTitle":1420,"status":133,"phases":1421,"primaryCompletion":1422,"completion":1423,"start":1424,"enrollment":983,"conditions":1425,"interventions":1427},"NCT00448838","Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[89],"2007-08","2011-03","2006-05",[1426],"Pancreatic Cancer",[1428,1429,1080],"Cetuximab","Gemcitabine Hydrochloride",{"intervention":1004,"totalTrials":93,"cells":1431},{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1442,"PHASE4":1448,"NA":1454},{"trials":1433,"activeCount":97},[],{"trials":1435,"activeCount":97},[],{"trials":1437,"activeCount":142,"soonestReadout":68},[1438],{"nctId":66,"briefTitle":67,"status":302,"phases":1439,"primaryCompletion":68,"completion":68,"start":1019,"enrollment":1020,"conditions":1440,"interventions":1441},[86],[1022,1023,1024],[69,839,1004,1026,1027],{"trials":1443,"activeCount":97},[1444],{"nctId":1045,"briefTitle":1046,"status":121,"phases":1445,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":97,"conditions":1446,"interventions":1447},[87],[1051],[839,1002,1053,1054,1055,1004],{"trials":1449,"activeCount":97},[1450],{"nctId":991,"briefTitle":992,"status":133,"phases":1451,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":1452,"interventions":1453},[88],[358,998,999],[837,839,1001,1002,1003,1004,1005],{"trials":1455,"activeCount":97},[],{"intervention":1457,"totalTrials":818,"cells":1458},"Aspirin",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1475,"PHASE4":1477,"NA":1491},{"trials":1460,"activeCount":97},[],{"trials":1462,"activeCount":97},[],{"trials":1464,"activeCount":142,"soonestReadout":1469},[1465],{"nctId":1466,"briefTitle":1467,"status":302,"phases":1468,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":1471,"conditions":1472,"interventions":1474},"NCT04295486","Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty",[86],"2027-03-01","2021-03-01",5478,[1473],"Venous Thromboembolism",[1457],{"trials":1476,"activeCount":97},[],{"trials":1478,"activeCount":97},[1479],{"nctId":1480,"briefTitle":1481,"status":1088,"phases":1482,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":1485,"conditions":1486,"interventions":1489},"NCT02396732","Aspirin and Enoxaparin for VTE in Trauma",[88],"2018-05-15","2016-02",31,[1473,1487,1488],"Thromboprophylaxis","Trauma",[1457,1490],"Enoxaparin",{"trials":1492,"activeCount":97},[],{"intervention":69,"totalTrials":818,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1505,"PHASE4":1519,"NA":1521},{"trials":1496,"activeCount":97},[],{"trials":1498,"activeCount":97},[],{"trials":1500,"activeCount":142,"soonestReadout":68},[1501],{"nctId":66,"briefTitle":67,"status":302,"phases":1502,"primaryCompletion":68,"completion":68,"start":1019,"enrollment":1020,"conditions":1503,"interventions":1504},[86],[1022,1023,1024],[69,839,1004,1026,1027],{"trials":1506,"activeCount":97},[1507],{"nctId":1508,"briefTitle":1509,"status":133,"phases":1510,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1517},"NCT05291598","Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)",[87],"2023-05-01","2022-05-01",223,[1515,1516],"Total Knee Replacement","Total Hip Replacement",[1518,69],"IV meloxicam",{"trials":1520,"activeCount":97},[],{"trials":1522,"activeCount":97},[],{"intervention":945,"totalTrials":1066,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1549,"PHASE3":1587,"PHASE4":1589,"NA":1591},{"trials":1526,"activeCount":97},[],{"trials":1528,"activeCount":97},[1529,1541],{"nctId":1530,"briefTitle":1531,"status":121,"phases":1532,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":97,"conditions":1536,"interventions":1538},"NCT03437070","Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma",[85],"2021-06","2023-06","2019-06",[1537],"Leiomyosarcoma",[1539,945,1540],"Trabectedin","Olaratumab",{"nctId":1542,"briefTitle":1543,"status":133,"phases":1544,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":93,"conditions":1547,"interventions":1548},"NCT00530101","The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity",[85],"2008-03","2004-07",[25],[945],{"trials":1550,"activeCount":142,"soonestReadout":935},[1551,1555,1559,1563,1567,1577],{"nctId":932,"briefTitle":933,"status":302,"phases":1552,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":1553,"interventions":1554},[86],[939,940],[942,943,944,945,946,837],{"nctId":1110,"briefTitle":1111,"status":133,"phases":1556,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":1557,"interventions":1558},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1128,"briefTitle":1129,"status":1088,"phases":1560,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":923,"conditions":1561,"interventions":1562},[86],[1134,1135,1136],[945,1121,1065,1138,1139,1118],{"nctId":1141,"briefTitle":1142,"status":133,"phases":1564,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":1565,"interventions":1566},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"nctId":1568,"briefTitle":1569,"status":1088,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1575},"NCT00450385","Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)",[86],"2016-05","2007-04-24",57,[1116],[1118,944,945,1576,1123],"Prednisone",{"nctId":1578,"briefTitle":1579,"status":133,"phases":1580,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":1584,"interventions":1585},"NCT00499122","NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer",[86],"2011-04","2007-06-04",41,[25],[944,1095,945,1586],"NOV 002",{"trials":1588,"activeCount":97},[],{"trials":1590,"activeCount":97},[],{"trials":1592,"activeCount":97},[],{"intervention":943,"totalTrials":974,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1627,"PHASE4":1629,"NA":1631},{"trials":1596,"activeCount":97},[],{"trials":1598,"activeCount":97},[],{"trials":1600,"activeCount":142,"soonestReadout":935},[1601,1605,1609,1613],{"nctId":932,"briefTitle":933,"status":302,"phases":1602,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":1603,"interventions":1604},[86],[939,940],[942,943,944,945,946,837],{"nctId":1110,"briefTitle":1111,"status":133,"phases":1606,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":1607,"interventions":1608},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1141,"briefTitle":1142,"status":133,"phases":1610,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":1611,"interventions":1612},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"nctId":1614,"briefTitle":1615,"status":1088,"phases":1616,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":818,"conditions":1620,"interventions":1625},"NCT04189952","Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma",[86],"2021-06-30","2022-03-01","2020-09-22",[1621,1622,1623,1624],"Diffuse Large B Cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Leukemia","Marginal Zone Lymphoma",[1626,1118,1120,1210,943],"Acalabrutinib",{"trials":1628,"activeCount":97},[],{"trials":1630,"activeCount":97},[],{"trials":1632,"activeCount":97},[],{"intervention":1170,"totalTrials":93,"cells":1634},{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1658,"PHASE4":1660,"NA":1662},{"trials":1636,"activeCount":97},[],{"trials":1638,"activeCount":97},[],{"trials":1640,"activeCount":142,"soonestReadout":968},[1641,1650,1654],{"nctId":1642,"briefTitle":1643,"status":133,"phases":1644,"primaryCompletion":1423,"completion":1423,"start":1645,"enrollment":1228,"conditions":1646,"interventions":1647},"NCT00503906","Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer",[86],"2007-06",[25],[1648,1170,1649],"Avastin","Abraxane",{"nctId":1397,"briefTitle":1398,"status":1088,"phases":1651,"primaryCompletion":1400,"completion":1400,"start":1401,"enrollment":1344,"conditions":1652,"interventions":1653},[85,86],[1403,1404,1405],[1170,1080,1407],{"nctId":1161,"briefTitle":1162,"status":302,"phases":1655,"primaryCompletion":968,"completion":968,"start":1164,"enrollment":739,"conditions":1656,"interventions":1657},[86],[1166,1167],[1169,1080,1065,1082,1170,1171],{"trials":1659,"activeCount":97},[],{"trials":1661,"activeCount":97},[],{"trials":1663,"activeCount":97},[],{"intervention":1665,"totalTrials":818,"cells":1666},"Sirolimus",{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1697,"PHASE4":1699,"NA":1701},{"trials":1668,"activeCount":97},[],{"trials":1670,"activeCount":97},[],{"trials":1672,"activeCount":142,"soonestReadout":1677},[1673,1683],{"nctId":1674,"briefTitle":1675,"status":302,"phases":1676,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":1679,"conditions":1680,"interventions":1682},"NCT04141020","Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms",[86],"2026-11-01","2021-10-27",80,[1681],"Cerebral Aneurysm",[1665],{"nctId":1684,"briefTitle":1685,"status":133,"phases":1686,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1344,"conditions":1689,"interventions":1693},"NCT00183248","Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients",[85,86],"2009-11","2004-09",[1690,1691,1692],"Kidney Transplantation","Kidney Disease","Kidney Failure",[1694,1695,1665,1696],"Alemtuzumab","Mycophenolate mofetil","Tacrolimus",{"trials":1698,"activeCount":97},[],{"trials":1700,"activeCount":97},[],{"trials":1702,"activeCount":97},[],{"intervention":942,"totalTrials":142,"cells":1704},{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1706,"activeCount":97},[],{"trials":1708,"activeCount":97},[],{"trials":1710,"activeCount":142,"soonestReadout":935},[1711],{"nctId":932,"briefTitle":933,"status":302,"phases":1712,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":1713,"interventions":1714},[86],[939,940],[942,943,944,945,946,837],{"trials":1716,"activeCount":97},[],{"trials":1718,"activeCount":97},[],{"trials":1720,"activeCount":97},[],{"intervention":946,"totalTrials":142,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1724,"activeCount":97},[],{"trials":1726,"activeCount":97},[],{"trials":1728,"activeCount":142,"soonestReadout":935},[1729],{"nctId":932,"briefTitle":933,"status":302,"phases":1730,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":1731,"interventions":1732},[86],[939,940],[942,943,944,945,946,837],{"trials":1734,"activeCount":97},[],{"trials":1736,"activeCount":97},[],{"trials":1738,"activeCount":97},[],{"intervention":1195,"totalTrials":142,"cells":1740},{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1742,"activeCount":97},[],{"trials":1744,"activeCount":97},[],{"trials":1746,"activeCount":142,"soonestReadout":330},[1747],{"nctId":1188,"briefTitle":1189,"status":302,"phases":1748,"primaryCompletion":330,"completion":330,"start":331,"enrollment":1191,"conditions":1749,"interventions":1750},[86],[1193],[1179,1195],{"trials":1752,"activeCount":97},[],{"trials":1754,"activeCount":97},[],{"trials":1756,"activeCount":97},[],{"intervention":1758,"totalTrials":142,"cells":1759},"Epcoritamab",{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1761,"activeCount":97},[],{"trials":1763,"activeCount":97},[],{"trials":1765,"activeCount":142,"soonestReadout":1770},[1766],{"nctId":1767,"briefTitle":1768,"status":302,"phases":1769,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":1203,"conditions":1772,"interventions":1775},"NCT06919939","Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed\u002FRefractory Large B-cell Lymphoma",[86],"2031-01-07","2026-01-07",[1773,1774],"Large B-cell Lymphoma","Relapse",[1758,1776],"Loncastuximab Tesirine",{"trials":1778,"activeCount":97},[],{"trials":1780,"activeCount":97},[],{"trials":1782,"activeCount":97},[],{"intervention":1776,"totalTrials":142,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1786,"activeCount":97},[],{"trials":1788,"activeCount":97},[],{"trials":1790,"activeCount":142,"soonestReadout":1770},[1791],{"nctId":1767,"briefTitle":1768,"status":302,"phases":1792,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":1203,"conditions":1793,"interventions":1794},[86],[1773,1774],[1758,1776],{"trials":1796,"activeCount":97},[],{"trials":1798,"activeCount":97},[],{"trials":1800,"activeCount":97},[],{"intervention":1802,"totalTrials":142,"cells":1803},"Autologous Serum Tears",{"EARLY_PHASE1":1804,"PHASE1":1806,"PHASE2":1808,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1805,"activeCount":97},[],{"trials":1807,"activeCount":97},[],{"trials":1809,"activeCount":142,"soonestReadout":1814},[1810],{"nctId":1811,"briefTitle":1812,"status":179,"phases":1813,"primaryCompletion":1814,"completion":1814,"start":1815,"enrollment":20,"conditions":1816,"interventions":1820},"NCT07413172","Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye",[86],"2028-07","2026-07",[1817,1818,1819],"Dry Eye","Eye Diseases","Eyes Dry Chronic",[1802,1821],"Biological - Autologous Serum Tears",{"trials":1823,"activeCount":97},[],{"trials":1825,"activeCount":97},[],{"trials":1827,"activeCount":97},[],{"intervention":1821,"totalTrials":142,"cells":1829},{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1831,"activeCount":97},[],{"trials":1833,"activeCount":97},[],{"trials":1835,"activeCount":142,"soonestReadout":1814},[1836],{"nctId":1811,"briefTitle":1812,"status":179,"phases":1837,"primaryCompletion":1814,"completion":1814,"start":1815,"enrollment":20,"conditions":1838,"interventions":1839},[86],[1817,1818,1819],[1802,1821],{"trials":1841,"activeCount":97},[],{"trials":1843,"activeCount":97},[],{"trials":1845,"activeCount":97},[],{"intervention":64,"totalTrials":142,"cells":1847},{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1849,"activeCount":97},[],{"trials":1851,"activeCount":97},[],{"trials":1853,"activeCount":142,"soonestReadout":63},[1854],{"nctId":61,"briefTitle":62,"status":109,"phases":1855,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":1858,"interventions":1862},[86],"2029-07-31","2023-06-12",[25,1859,1860,1861],"ER-positive Breast Cancer","HER2-negative Breast Cancer","Metastatic Breast Cancer",[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],"SERD+CDK4\u002F6i","mTOR inhibitor + AI","mTOR inhibitor + SERD","mTOR inhibitor + Selective estrogen receptor modulator","PI3K inhibitor + SERD","PI3K inhibitor + AI","Chemotherapy","Oral SERD","PARPi","AKT inhibitor",{"trials":1874,"activeCount":97},[],{"trials":1876,"activeCount":97},[],{"trials":1878,"activeCount":97},[],{"intervention":1863,"totalTrials":142,"cells":1880},{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1891,"PHASE4":1893,"NA":1895},{"trials":1882,"activeCount":97},[],{"trials":1884,"activeCount":97},[],{"trials":1886,"activeCount":142,"soonestReadout":63},[1887],{"nctId":61,"briefTitle":62,"status":109,"phases":1888,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":1889,"interventions":1890},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":1892,"activeCount":97},[],{"trials":1894,"activeCount":97},[],{"trials":1896,"activeCount":97},[],{"intervention":1864,"totalTrials":142,"cells":1898},{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1903,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1900,"activeCount":97},[],{"trials":1902,"activeCount":97},[],{"trials":1904,"activeCount":142,"soonestReadout":63},[1905],{"nctId":61,"briefTitle":62,"status":109,"phases":1906,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":1907,"interventions":1908},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":1910,"activeCount":97},[],{"trials":1912,"activeCount":97},[],{"trials":1914,"activeCount":97},[],{"intervention":1865,"totalTrials":142,"cells":1916},{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1918,"activeCount":97},[],{"trials":1920,"activeCount":97},[],{"trials":1922,"activeCount":142,"soonestReadout":63},[1923],{"nctId":61,"briefTitle":62,"status":109,"phases":1924,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":1925,"interventions":1926},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":1928,"activeCount":97},[],{"trials":1930,"activeCount":97},[],{"trials":1932,"activeCount":97},[],{"intervention":1866,"totalTrials":142,"cells":1934},{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1945,"PHASE4":1947,"NA":1949},{"trials":1936,"activeCount":97},[],{"trials":1938,"activeCount":97},[],{"trials":1940,"activeCount":142,"soonestReadout":63},[1941],{"nctId":61,"briefTitle":62,"status":109,"phases":1942,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":1943,"interventions":1944},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":1946,"activeCount":97},[],{"trials":1948,"activeCount":97},[],{"trials":1950,"activeCount":97},[],{"intervention":1867,"totalTrials":142,"cells":1952},{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1954,"activeCount":97},[],{"trials":1956,"activeCount":97},[],{"trials":1958,"activeCount":142,"soonestReadout":63},[1959],{"nctId":61,"briefTitle":62,"status":109,"phases":1960,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":1961,"interventions":1962},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":1964,"activeCount":97},[],{"trials":1966,"activeCount":97},[],{"trials":1968,"activeCount":97},[],{"intervention":1868,"totalTrials":142,"cells":1970},{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1972,"activeCount":97},[],{"trials":1974,"activeCount":97},[],{"trials":1976,"activeCount":142,"soonestReadout":63},[1977],{"nctId":61,"briefTitle":62,"status":109,"phases":1978,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":1979,"interventions":1980},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":1982,"activeCount":97},[],{"trials":1984,"activeCount":97},[],{"trials":1986,"activeCount":97},[],{"intervention":1869,"totalTrials":142,"cells":1988},{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":1999,"PHASE4":2001,"NA":2003},{"trials":1990,"activeCount":97},[],{"trials":1992,"activeCount":97},[],{"trials":1994,"activeCount":142,"soonestReadout":63},[1995],{"nctId":61,"briefTitle":62,"status":109,"phases":1996,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":1997,"interventions":1998},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":2000,"activeCount":97},[],{"trials":2002,"activeCount":97},[],{"trials":2004,"activeCount":97},[],{"intervention":1870,"totalTrials":142,"cells":2006},{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":2008,"activeCount":97},[],{"trials":2010,"activeCount":97},[],{"trials":2012,"activeCount":142,"soonestReadout":63},[2013],{"nctId":61,"briefTitle":62,"status":109,"phases":2014,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":2015,"interventions":2016},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":2018,"activeCount":97},[],{"trials":2020,"activeCount":97},[],{"trials":2022,"activeCount":97},[],{"intervention":1871,"totalTrials":142,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2035,"PHASE4":2037,"NA":2039},{"trials":2026,"activeCount":97},[],{"trials":2028,"activeCount":97},[],{"trials":2030,"activeCount":142,"soonestReadout":63},[2031],{"nctId":61,"briefTitle":62,"status":109,"phases":2032,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":2033,"interventions":2034},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":2036,"activeCount":97},[],{"trials":2038,"activeCount":97},[],{"trials":2040,"activeCount":97},[],{"intervention":1872,"totalTrials":142,"cells":2042},{"EARLY_PHASE1":2043,"PHASE1":2045,"PHASE2":2047,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2044,"activeCount":97},[],{"trials":2046,"activeCount":97},[],{"trials":2048,"activeCount":142,"soonestReadout":63},[2049],{"nctId":61,"briefTitle":62,"status":109,"phases":2050,"primaryCompletion":63,"completion":1856,"start":1857,"enrollment":306,"conditions":2051,"interventions":2052},[86],[25,1859,1860,1861],[64,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872],{"trials":2054,"activeCount":97},[],{"trials":2056,"activeCount":97},[],{"trials":2058,"activeCount":97},[],{"intervention":46,"totalTrials":142,"cells":2060},{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2062,"activeCount":97},[],{"trials":2064,"activeCount":97},[],{"trials":2066,"activeCount":142,"soonestReadout":45},[2067],{"nctId":43,"briefTitle":44,"status":109,"phases":2068,"primaryCompletion":45,"completion":45,"start":2069,"enrollment":1228,"conditions":2070,"interventions":2072},[86],"2023-04-11",[2071],"Chronic Obstructive Pulmonary Disease",[46,2073],"Bretzri",{"trials":2075,"activeCount":97},[],{"trials":2077,"activeCount":97},[],{"trials":2079,"activeCount":97},[],{"intervention":2073,"totalTrials":142,"cells":2081},{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2092,"PHASE4":2094,"NA":2096},{"trials":2083,"activeCount":97},[],{"trials":2085,"activeCount":97},[],{"trials":2087,"activeCount":142,"soonestReadout":45},[2088],{"nctId":43,"briefTitle":44,"status":109,"phases":2089,"primaryCompletion":45,"completion":45,"start":2069,"enrollment":1228,"conditions":2090,"interventions":2091},[86],[2071],[46,2073],{"trials":2093,"activeCount":97},[],{"trials":2095,"activeCount":97},[],{"trials":2097,"activeCount":97},[],{"intervention":2099,"totalTrials":142,"cells":2100},"Tebentafusp",{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2118,"PHASE4":2120,"NA":2122},{"trials":2102,"activeCount":97},[],{"trials":2104,"activeCount":97},[],{"trials":2106,"activeCount":142,"soonestReadout":2111},[2107],{"nctId":2108,"briefTitle":2109,"status":302,"phases":2110,"primaryCompletion":2111,"completion":2112,"start":2113,"enrollment":1228,"conditions":2114,"interventions":2117},"NCT06627244","Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",[86],"2028-02-17","2031-02-17","2025-02-14",[2115,2116],"Metastatic Uveal Melanoma","Metastatic Uveal Melanoma in the Liver",[2099],{"trials":2119,"activeCount":97},[],{"trials":2121,"activeCount":97},[],{"trials":2123,"activeCount":97},[],{"intervention":1026,"totalTrials":142,"cells":2125},{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2136,"PHASE4":2138,"NA":2140},{"trials":2127,"activeCount":97},[],{"trials":2129,"activeCount":97},[],{"trials":2131,"activeCount":142,"soonestReadout":68},[2132],{"nctId":66,"briefTitle":67,"status":302,"phases":2133,"primaryCompletion":68,"completion":68,"start":1019,"enrollment":1020,"conditions":2134,"interventions":2135},[86],[1022,1023,1024],[69,839,1004,1026,1027],{"trials":2137,"activeCount":97},[],{"trials":2139,"activeCount":97},[],{"trials":2141,"activeCount":97},[],{"intervention":1027,"totalTrials":142,"cells":2143},{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2154,"PHASE4":2156,"NA":2158},{"trials":2145,"activeCount":97},[],{"trials":2147,"activeCount":97},[],{"trials":2149,"activeCount":142,"soonestReadout":68},[2150],{"nctId":66,"briefTitle":67,"status":302,"phases":2151,"primaryCompletion":68,"completion":68,"start":1019,"enrollment":1020,"conditions":2152,"interventions":2153},[86],[1022,1023,1024],[69,839,1004,1026,1027],{"trials":2155,"activeCount":97},[],{"trials":2157,"activeCount":97},[],{"trials":2159,"activeCount":97},[],{"intervention":840,"totalTrials":142,"cells":2161},{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2172,"PHASE4":2174,"NA":2176},{"trials":2163,"activeCount":97},[],{"trials":2165,"activeCount":97},[],{"trials":2167,"activeCount":142,"soonestReadout":830},[2168],{"nctId":827,"briefTitle":828,"status":109,"phases":2169,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":2170,"interventions":2171},[86],[834],[836,837,838,839,817,840,841,842,843],{"trials":2173,"activeCount":97},[],{"trials":2175,"activeCount":97},[],{"trials":2177,"activeCount":97},[],{"intervention":841,"totalTrials":142,"cells":2179},{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2181,"activeCount":97},[],{"trials":2183,"activeCount":97},[],{"trials":2185,"activeCount":142,"soonestReadout":830},[2186],{"nctId":827,"briefTitle":828,"status":109,"phases":2187,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":2188,"interventions":2189},[86],[834],[836,837,838,839,817,840,841,842,843],{"trials":2191,"activeCount":97},[],{"trials":2193,"activeCount":97},[],{"trials":2195,"activeCount":97},[],{"intervention":842,"totalTrials":142,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2199,"activeCount":97},[],{"trials":2201,"activeCount":97},[],{"trials":2203,"activeCount":142,"soonestReadout":830},[2204],{"nctId":827,"briefTitle":828,"status":109,"phases":2205,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":2206,"interventions":2207},[86],[834],[836,837,838,839,817,840,841,842,843],{"trials":2209,"activeCount":97},[],{"trials":2211,"activeCount":97},[],{"trials":2213,"activeCount":97},[],{"intervention":843,"totalTrials":142,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2226,"PHASE4":2228,"NA":2230},{"trials":2217,"activeCount":97},[],{"trials":2219,"activeCount":97},[],{"trials":2221,"activeCount":142,"soonestReadout":830},[2222],{"nctId":827,"briefTitle":828,"status":109,"phases":2223,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":2224,"interventions":2225},[86],[834],[836,837,838,839,817,840,841,842,843],{"trials":2227,"activeCount":97},[],{"trials":2229,"activeCount":97},[],{"trials":2231,"activeCount":97},[],{"intervention":2233,"totalTrials":142,"cells":2234},"Ultra-Short-Term Androgen Deprivation Therapy with Relugolix",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2236,"activeCount":97},[],{"trials":2238,"activeCount":97},[],{"trials":2240,"activeCount":142,"soonestReadout":2245},[2241],{"nctId":2242,"briefTitle":2243,"status":302,"phases":2244,"primaryCompletion":2245,"completion":2246,"start":251,"enrollment":2247,"conditions":2248,"interventions":2249},"NCT06111313","The University of Miami Adapt (UAdapt) Trial",[86],"2028-11-30","2033-11-30",130,[19],[2233,2250],"ADT Standard of Care",{"trials":2252,"activeCount":97},[],{"trials":2254,"activeCount":97},[],{"trials":2256,"activeCount":97},[],{"intervention":2250,"totalTrials":142,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2260,"activeCount":97},[],{"trials":2262,"activeCount":97},[],{"trials":2264,"activeCount":142,"soonestReadout":2245},[2265],{"nctId":2242,"briefTitle":2243,"status":302,"phases":2266,"primaryCompletion":2245,"completion":2246,"start":251,"enrollment":2247,"conditions":2267,"interventions":2268},[86],[19],[2233,2250],{"trials":2270,"activeCount":97},[],{"trials":2272,"activeCount":97},[],{"trials":2274,"activeCount":97},[],{"intervention":2276,"totalTrials":142,"cells":2277},"Doxycycline",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2279,"activeCount":97},[],{"trials":2281,"activeCount":97},[],{"trials":2283,"activeCount":142,"soonestReadout":2288},[2284],{"nctId":2285,"briefTitle":2286,"status":179,"phases":2287,"primaryCompletion":2288,"completion":2289,"start":1815,"enrollment":1378,"conditions":2290,"interventions":2292},"NCT07498010","Doxycycline Use in Post-Operative Seromas",[86],"2027-05-10","2027-10-01",[2291],"Seroma",[2276],{"trials":2294,"activeCount":97},[],{"trials":2296,"activeCount":97},[],{"trials":2298,"activeCount":97},[],{"intervention":73,"totalTrials":142,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2302,"activeCount":97},[],{"trials":2304,"activeCount":97},[],{"trials":2306,"activeCount":142,"soonestReadout":68},[2307],{"nctId":71,"briefTitle":72,"status":109,"phases":2308,"primaryCompletion":68,"completion":68,"start":2309,"enrollment":23,"conditions":2310,"interventions":2312},[86],"2023-09-26",[25,2311],"Genitourinary Syndrome of Menopause",[73],{"trials":2314,"activeCount":97},[],{"trials":2316,"activeCount":97},[],{"trials":2318,"activeCount":97},[],{"intervention":2320,"totalTrials":142,"cells":2321},"Emapalumab",{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2341,"PHASE4":2343,"NA":2345},{"trials":2323,"activeCount":97},[],{"trials":2325,"activeCount":97},[],{"trials":2327,"activeCount":142,"soonestReadout":477},[2328],{"nctId":2329,"briefTitle":2330,"status":179,"phases":2331,"primaryCompletion":477,"completion":477,"start":478,"enrollment":1009,"conditions":2332,"interventions":2340},"NCT07486869","Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study",[86],[2333,2334,2335,2336,2337,2338,2339],"Dermatomyositis","Dermatomyositis Sine Myositis","Dermatomyositis With Myopathy","Dermatomyositis With Respiratory Involvement","Dermatomyositis With Organ Involvement","Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[2320],{"trials":2342,"activeCount":97},[],{"trials":2344,"activeCount":97},[],{"trials":2346,"activeCount":97},[],{"intervention":2348,"totalTrials":142,"cells":2349},"BioDFence G3 Placental Tissue Membrane",{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2367,"PHASE4":2369,"NA":2371},{"trials":2351,"activeCount":97},[],{"trials":2353,"activeCount":97},[],{"trials":2355,"activeCount":142,"soonestReadout":2360},[2356],{"nctId":2357,"briefTitle":2358,"status":109,"phases":2359,"primaryCompletion":2360,"completion":2361,"start":2362,"enrollment":2363,"conditions":2364,"interventions":2366},"NCT05842057","Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy",[86],"2027-08-31","2028-08-31","2023-08-24",118,[19,2365],"Erectile Dysfunction Following Radical Prostatectomy",[2348],{"trials":2368,"activeCount":97},[],{"trials":2370,"activeCount":97},[],{"trials":2372,"activeCount":97},[],{"intervention":1292,"totalTrials":142,"cells":2374},{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2379,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2376,"activeCount":97},[],{"trials":2378,"activeCount":97},[],{"trials":2380,"activeCount":142,"soonestReadout":111},[2381],{"nctId":1285,"briefTitle":1286,"status":302,"phases":2382,"primaryCompletion":111,"completion":893,"start":1288,"enrollment":937,"conditions":2383,"interventions":2384},[86],[1290],[1292,1266],{"trials":2386,"activeCount":97},[],{"trials":2388,"activeCount":97},[],{"trials":2390,"activeCount":97},[],{"intervention":2392,"totalTrials":142,"cells":2393},"Loncastuximab tesirine 150 µg\u002FKg",{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2395,"activeCount":97},[],{"trials":2397,"activeCount":97},[],{"trials":2399,"activeCount":142,"soonestReadout":2404},[2400],{"nctId":2401,"briefTitle":2402,"status":302,"phases":2403,"primaryCompletion":2404,"completion":2405,"start":2406,"enrollment":739,"conditions":2407,"interventions":2408},"NCT05296070","Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed\u002FRefractory Marginal Zone Lymphoma",[86],"2028-06-30","2029-06-30","2022-06-21",[1624],[2392,2409],"Loncastuximab tesirine 75µg\u002FKg",{"trials":2411,"activeCount":97},[],{"trials":2413,"activeCount":97},[],{"trials":2415,"activeCount":97},[],{"intervention":2409,"totalTrials":142,"cells":2417},{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2419,"activeCount":97},[],{"trials":2421,"activeCount":97},[],{"trials":2423,"activeCount":142,"soonestReadout":2404},[2424],{"nctId":2401,"briefTitle":2402,"status":302,"phases":2425,"primaryCompletion":2404,"completion":2405,"start":2406,"enrollment":739,"conditions":2426,"interventions":2427},[86],[1624],[2392,2409],{"trials":2429,"activeCount":97},[],{"trials":2431,"activeCount":97},[],{"trials":2433,"activeCount":97},[],{"intervention":2435,"totalTrials":142,"cells":2436},"Epinephrine",{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2441,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2438,"activeCount":97},[],{"trials":2440,"activeCount":97},[],{"trials":2442,"activeCount":142,"soonestReadout":2447},[2443],{"nctId":2444,"briefTitle":2445,"status":302,"phases":2446,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":20,"conditions":2449,"interventions":2451},"NCT07392580","Intralesional Chemotherapy (IC): Cisplatin + Epinephrine",[86],"2031-09-01","2026-09-01",[2450],"Laryngeal Squamous Cell Carcinoma",[1220,2435],{"trials":2453,"activeCount":97},[],{"trials":2455,"activeCount":97},[],{"trials":2457,"activeCount":97},[],{"intervention":962,"totalTrials":142,"cells":2459},{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2461,"activeCount":97},[],{"trials":2463,"activeCount":97},[],{"trials":2465,"activeCount":142,"soonestReadout":955},[2466],{"nctId":952,"briefTitle":953,"status":302,"phases":2467,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2468,"interventions":2469},[86],[960],[962,963,837],{"trials":2471,"activeCount":97},[],{"trials":2473,"activeCount":97},[],{"trials":2475,"activeCount":97},[],{"intervention":963,"totalTrials":142,"cells":2477},{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2482,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[],{"trials":2483,"activeCount":142,"soonestReadout":955},[2484],{"nctId":952,"briefTitle":953,"status":302,"phases":2485,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2486,"interventions":2487},[86],[960],[962,963,837],{"trials":2489,"activeCount":97},[],{"trials":2491,"activeCount":97},[],{"trials":2493,"activeCount":97},[],{"intervention":2495,"totalTrials":142,"cells":2496},"SIACI of cetuximab and bevacizumab",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2520,"PHASE4":2522,"NA":2524},{"trials":2498,"activeCount":97},[],{"trials":2500,"activeCount":97},[],{"trials":2502,"activeCount":142,"soonestReadout":2507},[2503],{"nctId":2504,"briefTitle":2505,"status":302,"phases":2506,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":20,"conditions":2510,"interventions":2519},"NCT05956821","Treatment of Relapsed\u002FRefractory Intracranial Glioma in Patients Under 22 Years of Age",[85,86],"2029-10-01","2029-12-01","2025-06-19",[2511,2512,2513,2514,2515,2516,2517,2518],"Glioblastoma Multiforme","Anaplastic Astrocytoma","Fibrillary Astrocytomas","Oligodendroglioma","Diffuse Intrinsic Brainstem Glioma","Diffuse Intrinsic Pontine Glioma","DIPG Brain Tumor","H3 K27M",[2495],{"trials":2521,"activeCount":97},[],{"trials":2523,"activeCount":97},[],{"trials":2525,"activeCount":97},[],{"intervention":2527,"totalTrials":142,"cells":2528},"Axatilimab",{"EARLY_PHASE1":2529,"PHASE1":2531,"PHASE2":2533,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2530,"activeCount":97},[],{"trials":2532,"activeCount":97},[],{"trials":2534,"activeCount":142,"soonestReadout":2539},[2535],{"nctId":2536,"briefTitle":2537,"status":302,"phases":2538,"primaryCompletion":2539,"completion":2539,"start":2540,"enrollment":2541,"conditions":2542,"interventions":2545},"NCT06663722","Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease",[86],"2030-05-05","2025-05-05",49,[2543,2544],"Chronic Graft Versus Host Disease","cGVHD",[2527],{"trials":2547,"activeCount":97},[],{"trials":2549,"activeCount":97},[],{"trials":2551,"activeCount":97},[],{"intervention":1171,"totalTrials":142,"cells":2553},{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2555,"activeCount":97},[],{"trials":2557,"activeCount":97},[],{"trials":2559,"activeCount":142,"soonestReadout":968},[2560],{"nctId":1161,"briefTitle":1162,"status":302,"phases":2561,"primaryCompletion":968,"completion":968,"start":1164,"enrollment":739,"conditions":2562,"interventions":2563},[86],[1166,1167],[1169,1080,1065,1082,1170,1171],{"trials":2565,"activeCount":97},[],{"trials":2567,"activeCount":97},[],{"trials":2569,"activeCount":97},[],{"intervention":2571,"totalTrials":142,"cells":2572},"Quisinostat",{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2589,"PHASE4":2591,"NA":2593},{"trials":2574,"activeCount":97},[],{"trials":2576,"activeCount":97},[],{"trials":2578,"activeCount":142,"soonestReadout":2583},[2579],{"nctId":2580,"briefTitle":2581,"status":302,"phases":2582,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":2585,"conditions":2586,"interventions":2588},"NCT06932757","Adjuvant Quisinostat in High-Risk Uveal Melanoma",[86],"2030-05-27","2025-05-27",63,[2587],"Uveal Melanoma",[2571],{"trials":2590,"activeCount":97},[],{"trials":2592,"activeCount":97},[],{"trials":2594,"activeCount":97},[],{"intervention":973,"totalTrials":142,"cells":2596},{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2607,"PHASE4":2609,"NA":2611},{"trials":2598,"activeCount":97},[],{"trials":2600,"activeCount":97},[],{"trials":2602,"activeCount":142,"soonestReadout":968},[2603],{"nctId":965,"briefTitle":966,"status":302,"phases":2604,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":2605,"interventions":2606},[86],[834],[838,837,973],{"trials":2608,"activeCount":97},[],{"trials":2610,"activeCount":97},[],{"trials":2612,"activeCount":97},[],{"intervention":77,"totalTrials":142,"cells":2614},{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2619,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2616,"activeCount":97},[],{"trials":2618,"activeCount":97},[],{"trials":2620,"activeCount":142,"soonestReadout":68},[2621],{"nctId":75,"briefTitle":76,"status":302,"phases":2622,"primaryCompletion":68,"completion":68,"start":2623,"enrollment":739,"conditions":2624,"interventions":2626},[86],"2024-09-30",[2625],"Traumatic Brain Injury",[77],{"trials":2628,"activeCount":97},[],{"trials":2630,"activeCount":97},[],{"trials":2632,"activeCount":97},[],{"intervention":54,"totalTrials":142,"cells":2634},{"EARLY_PHASE1":2635,"PHASE1":2637,"PHASE2":2639,"PHASE3":2648,"PHASE4":2650,"NA":2652},{"trials":2636,"activeCount":97},[],{"trials":2638,"activeCount":97},[],{"trials":2640,"activeCount":142,"soonestReadout":45},[2641],{"nctId":52,"briefTitle":53,"status":302,"phases":2642,"primaryCompletion":45,"completion":45,"start":2643,"enrollment":20,"conditions":2644,"interventions":2647},[85,86],"2025-06-16",[2645,2646],"SCI - Spinal Cord Injury","Neuropathic Pain",[54],{"trials":2649,"activeCount":97},[],{"trials":2651,"activeCount":97},[],{"trials":2653,"activeCount":97},[],{"intervention":2655,"totalTrials":142,"cells":2656},"Androgen Deprivation Therapy",{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2676,"PHASE4":2678,"NA":2680},{"trials":2658,"activeCount":97},[],{"trials":2660,"activeCount":97},[],{"trials":2662,"activeCount":142,"soonestReadout":2667},[2663],{"nctId":2664,"briefTitle":2665,"status":302,"phases":2666,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":2670,"conditions":2671,"interventions":2674},"NCT06392295","PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer",[86],"2027-08-01","2029-08-01","2024-07-03",34,[19,2672,2673],"Prostate Adenocarcinoma","Hormone Sensitive Prostate Cancer",[2655,2675],"Androgen Receptor Signaling Inhibitor",{"trials":2677,"activeCount":97},[],{"trials":2679,"activeCount":97},[],{"trials":2681,"activeCount":97},[],{"intervention":2675,"totalTrials":142,"cells":2683},{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2688,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2685,"activeCount":97},[],{"trials":2687,"activeCount":97},[],{"trials":2689,"activeCount":142,"soonestReadout":2667},[2690],{"nctId":2664,"briefTitle":2665,"status":302,"phases":2691,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":2670,"conditions":2692,"interventions":2693},[86],[19,2672,2673],[2655,2675],{"trials":2695,"activeCount":97},[],{"trials":2697,"activeCount":97},[],{"trials":2699,"activeCount":97},[],{"intervention":1232,"totalTrials":142,"cells":2701},{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2706,"PHASE3":2712,"PHASE4":2714,"NA":2716},{"trials":2703,"activeCount":97},[],{"trials":2705,"activeCount":97},[],{"trials":2707,"activeCount":142,"soonestReadout":1225},[2708],{"nctId":1222,"briefTitle":1223,"status":302,"phases":2709,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":2710,"interventions":2711},[86],[1230],[1179,1232],{"trials":2713,"activeCount":97},[],{"trials":2715,"activeCount":97},[],{"trials":2717,"activeCount":97},[],{"intervention":1220,"totalTrials":1344,"cells":2719},{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2751,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2721,"activeCount":97},[],{"trials":2723,"activeCount":97},[2724,2734,2742],{"nctId":2725,"briefTitle":2726,"status":133,"phases":2727,"primaryCompletion":2728,"completion":2728,"start":1114,"enrollment":142,"conditions":2729,"interventions":2730},"NCT00077051","Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)",[85],"2007-07",[35],[2731,2732,2733],"cisplatin","cytochlor","tetrahydrouridine",{"nctId":2735,"briefTitle":2736,"status":133,"phases":2737,"primaryCompletion":1423,"completion":1423,"start":2738,"enrollment":33,"conditions":2739,"interventions":2741},"NCT00448643","Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery",[85],"2002-05",[2740],"Endometrial Cancer",[1220],{"nctId":2743,"briefTitle":2744,"status":133,"phases":2745,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":1066,"conditions":2748,"interventions":2749},"NCT01485731","Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer",[85],"2015-02","2012-01",[1218],[2750,1220],"Nelfinavir",{"trials":2752,"activeCount":142,"soonestReadout":2447},[2753,2766,2770,2781,2785],{"nctId":2754,"briefTitle":2755,"status":133,"phases":2756,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":2760,"interventions":2762},"NCT00003582","Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer",[85,86],"1996-12","1988-05",36,[2761,35],"Carcinoma of Unknown Primary",[2763,2731,2764,2765],"amifostine trihydrate","fluorouracil","paclitaxel",{"nctId":2444,"briefTitle":2445,"status":302,"phases":2767,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":20,"conditions":2768,"interventions":2769},[86],[2450],[1220,2435],{"nctId":2771,"briefTitle":2772,"status":133,"phases":2773,"primaryCompletion":2774,"completion":2774,"start":2775,"conditions":2776,"interventions":2778},"NCT00002492","Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma",[86],"2000-02","1991-11",[2777],"Sarcoma",[2731,2779,2780],"doxorubicin hydrochloride","isolated limb perfusion",{"nctId":1212,"briefTitle":1213,"status":1088,"phases":2782,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":30,"conditions":2783,"interventions":2784},[86],[1218],[1179,1209,1220,1210,1159],{"nctId":2786,"briefTitle":2787,"status":133,"phases":2788,"primaryCompletion":2789,"completion":2789,"start":2790,"enrollment":2791,"conditions":2792,"interventions":2794},"NCT00875615","Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery",[86],"2012-06","2008-12",11,[2793],"Liver Cancer",[1210,1220,1407],{"trials":2796,"activeCount":97},[],{"trials":2798,"activeCount":97},[],{"trials":2800,"activeCount":97},[2801],{"nctId":2802,"briefTitle":2803,"status":133,"phases":2804,"primaryCompletion":2805,"start":2806,"enrollment":923,"conditions":2807,"interventions":2810},"NCT01209520","Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy",[89],"2013-12","2009-07",[1390,2808,2809],"Non Small Cell Lung Carcinoma","Hypermethylation",[1220,1210,1209,2811,2812,1095,2813],"Vidaza","Vinorelbine","Pemetrexed",{"intervention":944,"totalTrials":2815,"cells":2816},7,{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2843,"PHASE4":2845,"NA":2847},{"trials":2818,"activeCount":97},[],{"trials":2820,"activeCount":97},[],{"trials":2822,"activeCount":142,"soonestReadout":935},[2823,2827,2831,2835,2839],{"nctId":932,"briefTitle":933,"status":302,"phases":2824,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":2825,"interventions":2826},[86],[939,940],[942,943,944,945,946,837],{"nctId":1110,"briefTitle":1111,"status":133,"phases":2828,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":2829,"interventions":2830},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1141,"briefTitle":1142,"status":133,"phases":2832,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":2833,"interventions":2834},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"nctId":1568,"briefTitle":1569,"status":1088,"phases":2836,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":2837,"interventions":2838},[86],[1116],[1118,944,945,1576,1123],{"nctId":1578,"briefTitle":1579,"status":133,"phases":2840,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":2841,"interventions":2842},[86],[25],[944,1095,945,1586],{"trials":2844,"activeCount":97},[],{"trials":2846,"activeCount":97},[],{"trials":2848,"activeCount":97},[2849,2864],{"nctId":2850,"briefTitle":2851,"status":121,"phases":2852,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":2854,"interventions":2855},"NCT00513188","Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma",[89],"2007-02",[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],"denileukin diftitox","cyclophosphamide","cytarabine","leucovorin calcium","methotrexate","prednisone","vincristine sulfate","protein expression analysis",{"nctId":2865,"briefTitle":2866,"status":1088,"phases":2867,"primaryCompletion":2868,"completion":2869,"start":2870,"enrollment":93,"conditions":2871,"interventions":2873},"NCT00772668","Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III\u002FIV FL or MZL",[89],"2010-12","2011-02","2009-09-25",[1116,2872,1624],"Follicular Lymphoma",[1118,836,944,1576],{"intervention":836,"totalTrials":93,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2891,"PHASE3":2897,"PHASE4":2899,"NA":2901},{"trials":2877,"activeCount":97},[],{"trials":2879,"activeCount":97},[2880],{"nctId":2881,"briefTitle":2882,"status":121,"phases":2883,"primaryCompletion":2884,"completion":2884,"start":1645,"enrollment":97,"conditions":2885,"interventions":2887},"NCT00504101","Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma",[85],"2011-06",[2886],"Multiple Myeloma and Plasma Cell Neoplasm",[2888,836,2889,2890],"Arsenic trioxide","Melphalan","Autologous hematopoietic stem cell transplantation",{"trials":2892,"activeCount":142,"soonestReadout":830},[2893],{"nctId":827,"briefTitle":828,"status":109,"phases":2894,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":2895,"interventions":2896},[86],[834],[836,837,838,839,817,840,841,842,843],{"trials":2898,"activeCount":97},[],{"trials":2900,"activeCount":97},[],{"trials":2902,"activeCount":97},[2903],{"nctId":2865,"briefTitle":2866,"status":1088,"phases":2904,"primaryCompletion":2868,"completion":2869,"start":2870,"enrollment":93,"conditions":2905,"interventions":2906},[89],[1116,2872,1624],[1118,836,944,1576],{"intervention":1081,"totalTrials":93,"cells":2908},{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2917,"PHASE3":2932,"PHASE4":2934,"NA":2936},{"trials":2910,"activeCount":97},[],{"trials":2912,"activeCount":142,"soonestReadout":81},[2913],{"nctId":79,"briefTitle":80,"status":302,"phases":2914,"primaryCompletion":81,"completion":1074,"start":1075,"enrollment":1076,"conditions":2915,"interventions":2916},[85],[1078],[82,1065,1080,1081,1082],{"trials":2918,"activeCount":97},[2919,2923],{"nctId":1357,"briefTitle":1358,"status":133,"phases":2920,"primaryCompletion":1360,"completion":1361,"start":1362,"enrollment":1228,"conditions":2921,"interventions":2922},[86],[35],[1365,1366],{"nctId":2924,"briefTitle":2925,"status":133,"phases":2926,"primaryCompletion":2927,"completion":2928,"start":1546,"enrollment":2929,"conditions":2930,"interventions":2931},"NCT00290693","Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer",[86],"2008-08","2010-06",45,[1426],[1081,1095],{"trials":2933,"activeCount":97},[],{"trials":2935,"activeCount":97},[],{"trials":2937,"activeCount":97},[],{"intervention":2939,"totalTrials":818,"cells":2940},"Temozolomide",{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2958,"PHASE3":2969,"PHASE4":2971,"NA":2973},{"trials":2942,"activeCount":97},[],{"trials":2944,"activeCount":142,"soonestReadout":2949},[2945],{"nctId":2946,"briefTitle":2947,"status":302,"phases":2948,"primaryCompletion":2949,"completion":2950,"start":2951,"enrollment":306,"conditions":2952,"interventions":2954},"NCT06428045","STARLITE for Unresectable High-Grade Gliomas",[85],"2029-04-30","2030-04-30","2025-04-15",[2953],"High Grade Glioma",[2955,2956,2957,2939],"Abacavir","Lamivudine","Ritonavir",{"trials":2959,"activeCount":97},[2960],{"nctId":2961,"briefTitle":2962,"status":1088,"phases":2963,"primaryCompletion":2964,"completion":2964,"start":2965,"enrollment":142,"conditions":2966,"interventions":2968},"NCT02394665","Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma",[86],"2016-09","2015-03",[2967],"Glioblastoma",[2939],{"trials":2970,"activeCount":97},[],{"trials":2972,"activeCount":97},[],{"trials":2974,"activeCount":97},[],{"intervention":2976,"totalTrials":142,"cells":2977},"Botulinum neurotoxin",{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":2991,"PHASE3":2993,"PHASE4":2995,"NA":2997},{"trials":2979,"activeCount":97},[],{"trials":2981,"activeCount":142,"soonestReadout":2986},[2982],{"nctId":2983,"briefTitle":2984,"status":302,"phases":2985,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":1228,"conditions":2988,"interventions":2990},"NCT06796985","Botox for Chronic Pelvic Pain",[85],"2027-03-22","2025-02-24",[2989],"Pelvic Floor Disorders",[2976],{"trials":2992,"activeCount":97},[],{"trials":2994,"activeCount":97},[],{"trials":2996,"activeCount":97},[],{"trials":2998,"activeCount":97},[],{"intervention":2955,"totalTrials":142,"cells":3000},{"EARLY_PHASE1":3001,"PHASE1":3003,"PHASE2":3009,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":3002,"activeCount":97},[],{"trials":3004,"activeCount":142,"soonestReadout":2949},[3005],{"nctId":2946,"briefTitle":2947,"status":302,"phases":3006,"primaryCompletion":2949,"completion":2950,"start":2951,"enrollment":306,"conditions":3007,"interventions":3008},[85],[2953],[2955,2956,2957,2939],{"trials":3010,"activeCount":97},[],{"trials":3012,"activeCount":97},[],{"trials":3014,"activeCount":97},[],{"trials":3016,"activeCount":97},[],{"intervention":2956,"totalTrials":142,"cells":3018},{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3027,"PHASE3":3029,"PHASE4":3031,"NA":3033},{"trials":3020,"activeCount":97},[],{"trials":3022,"activeCount":142,"soonestReadout":2949},[3023],{"nctId":2946,"briefTitle":2947,"status":302,"phases":3024,"primaryCompletion":2949,"completion":2950,"start":2951,"enrollment":306,"conditions":3025,"interventions":3026},[85],[2953],[2955,2956,2957,2939],{"trials":3028,"activeCount":97},[],{"trials":3030,"activeCount":97},[],{"trials":3032,"activeCount":97},[],{"trials":3034,"activeCount":97},[],{"intervention":2957,"totalTrials":142,"cells":3036},{"EARLY_PHASE1":3037,"PHASE1":3039,"PHASE2":3045,"PHASE3":3047,"PHASE4":3049,"NA":3051},{"trials":3038,"activeCount":97},[],{"trials":3040,"activeCount":142,"soonestReadout":2949},[3041],{"nctId":2946,"briefTitle":2947,"status":302,"phases":3042,"primaryCompletion":2949,"completion":2950,"start":2951,"enrollment":306,"conditions":3043,"interventions":3044},[85],[2953],[2955,2956,2957,2939],{"trials":3046,"activeCount":97},[],{"trials":3048,"activeCount":97},[],{"trials":3050,"activeCount":97},[],{"trials":3052,"activeCount":97},[],{"intervention":3054,"totalTrials":142,"cells":3055},"Methylene Blue 10 MG\u002FML",{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3057,"activeCount":97},[],{"trials":3059,"activeCount":142,"soonestReadout":830},[3060],{"nctId":3061,"briefTitle":3062,"status":302,"phases":3063,"primaryCompletion":830,"completion":830,"start":3064,"enrollment":20,"conditions":3065,"interventions":3069},"NCT07324954","Methylene Blue in Total Knee Arthroplasty (TKA)",[85],"2026-02-04",[3066,3067,3068],"Total Knee Arthroplasty","Prosthetic-joint Infection","Irrigation",[3054],{"trials":3071,"activeCount":97},[],{"trials":3073,"activeCount":97},[],{"trials":3075,"activeCount":97},[],{"trials":3077,"activeCount":97},[],{"intervention":1159,"totalTrials":93,"cells":3079},{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3084,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3081,"activeCount":97},[],{"trials":3083,"activeCount":97},[],{"trials":3085,"activeCount":97},[3086,3090],{"nctId":1212,"briefTitle":1213,"status":1088,"phases":3087,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":30,"conditions":3088,"interventions":3089},[86],[1218],[1179,1209,1220,1210,1159],{"nctId":1152,"briefTitle":1153,"status":1088,"phases":3091,"primaryCompletion":1091,"completion":1091,"start":1155,"enrollment":1076,"conditions":3092,"interventions":3093},[86],[1157],[1159,1096,1082,1065],{"trials":3095,"activeCount":97},[],{"trials":3097,"activeCount":97},[],{"trials":3099,"activeCount":142,"soonestReadout":3104},[3100],{"nctId":3101,"briefTitle":3102,"status":302,"phases":3103,"primaryCompletion":3104,"completion":3105,"start":3106,"enrollment":3107,"conditions":3108,"interventions":3110},"NCT05284643","Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma",[89],"2027-09-30","2029-09-30","2022-09-30",96,[3109],"Recurrent Glioblastoma",[1159],{"intervention":3112,"totalTrials":142,"cells":3113},"PRGF",{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3122,"NA":3124},{"trials":3115,"activeCount":97},[],{"trials":3117,"activeCount":97},[],{"trials":3119,"activeCount":97},[],{"trials":3121,"activeCount":97},[],{"trials":3123,"activeCount":97},[],{"trials":3125,"activeCount":142,"soonestReadout":3130},[3126],{"nctId":3127,"briefTitle":3128,"status":302,"phases":3129,"primaryCompletion":3130,"completion":400,"start":3131,"enrollment":137,"conditions":3132,"interventions":3135},"NCT06261346","Plasma Rich in Growth Factors in Corneal Endothelial Transplantation",[89],"2027-10-30","2024-07-15",[3133,3134],"Fuchs' Endothelial Dystrophy","Corneal Edema",[3112],{"intervention":3137,"totalTrials":93,"cells":3138},"Thymoglobulin",{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3145,"PHASE4":3147,"NA":3178},{"trials":3140,"activeCount":97},[],{"trials":3142,"activeCount":97},[],{"trials":3144,"activeCount":97},[],{"trials":3146,"activeCount":97},[],{"trials":3148,"activeCount":97},[3149,3162,3170],{"nctId":3150,"briefTitle":3151,"status":133,"phases":3152,"primaryCompletion":3153,"completion":3154,"start":3155,"enrollment":3156,"conditions":3157,"interventions":3159},"NCT00681343","Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation",[88],"2006-10","2007-10","2002-09",38,[3158],"Living-Donor Kidney Transplant",[3137,3160,3161],"Campath-1H","Daclizumab",{"nctId":3163,"briefTitle":3164,"status":133,"phases":3165,"primaryCompletion":1387,"completion":1387,"start":3166,"enrollment":453,"conditions":3167,"interventions":3169},"NCT01172418","Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols",[88],"2006-02",[3168],"Transplant; Failure, Kidney",[1694,3161,3137],{"nctId":3171,"briefTitle":3172,"status":133,"phases":3173,"primaryCompletion":1688,"completion":1377,"start":3174,"enrollment":895,"conditions":3175,"interventions":3177},"NCT00685061","Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation",[88],"2002-11",[3176],"Renal Transplantation",[3137,3160,3161],{"trials":3179,"activeCount":97},[],{"intervention":3161,"totalTrials":93,"cells":3181},{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3186,"PHASE3":3188,"PHASE4":3190,"NA":3204},{"trials":3183,"activeCount":97},[],{"trials":3185,"activeCount":97},[],{"trials":3187,"activeCount":97},[],{"trials":3189,"activeCount":97},[],{"trials":3191,"activeCount":97},[3192,3196,3200],{"nctId":3150,"briefTitle":3151,"status":133,"phases":3193,"primaryCompletion":3153,"completion":3154,"start":3155,"enrollment":3156,"conditions":3194,"interventions":3195},[88],[3158],[3137,3160,3161],{"nctId":3163,"briefTitle":3164,"status":133,"phases":3197,"primaryCompletion":1387,"completion":1387,"start":3166,"enrollment":453,"conditions":3198,"interventions":3199},[88],[3168],[1694,3161,3137],{"nctId":3171,"briefTitle":3172,"status":133,"phases":3201,"primaryCompletion":1688,"completion":1377,"start":3174,"enrollment":895,"conditions":3202,"interventions":3203},[88],[3176],[3137,3160,3161],{"trials":3205,"activeCount":97},[],{"intervention":1005,"totalTrials":818,"cells":3207},{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3214,"PHASE4":3216,"NA":3233},{"trials":3209,"activeCount":97},[],{"trials":3211,"activeCount":97},[],{"trials":3213,"activeCount":97},[],{"trials":3215,"activeCount":97},[],{"trials":3217,"activeCount":97},[3218,3229],{"nctId":3219,"briefTitle":3220,"status":121,"phases":3221,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":97,"conditions":3224,"interventions":3226},"NCT06114121","Intrathecal Morphine vs. Intrathecal Morphine and Regional Anesthesia After Cesarean Section.",[88],"2024-09-10","2024-07-10",[3225],"Post-operative Pain",[3227,1005,3228],"Duramorph","Bupivacaine",{"nctId":991,"briefTitle":992,"status":133,"phases":3230,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":3231,"interventions":3232},[88],[358,998,999],[837,839,1001,1002,1003,1004,1005],{"trials":3234,"activeCount":97},[],{"intervention":3160,"totalTrials":818,"cells":3236},{"EARLY_PHASE1":3237,"PHASE1":3239,"PHASE2":3241,"PHASE3":3243,"PHASE4":3245,"NA":3255},{"trials":3238,"activeCount":97},[],{"trials":3240,"activeCount":97},[],{"trials":3242,"activeCount":97},[],{"trials":3244,"activeCount":97},[],{"trials":3246,"activeCount":97},[3247,3251],{"nctId":3150,"briefTitle":3151,"status":133,"phases":3248,"primaryCompletion":3153,"completion":3154,"start":3155,"enrollment":3156,"conditions":3249,"interventions":3250},[88],[3158],[3137,3160,3161],{"nctId":3171,"briefTitle":3172,"status":133,"phases":3252,"primaryCompletion":1688,"completion":1377,"start":3174,"enrollment":895,"conditions":3253,"interventions":3254},[88],[3176],[3137,3160,3161],{"trials":3256,"activeCount":97},[],{"intervention":1002,"totalTrials":818,"cells":3258},{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3263,"PHASE3":3265,"PHASE4":3271,"NA":3277},{"trials":3260,"activeCount":97},[],{"trials":3262,"activeCount":97},[],{"trials":3264,"activeCount":97},[],{"trials":3266,"activeCount":97},[3267],{"nctId":1045,"briefTitle":1046,"status":121,"phases":3268,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":97,"conditions":3269,"interventions":3270},[87],[1051],[839,1002,1053,1054,1055,1004],{"trials":3272,"activeCount":97},[3273],{"nctId":991,"briefTitle":992,"status":133,"phases":3274,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":3275,"interventions":3276},[88],[358,998,999],[837,839,1001,1002,1003,1004,1005],{"trials":3278,"activeCount":97},[],{"intervention":3280,"totalTrials":818,"cells":3281},"Nicoderm C-Q Transdermal Product",{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3288,"PHASE4":3290,"NA":3311},{"trials":3283,"activeCount":97},[],{"trials":3285,"activeCount":97},[],{"trials":3287,"activeCount":97},[],{"trials":3289,"activeCount":97},[],{"trials":3291,"activeCount":97},[3292,3300],{"nctId":3293,"briefTitle":3294,"status":1088,"phases":3295,"primaryCompletion":3296,"completion":3296,"start":3297,"enrollment":20,"conditions":3298,"interventions":3299},"NCT04038255","Mindfulness Based Smoking Cessation Among Cancer Survivors",[88],"2024-05-19","2019-09-28",[720],[3280],{"nctId":3301,"briefTitle":3302,"status":133,"phases":3303,"primaryCompletion":3304,"completion":3304,"start":3305,"enrollment":3306,"conditions":3307,"interventions":3310},"NCT03999411","Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients",[88],"2020-10-14","2019-09-09",39,[3308,718,3309],"Smoking","HIV",[3280],{"trials":3312,"activeCount":97},[],{"intervention":3314,"totalTrials":818,"cells":3315},"Vortioxetine",{"EARLY_PHASE1":3316,"PHASE1":3318,"PHASE2":3320,"PHASE3":3322,"PHASE4":3324,"NA":3347},{"trials":3317,"activeCount":97},[],{"trials":3319,"activeCount":97},[],{"trials":3321,"activeCount":97},[],{"trials":3323,"activeCount":97},[],{"trials":3325,"activeCount":97},[3326,3337],{"nctId":3327,"briefTitle":3328,"status":121,"phases":3329,"primaryCompletion":3330,"completion":3331,"start":3332,"enrollment":97,"conditions":3333,"interventions":3336},"NCT02637466","Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers",[88],"2018-07","2019-07","2016-07",[3334,3335],"Unipolar Major Depression","Stage I, II or III Breast Cancer",[3314],{"nctId":3338,"briefTitle":3339,"status":133,"phases":3340,"primaryCompletion":3341,"completion":3342,"start":3343,"enrollment":1583,"conditions":3344,"interventions":3346},"NCT02637895","Vortioxetine for Posttraumatic Stress Disorder",[88],"2020-01-22","2020-02-06","2016-12",[3345],"Post-Traumatic Stress Disorder",[3314],{"trials":3348,"activeCount":97},[],{"intervention":3350,"totalTrials":818,"cells":3351},"Valproate",{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3369,"PHASE4":3371,"NA":3384},{"trials":3353,"activeCount":97},[],{"trials":3355,"activeCount":97},[],{"trials":3357,"activeCount":97},[3358],{"nctId":3359,"briefTitle":3360,"status":133,"phases":3361,"primaryCompletion":136,"completion":136,"start":3362,"enrollment":3363,"conditions":3364,"interventions":3367},"NCT00240110","Valproate Efficacy in Cocaine-Bipolar Comorbidity",[85,86],"2006-03",152,[3365,3366],"Bipolar Disorder","Cocaine Dependence",[3350,3368],"Lithium Carbonate",{"trials":3370,"activeCount":97},[],{"trials":3372,"activeCount":97},[3373],{"nctId":3374,"briefTitle":3375,"status":121,"phases":3376,"primaryCompletion":3377,"completion":3377,"start":3377,"enrollment":97,"conditions":3378,"interventions":3382},"NCT04513314","Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium",[88],"2023-03-28",[3379,3380,3381],"Covid19","Hyperactive Delirium","Pneumonia, Viral",[3350,3383],"Quetiapine",{"trials":3385,"activeCount":97},[],{"intervention":1694,"totalTrials":818,"cells":3387},{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3392,"PHASE3":3398,"PHASE4":3400,"NA":3406},{"trials":3389,"activeCount":97},[],{"trials":3391,"activeCount":97},[],{"trials":3393,"activeCount":97},[3394],{"nctId":1684,"briefTitle":1685,"status":133,"phases":3395,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1344,"conditions":3396,"interventions":3397},[85,86],[1690,1691,1692],[1694,1695,1665,1696],{"trials":3399,"activeCount":97},[],{"trials":3401,"activeCount":97},[3402],{"nctId":3163,"briefTitle":3164,"status":133,"phases":3403,"primaryCompletion":1387,"completion":1387,"start":3166,"enrollment":453,"conditions":3404,"interventions":3405},[88],[3168],[1694,3161,3137],{"trials":3407,"activeCount":97},[],{"intervention":141,"totalTrials":818,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3414,"PHASE3":3416,"PHASE4":3418,"NA":3433},{"trials":3411,"activeCount":97},[],{"trials":3413,"activeCount":97},[],{"trials":3415,"activeCount":97},[],{"trials":3417,"activeCount":97},[],{"trials":3419,"activeCount":97},[3420,3429],{"nctId":3421,"briefTitle":3422,"status":133,"phases":3423,"primaryCompletion":3424,"completion":3424,"start":3425,"enrollment":137,"conditions":3426,"interventions":3427},"NCT02235298","Dapagliflozin Effects on Epicardial Fat",[88],"2020-09-10","2015-09",[139],[3428,141],"Dapagliflozin",{"nctId":131,"briefTitle":132,"status":133,"phases":3430,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":3431,"interventions":3432},[88],[139,128,27],[92,141],{"trials":3434,"activeCount":97},[],{"intervention":3436,"totalTrials":142,"cells":3437},"Liposomal bupivacaine",{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3442,"PHASE3":3444,"PHASE4":3446,"NA":3458},{"trials":3439,"activeCount":97},[],{"trials":3441,"activeCount":97},[],{"trials":3443,"activeCount":97},[],{"trials":3445,"activeCount":97},[],{"trials":3447,"activeCount":97},[3448],{"nctId":3449,"briefTitle":3450,"status":121,"phases":3451,"primaryCompletion":1201,"completion":1201,"start":3452,"enrollment":97,"conditions":3453,"interventions":3457},"NCT04539730","Liposomal Bupivacaine in Adductor Canal Blocks (ACB)",[88],"2021-12-01",[998,3454,3455,3456],"Adductor Canal Block","Peripheral Nerve Block","Opioid Use",[3436],{"trials":3459,"activeCount":97},[],{"intervention":3461,"totalTrials":142,"cells":3462},"Natesto",{"EARLY_PHASE1":3463,"PHASE1":3465,"PHASE2":3467,"PHASE3":3469,"PHASE4":3471,"NA":3481},{"trials":3464,"activeCount":97},[],{"trials":3466,"activeCount":97},[],{"trials":3468,"activeCount":97},[],{"trials":3470,"activeCount":97},[],{"trials":3472,"activeCount":97},[3473],{"nctId":3474,"briefTitle":3475,"status":133,"phases":3476,"primaryCompletion":3477,"completion":3477,"start":3478,"enrollment":113,"conditions":3479,"interventions":3480},"NCT03203681","Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters",[88],"2020-06-01","2017-10-27",[282],[3461],{"trials":3482,"activeCount":97},[],{"intervention":3227,"totalTrials":142,"cells":3484},{"EARLY_PHASE1":3485,"PHASE1":3487,"PHASE2":3489,"PHASE3":3491,"PHASE4":3493,"NA":3499},{"trials":3486,"activeCount":97},[],{"trials":3488,"activeCount":97},[],{"trials":3490,"activeCount":97},[],{"trials":3492,"activeCount":97},[],{"trials":3494,"activeCount":97},[3495],{"nctId":3219,"briefTitle":3220,"status":121,"phases":3496,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":97,"conditions":3497,"interventions":3498},[88],[3225],[3227,1005,3228],{"trials":3500,"activeCount":97},[],{"intervention":3228,"totalTrials":142,"cells":3502},{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3507,"PHASE3":3509,"PHASE4":3511,"NA":3517},{"trials":3504,"activeCount":97},[],{"trials":3506,"activeCount":97},[],{"trials":3508,"activeCount":97},[],{"trials":3510,"activeCount":97},[],{"trials":3512,"activeCount":97},[3513],{"nctId":3219,"briefTitle":3220,"status":121,"phases":3514,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":97,"conditions":3515,"interventions":3516},[88],[3225],[3227,1005,3228],{"trials":3518,"activeCount":97},[],{"intervention":3520,"totalTrials":142,"cells":3521},"Protamine fixed dose",{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3542},{"trials":3523,"activeCount":97},[],{"trials":3525,"activeCount":97},[],{"trials":3527,"activeCount":97},[],{"trials":3529,"activeCount":97},[],{"trials":3531,"activeCount":97},[3532],{"nctId":3533,"briefTitle":3534,"status":133,"phases":3535,"primaryCompletion":3536,"completion":3536,"start":3537,"enrollment":2247,"conditions":3538,"interventions":3540},"NCT05426031","Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass",[88],"2023-06-01","2022-06-28",[3539],"Coagulation; Intravascular",[3520,3541],"Protamine ratio dose",{"trials":3543,"activeCount":97},[],{"intervention":3541,"totalTrials":142,"cells":3545},{"EARLY_PHASE1":3546,"PHASE1":3548,"PHASE2":3550,"PHASE3":3552,"PHASE4":3554,"NA":3560},{"trials":3547,"activeCount":97},[],{"trials":3549,"activeCount":97},[],{"trials":3551,"activeCount":97},[],{"trials":3553,"activeCount":97},[],{"trials":3555,"activeCount":97},[3556],{"nctId":3533,"briefTitle":3534,"status":133,"phases":3557,"primaryCompletion":3536,"completion":3536,"start":3537,"enrollment":2247,"conditions":3558,"interventions":3559},[88],[3539],[3520,3541],{"trials":3561,"activeCount":97},[],{"intervention":3563,"totalTrials":142,"cells":3564},"Insulin Glargine",{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3569,"PHASE3":3571,"PHASE4":3573,"NA":3586},{"trials":3566,"activeCount":97},[],{"trials":3568,"activeCount":97},[],{"trials":3570,"activeCount":97},[],{"trials":3572,"activeCount":97},[],{"trials":3574,"activeCount":97},[3575],{"nctId":3576,"briefTitle":3577,"status":1088,"phases":3578,"primaryCompletion":3579,"completion":3579,"start":3580,"enrollment":2815,"conditions":3581,"interventions":3583},"NCT03660553","Simplified Insulin Regimen for the Elderly",[88],"2022-06-30","2018-10-10",[3582],"Type 2 Diabetes Mellitus",[3563,3563,3584,3585],"Insulin Aspart","Insulin Lispro",{"trials":3587,"activeCount":97},[],{"intervention":3584,"totalTrials":142,"cells":3589},{"EARLY_PHASE1":3590,"PHASE1":3592,"PHASE2":3594,"PHASE3":3596,"PHASE4":3598,"NA":3604},{"trials":3591,"activeCount":97},[],{"trials":3593,"activeCount":97},[],{"trials":3595,"activeCount":97},[],{"trials":3597,"activeCount":97},[],{"trials":3599,"activeCount":97},[3600],{"nctId":3576,"briefTitle":3577,"status":1088,"phases":3601,"primaryCompletion":3579,"completion":3579,"start":3580,"enrollment":2815,"conditions":3602,"interventions":3603},[88],[3582],[3563,3563,3584,3585],{"trials":3605,"activeCount":97},[],{"intervention":3585,"totalTrials":142,"cells":3607},{"EARLY_PHASE1":3608,"PHASE1":3610,"PHASE2":3612,"PHASE3":3614,"PHASE4":3616,"NA":3622},{"trials":3609,"activeCount":97},[],{"trials":3611,"activeCount":97},[],{"trials":3613,"activeCount":97},[],{"trials":3615,"activeCount":97},[],{"trials":3617,"activeCount":97},[3618],{"nctId":3576,"briefTitle":3577,"status":1088,"phases":3619,"primaryCompletion":3579,"completion":3579,"start":3580,"enrollment":2815,"conditions":3620,"interventions":3621},[88],[3582],[3563,3563,3584,3585],{"trials":3623,"activeCount":97},[],{"intervention":3625,"totalTrials":142,"cells":3626},"Mitomycin C",{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3633,"PHASE4":3635,"NA":3646},{"trials":3628,"activeCount":97},[],{"trials":3630,"activeCount":97},[],{"trials":3632,"activeCount":97},[],{"trials":3634,"activeCount":97},[],{"trials":3636,"activeCount":97},[3637],{"nctId":3638,"briefTitle":3639,"status":133,"phases":3640,"primaryCompletion":3641,"completion":3641,"start":3642,"enrollment":3643,"conditions":3644,"interventions":3645},"NCT00666237","Primary Tube Versus Trabeculectomy Study",[88],"2021-04-01","2008-04-01",242,[646],[3625],{"trials":3647,"activeCount":97},[],{"intervention":1001,"totalTrials":142,"cells":3649},{"EARLY_PHASE1":3650,"PHASE1":3652,"PHASE2":3654,"PHASE3":3656,"PHASE4":3658,"NA":3664},{"trials":3651,"activeCount":97},[],{"trials":3653,"activeCount":97},[],{"trials":3655,"activeCount":97},[],{"trials":3657,"activeCount":97},[],{"trials":3659,"activeCount":97},[3660],{"nctId":991,"briefTitle":992,"status":133,"phases":3661,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":3662,"interventions":3663},[88],[358,998,999],[837,839,1001,1002,1003,1004,1005],{"trials":3665,"activeCount":97},[],{"intervention":1003,"totalTrials":142,"cells":3667},{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3674,"PHASE4":3676,"NA":3682},{"trials":3669,"activeCount":97},[],{"trials":3671,"activeCount":97},[],{"trials":3673,"activeCount":97},[],{"trials":3675,"activeCount":97},[],{"trials":3677,"activeCount":97},[3678],{"nctId":991,"briefTitle":992,"status":133,"phases":3679,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":3680,"interventions":3681},[88],[358,998,999],[837,839,1001,1002,1003,1004,1005],{"trials":3683,"activeCount":97},[],{"intervention":3685,"totalTrials":142,"cells":3686},"Botulinum toxin",{"EARLY_PHASE1":3687,"PHASE1":3689,"PHASE2":3691,"PHASE3":3693,"PHASE4":3695,"NA":3707},{"trials":3688,"activeCount":97},[],{"trials":3690,"activeCount":97},[],{"trials":3692,"activeCount":97},[],{"trials":3694,"activeCount":97},[],{"trials":3696,"activeCount":97},[3697],{"nctId":3698,"briefTitle":3699,"status":1088,"phases":3700,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":818,"conditions":3703,"interventions":3706},"NCT06080438","Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure",[88],"2024-07-28","2022-11-29",[3704,3705],"Tears; Excess","Eyelid Spasm",[3685],{"trials":3708,"activeCount":97},[],{"intervention":3710,"totalTrials":142,"cells":3711},"Standard of Care Antibiotic Therapy",{"EARLY_PHASE1":3712,"PHASE1":3714,"PHASE2":3716,"PHASE3":3718,"PHASE4":3720,"NA":3731},{"trials":3713,"activeCount":97},[],{"trials":3715,"activeCount":97},[],{"trials":3717,"activeCount":97},[],{"trials":3719,"activeCount":97},[],{"trials":3721,"activeCount":97},[3722],{"nctId":3723,"briefTitle":3724,"status":1088,"phases":3725,"primaryCompletion":3726,"completion":3726,"start":3727,"enrollment":10,"conditions":3728,"interventions":3730},"NCT05545735","The Duration of Antibiotic Therapy for Early (DATE) Ventilator Associated Pneumonia (VAP): 4 vs. 7 Days",[88],"2025-02-27","2023-05-08",[3729],"Ventilator Associated Pneumonia",[3710],{"trials":3732,"activeCount":97},[],{"intervention":3734,"totalTrials":142,"cells":3735},"Tacrolimus\u002FSirolimus",{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3742,"PHASE4":3744,"NA":3758},{"trials":3737,"activeCount":97},[],{"trials":3739,"activeCount":97},[],{"trials":3741,"activeCount":97},[],{"trials":3743,"activeCount":97},[],{"trials":3745,"activeCount":97},[3746],{"nctId":3747,"briefTitle":3748,"status":133,"phases":3749,"primaryCompletion":3750,"completion":3751,"start":3752,"enrollment":184,"conditions":3753,"interventions":3755},"NCT00681213","Tacrolimus\u002FSirolimus Versus Tacrolimus\u002FMycophenolate Mofetil (MMF) Versus Neoral\u002FSirolimus in Adult, Primary Kidney Transplantation",[88],"2001-12","2002-12","2000-05",[3754],"Adult Primary Kidney Transplantation",[3734,3756,3757],"Tacrolimus\u002FMMF","Neoral\u002FSirolimus",{"trials":3759,"activeCount":97},[],{"intervention":3756,"totalTrials":142,"cells":3761},{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3768,"PHASE4":3770,"NA":3776},{"trials":3763,"activeCount":97},[],{"trials":3765,"activeCount":97},[],{"trials":3767,"activeCount":97},[],{"trials":3769,"activeCount":97},[],{"trials":3771,"activeCount":97},[3772],{"nctId":3747,"briefTitle":3748,"status":133,"phases":3773,"primaryCompletion":3750,"completion":3751,"start":3752,"enrollment":184,"conditions":3774,"interventions":3775},[88],[3754],[3734,3756,3757],{"trials":3777,"activeCount":97},[],{"intervention":3757,"totalTrials":142,"cells":3779},{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3786,"PHASE4":3788,"NA":3794},{"trials":3781,"activeCount":97},[],{"trials":3783,"activeCount":97},[],{"trials":3785,"activeCount":97},[],{"trials":3787,"activeCount":97},[],{"trials":3789,"activeCount":97},[3790],{"nctId":3747,"briefTitle":3748,"status":133,"phases":3791,"primaryCompletion":3750,"completion":3751,"start":3752,"enrollment":184,"conditions":3792,"interventions":3793},[88],[3754],[3734,3756,3757],{"trials":3795,"activeCount":97},[],{"intervention":3797,"totalTrials":142,"cells":3798},"nebivolol",{"EARLY_PHASE1":3799,"PHASE1":3801,"PHASE2":3803,"PHASE3":3805,"PHASE4":3807,"NA":3819},{"trials":3800,"activeCount":97},[],{"trials":3802,"activeCount":97},[],{"trials":3804,"activeCount":97},[],{"trials":3806,"activeCount":97},[],{"trials":3808,"activeCount":97},[3809],{"nctId":3810,"briefTitle":3811,"status":133,"phases":3812,"primaryCompletion":3813,"completion":3814,"start":2868,"enrollment":306,"conditions":3815,"interventions":3817},"NCT00992056","Nebivolol Versus Metoprolol: Sodium Sensitivity",[88],"2012-02","2012-05",[3816],"Hypertension",[3797,3818],"Metoprolol",{"trials":3820,"activeCount":97},[],{"intervention":3818,"totalTrials":142,"cells":3822},{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3829,"PHASE4":3831,"NA":3837},{"trials":3824,"activeCount":97},[],{"trials":3826,"activeCount":97},[],{"trials":3828,"activeCount":97},[],{"trials":3830,"activeCount":97},[],{"trials":3832,"activeCount":97},[3833],{"nctId":3810,"briefTitle":3811,"status":133,"phases":3834,"primaryCompletion":3813,"completion":3814,"start":2868,"enrollment":306,"conditions":3835,"interventions":3836},[88],[3816],[3797,3818],{"trials":3838,"activeCount":97},[],{"intervention":3840,"totalTrials":142,"cells":3841},"Paliperidone Palmitate",{"EARLY_PHASE1":3842,"PHASE1":3844,"PHASE2":3846,"PHASE3":3848,"PHASE4":3850,"NA":3860},{"trials":3843,"activeCount":97},[],{"trials":3845,"activeCount":97},[],{"trials":3847,"activeCount":97},[],{"trials":3849,"activeCount":97},[],{"trials":3851,"activeCount":97},[3852],{"nctId":3853,"briefTitle":3854,"status":121,"phases":3855,"primaryCompletion":3856,"completion":3813,"start":3857,"enrollment":97,"conditions":3858,"interventions":3859},"NCT01211704","Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism",[88],"2011-12","2010-10",[3365],[3840],{"trials":3861,"activeCount":97},[],{"intervention":3863,"totalTrials":142,"cells":3864},"Lopinavir\u002Fritonavir and ritonavir",{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3885},{"trials":3866,"activeCount":97},[],{"trials":3868,"activeCount":97},[],{"trials":3870,"activeCount":97},[],{"trials":3872,"activeCount":97},[],{"trials":3874,"activeCount":97},[3875],{"nctId":3876,"briefTitle":3877,"status":1088,"phases":3878,"primaryCompletion":3879,"completion":3880,"start":1484,"enrollment":1344,"conditions":3881,"interventions":3884},"NCT01700790","Pharmacokinetic Study of Super-boosted Lopinavir\u002FRitonavir Given With Rifampin",[88],"2018-11-17","2018-12-31",[3882,3883],"AIDS","Tuberculosis",[3863],{"trials":3886,"activeCount":97},[],{"intervention":3888,"totalTrials":142,"cells":3889},"Nicorette Gum",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3896,"PHASE4":3898,"NA":3910},{"trials":3891,"activeCount":97},[],{"trials":3893,"activeCount":97},[],{"trials":3895,"activeCount":97},[],{"trials":3897,"activeCount":97},[],{"trials":3899,"activeCount":97},[3900],{"nctId":3901,"briefTitle":3902,"status":133,"phases":3903,"primaryCompletion":3904,"completion":3904,"start":3905,"enrollment":3906,"conditions":3907,"interventions":3908},"NCT02873377","Smoking Cessation in Hispanic Construction Workers",[88],"2018-10-11","2017-04-13",134,[718],[3888,3909],"Nicoderm CQ",{"trials":3911,"activeCount":97},[],{"intervention":3909,"totalTrials":142,"cells":3913},{"EARLY_PHASE1":3914,"PHASE1":3916,"PHASE2":3918,"PHASE3":3920,"PHASE4":3922,"NA":3928},{"trials":3915,"activeCount":97},[],{"trials":3917,"activeCount":97},[],{"trials":3919,"activeCount":97},[],{"trials":3921,"activeCount":97},[],{"trials":3923,"activeCount":97},[3924],{"nctId":3901,"briefTitle":3902,"status":133,"phases":3925,"primaryCompletion":3904,"completion":3904,"start":3905,"enrollment":3906,"conditions":3926,"interventions":3927},[88],[718],[3888,3909],{"trials":3929,"activeCount":97},[],{"intervention":3931,"totalTrials":142,"cells":3932},"Phenylephrine Ophthalmic",{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3939,"PHASE4":3941,"NA":3952},{"trials":3934,"activeCount":97},[],{"trials":3936,"activeCount":97},[],{"trials":3938,"activeCount":97},[],{"trials":3940,"activeCount":97},[],{"trials":3942,"activeCount":97},[3943],{"nctId":3944,"briefTitle":3945,"status":133,"phases":3946,"primaryCompletion":3947,"completion":3947,"start":3948,"enrollment":23,"conditions":3949,"interventions":3951},"NCT05890027","Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation",[88],"2025-04-01","2024-03-19",[3950],"Ptosis, Eyelid",[3931],{"trials":3953,"activeCount":97},[],{"intervention":1490,"totalTrials":142,"cells":3955},{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3962,"PHASE4":3964,"NA":3970},{"trials":3957,"activeCount":97},[],{"trials":3959,"activeCount":97},[],{"trials":3961,"activeCount":97},[],{"trials":3963,"activeCount":97},[],{"trials":3965,"activeCount":97},[3966],{"nctId":1480,"briefTitle":1481,"status":1088,"phases":3967,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":1485,"conditions":3968,"interventions":3969},[88],[1473,1487,1488],[1457,1490],{"trials":3971,"activeCount":97},[],{"intervention":3973,"totalTrials":142,"cells":3974},"Secukinumab",{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3979,"PHASE3":3981,"PHASE4":3983,"NA":3996},{"trials":3976,"activeCount":97},[],{"trials":3978,"activeCount":97},[],{"trials":3980,"activeCount":97},[],{"trials":3982,"activeCount":97},[],{"trials":3984,"activeCount":97},[3985],{"nctId":3986,"briefTitle":3987,"status":133,"phases":3988,"primaryCompletion":3989,"completion":3990,"start":3991,"enrollment":20,"conditions":3992,"interventions":3995},"NCT04717466","Brain Changes in Psoriasis After Secukinumab Treatment",[88],"2024-05-16","2025-03-04","2021-06-29",[3993,3994],"Psoriasis","Healthy",[3973],{"trials":3997,"activeCount":97},[],{"intervention":3999,"totalTrials":142,"cells":4000},"Raltegravir",{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4007,"PHASE4":4009,"NA":4021},{"trials":4002,"activeCount":97},[],{"trials":4004,"activeCount":97},[],{"trials":4006,"activeCount":97},[],{"trials":4008,"activeCount":97},[],{"trials":4010,"activeCount":97},[4011],{"nctId":4012,"briefTitle":4013,"status":1088,"phases":4014,"primaryCompletion":4015,"completion":4016,"start":4017,"enrollment":4018,"conditions":4019,"interventions":4020},"NCT01245101","Addition of Raltegravir to Established Antiretroviral Suppressive Therapy",[88],"2012-10","2013-05","2010-11",15,[3309],[3999,3999],{"trials":4022,"activeCount":97},[],{"intervention":4024,"totalTrials":142,"cells":4025},"Biktarvy 50Mg-200Mg-25Mg",{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4047},{"trials":4027,"activeCount":97},[],{"trials":4029,"activeCount":97},[],{"trials":4031,"activeCount":97},[],{"trials":4033,"activeCount":97},[],{"trials":4035,"activeCount":97},[4036],{"nctId":4037,"briefTitle":4038,"status":133,"phases":4039,"primaryCompletion":4040,"completion":4040,"start":4041,"enrollment":10,"conditions":4042,"interventions":4046},"NCT04650269","Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program",[88],"2023-12-31","2021-03-04",[4043,4044,4045],"Harm Reduction","HIV Infections","Drug Use",[4024],{"trials":4048,"activeCount":97},[],{"intervention":4050,"totalTrials":142,"cells":4051},"Descovy 200Mg 25Mg",{"EARLY_PHASE1":4052,"PHASE1":4054,"PHASE2":4056,"PHASE3":4058,"PHASE4":4060,"NA":4072},{"trials":4053,"activeCount":97},[],{"trials":4055,"activeCount":97},[],{"trials":4057,"activeCount":97},[],{"trials":4059,"activeCount":97},[],{"trials":4061,"activeCount":97},[4062],{"nctId":4063,"briefTitle":4064,"status":133,"phases":4065,"primaryCompletion":4066,"completion":4066,"start":4067,"enrollment":895,"conditions":4068,"interventions":4071},"NCT04782180","PrEP at a Syringe Services Program",[88],"2024-11-11","2022-02-01",[4069,4070],"Hiv","Substance Use Disorders",[4050],{"trials":4073,"activeCount":97},[],{"intervention":4075,"totalTrials":142,"cells":4076},"Linagliptin",{"EARLY_PHASE1":4077,"PHASE1":4079,"PHASE2":4081,"PHASE3":4083,"PHASE4":4085,"NA":4096},{"trials":4078,"activeCount":97},[],{"trials":4080,"activeCount":97},[],{"trials":4082,"activeCount":97},[],{"trials":4084,"activeCount":97},[],{"trials":4086,"activeCount":97},[4087],{"nctId":4088,"briefTitle":4089,"status":121,"phases":4090,"primaryCompletion":4091,"completion":4091,"start":1617,"enrollment":97,"conditions":4092,"interventions":4094},"NCT04341935","Effects of DPP4 Inhibition on COVID-19",[88],"2021-12-30",[4093,139],"Coronavirus Infection",[4075,4095],"Insulin regimen",{"trials":4097,"activeCount":97},[],{"intervention":4095,"totalTrials":142,"cells":4099},{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4104,"PHASE3":4106,"PHASE4":4108,"NA":4114},{"trials":4101,"activeCount":97},[],{"trials":4103,"activeCount":97},[],{"trials":4105,"activeCount":97},[],{"trials":4107,"activeCount":97},[],{"trials":4109,"activeCount":97},[4110],{"nctId":4088,"briefTitle":4089,"status":121,"phases":4111,"primaryCompletion":4091,"completion":4091,"start":1617,"enrollment":97,"conditions":4112,"interventions":4113},[88],[4093,139],[4075,4095],{"trials":4115,"activeCount":97},[],{"intervention":4117,"totalTrials":142,"cells":4118},"Losartan 50 mg",{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4125,"PHASE4":4127,"NA":4140},{"trials":4120,"activeCount":97},[],{"trials":4122,"activeCount":97},[],{"trials":4124,"activeCount":97},[],{"trials":4126,"activeCount":97},[],{"trials":4128,"activeCount":97},[4129],{"nctId":4130,"briefTitle":4131,"status":1088,"phases":4132,"primaryCompletion":4133,"completion":4133,"start":4134,"enrollment":1485,"conditions":4135,"interventions":4138},"NCT02416102","Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis",[88],"2017-04-03","2016-03-31",[4136,4137],"COPD","Chronic Bronchitis",[4117,4139],"Losartan 100 mg",{"trials":4141,"activeCount":97},[],{"intervention":4139,"totalTrials":142,"cells":4143},{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4158},{"trials":4145,"activeCount":97},[],{"trials":4147,"activeCount":97},[],{"trials":4149,"activeCount":97},[],{"trials":4151,"activeCount":97},[],{"trials":4153,"activeCount":97},[4154],{"nctId":4130,"briefTitle":4131,"status":1088,"phases":4155,"primaryCompletion":4133,"completion":4133,"start":4134,"enrollment":1485,"conditions":4156,"interventions":4157},[88],[4136,4137],[4117,4139],{"trials":4159,"activeCount":97},[],{"intervention":4161,"totalTrials":142,"cells":4162},"Oxymetazoline hydrochloride 0.1% ophthalmic solution",{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4169,"PHASE4":4171,"NA":4184},{"trials":4164,"activeCount":97},[],{"trials":4166,"activeCount":97},[],{"trials":4168,"activeCount":97},[],{"trials":4170,"activeCount":97},[],{"trials":4172,"activeCount":97},[4173],{"nctId":4174,"briefTitle":4175,"status":133,"phases":4176,"primaryCompletion":4177,"completion":4177,"start":4178,"enrollment":4179,"conditions":4180,"interventions":4183},"NCT04831047","The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance",[88],"2022-04-01","2021-06-08",114,[3950,4181,4182],"Conjunctiva Inflamed","Eye Manifestations",[4161],{"trials":4185,"activeCount":97},[],{"intervention":3383,"totalTrials":142,"cells":4187},{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4192,"PHASE3":4194,"PHASE4":4196,"NA":4202},{"trials":4189,"activeCount":97},[],{"trials":4191,"activeCount":97},[],{"trials":4193,"activeCount":97},[],{"trials":4195,"activeCount":97},[],{"trials":4197,"activeCount":97},[4198],{"nctId":3374,"briefTitle":3375,"status":121,"phases":4199,"primaryCompletion":3377,"completion":3377,"start":3377,"enrollment":97,"conditions":4200,"interventions":4201},[88],[3379,3380,3381],[3350,3383],{"trials":4203,"activeCount":97},[],{"intervention":4205,"totalTrials":142,"cells":4206},"Nicotine Replacement Therapy",{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4213,"PHASE4":4215,"NA":4226},{"trials":4208,"activeCount":97},[],{"trials":4210,"activeCount":97},[],{"trials":4212,"activeCount":97},[],{"trials":4214,"activeCount":97},[],{"trials":4216,"activeCount":97},[4217],{"nctId":4218,"briefTitle":4219,"status":133,"phases":4220,"primaryCompletion":4221,"completion":4221,"start":4222,"enrollment":4223,"conditions":4224,"interventions":4225},"NCT05030766","Testing Integrative Smoking Cessation for HIV Patients",[88],"2024-05-23","2022-01-04",95,[3308,718,4044],[4205],{"trials":4227,"activeCount":97},[],{"intervention":4229,"totalTrials":142,"cells":4230},"Tacrolimus, Myfortic and Sirolimus",{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4237,"PHASE4":4239,"NA":4250},{"trials":4232,"activeCount":97},[],{"trials":4234,"activeCount":97},[],{"trials":4236,"activeCount":97},[],{"trials":4238,"activeCount":97},[],{"trials":4240,"activeCount":97},[4241],{"nctId":4242,"briefTitle":4243,"status":121,"phases":4244,"primaryCompletion":4245,"completion":4245,"start":4246,"enrollment":97,"conditions":4247,"interventions":4249},"NCT01038505","Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus",[88],"2013-01","2010-01",[4248],"Living Donor Kidney Transplants Patients",[4229],{"trials":4251,"activeCount":97},[],{"intervention":4253,"totalTrials":142,"cells":4254},"Brimonidine tartrate ophthalmic solution 0.025%",{"EARLY_PHASE1":4255,"PHASE1":4257,"PHASE2":4259,"PHASE3":4261,"PHASE4":4263,"NA":4275},{"trials":4256,"activeCount":97},[],{"trials":4258,"activeCount":97},[],{"trials":4260,"activeCount":97},[],{"trials":4262,"activeCount":97},[],{"trials":4264,"activeCount":97},[4265],{"nctId":4266,"briefTitle":4267,"status":133,"phases":4268,"primaryCompletion":4269,"completion":4269,"start":4270,"enrollment":4271,"conditions":4272,"interventions":4274},"NCT03782701","The Effect of Lumify™ Eyedrops on Eyelid Position",[88],"2020-04-01","2019-06-18",43,[4273],"Eyelid Droop",[4253],{"trials":4276,"activeCount":97},[],{"intervention":4278,"totalTrials":142,"cells":4279},"Influenza vaccine",{"EARLY_PHASE1":4280,"PHASE1":4282,"PHASE2":4284,"PHASE3":4286,"PHASE4":4288,"NA":4299},{"trials":4281,"activeCount":97},[],{"trials":4283,"activeCount":97},[],{"trials":4285,"activeCount":97},[],{"trials":4287,"activeCount":97},[],{"trials":4289,"activeCount":97},[4290],{"nctId":4291,"briefTitle":4292,"status":133,"phases":4293,"primaryCompletion":1049,"completion":1049,"start":4294,"enrollment":4295,"conditions":4296,"interventions":4298},"NCT03955991","VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)",[88],"2016-07-21",109,[4297],"Stress",[4278],{"trials":4300,"activeCount":97},[],{"intervention":4302,"totalTrials":142,"cells":4303},"Mupirocin",{"EARLY_PHASE1":4304,"PHASE1":4306,"PHASE2":4308,"PHASE3":4310,"PHASE4":4312,"NA":4324},{"trials":4305,"activeCount":97},[],{"trials":4307,"activeCount":97},[],{"trials":4309,"activeCount":97},[],{"trials":4311,"activeCount":97},[],{"trials":4313,"activeCount":97},[4314],{"nctId":4315,"briefTitle":4316,"status":133,"phases":4317,"primaryCompletion":4318,"completion":4318,"start":4319,"enrollment":4320,"conditions":4321,"interventions":4323},"NCT02218307","The Use of Antibiotic Sinonasal Rinse After Sinus Surgery",[88],"2015-06","2011-11",68,[4322],"Chronic Rhinosinusitis",[4302],{"trials":4325,"activeCount":97},[],{"intervention":4327,"totalTrials":142,"cells":4328},"Aripiprazole Lauroxil",{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4333,"PHASE3":4335,"PHASE4":4337,"NA":4348},{"trials":4330,"activeCount":97},[],{"trials":4332,"activeCount":97},[],{"trials":4334,"activeCount":97},[],{"trials":4336,"activeCount":97},[],{"trials":4338,"activeCount":97},[4339],{"nctId":4340,"briefTitle":4341,"status":1088,"phases":4342,"primaryCompletion":4343,"completion":4343,"start":4344,"enrollment":142,"conditions":4345,"interventions":4347},"NCT05662306","C-Cog in Early Course Schizophrenia Study",[88],"2025-03-03","2024-01-23",[4346],"Schizophrenia",[4327],{"trials":4349,"activeCount":97},[],{"intervention":4351,"totalTrials":142,"cells":4352},"Betadine",{"EARLY_PHASE1":4353,"PHASE1":4355,"PHASE2":4357,"PHASE3":4359,"PHASE4":4361,"NA":4375},{"trials":4354,"activeCount":97},[],{"trials":4356,"activeCount":97},[],{"trials":4358,"activeCount":97},[],{"trials":4360,"activeCount":97},[],{"trials":4362,"activeCount":97},[4363],{"nctId":4364,"briefTitle":4365,"status":4366,"phases":4367,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":4370,"conditions":4371,"interventions":4373},"NCT04981860","Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine","SUSPENDED",[88],"2025-12-01","2021-08-06",230,[4372],"Eye Infections, Bacterial",[4351,4374],"Avenova",{"trials":4376,"activeCount":97},[],{"intervention":4374,"totalTrials":142,"cells":4378},{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4383,"PHASE3":4385,"PHASE4":4387,"NA":4393},{"trials":4380,"activeCount":97},[],{"trials":4382,"activeCount":97},[],{"trials":4384,"activeCount":97},[],{"trials":4386,"activeCount":97},[],{"trials":4388,"activeCount":97},[4389],{"nctId":4364,"briefTitle":4365,"status":4366,"phases":4390,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":4370,"conditions":4391,"interventions":4392},[88],[4372],[4351,4374],{"trials":4394,"activeCount":97},[],{"intervention":4396,"totalTrials":142,"cells":4397},"Jatenzo",{"EARLY_PHASE1":4398,"PHASE1":4400,"PHASE2":4402,"PHASE3":4404,"PHASE4":4406,"NA":4417},{"trials":4399,"activeCount":97},[],{"trials":4401,"activeCount":97},[],{"trials":4403,"activeCount":97},[],{"trials":4405,"activeCount":97},[],{"trials":4407,"activeCount":97},[4408],{"nctId":4409,"briefTitle":4410,"status":133,"phases":4411,"primaryCompletion":4412,"completion":4412,"start":4413,"enrollment":1583,"conditions":4414,"interventions":4416},"NCT04983940","Patient Satisfaction After Switching to Oral Testosterone Undecanoate",[88],"2023-04-06","2021-06-18",[4415],"Testosterone Deficiency",[4396],{"trials":4418,"activeCount":97},[],{"intervention":3428,"totalTrials":142,"cells":4420},{"EARLY_PHASE1":4421,"PHASE1":4423,"PHASE2":4425,"PHASE3":4427,"PHASE4":4429,"NA":4435},{"trials":4422,"activeCount":97},[],{"trials":4424,"activeCount":97},[],{"trials":4426,"activeCount":97},[],{"trials":4428,"activeCount":97},[],{"trials":4430,"activeCount":97},[4431],{"nctId":3421,"briefTitle":3422,"status":133,"phases":4432,"primaryCompletion":3424,"completion":3424,"start":3425,"enrollment":137,"conditions":4433,"interventions":4434},[88],[139],[3428,141],{"trials":4436,"activeCount":97},[],{"intervention":4438,"totalTrials":142,"cells":4439},"PEG-interferon alfa-2b",{"EARLY_PHASE1":4440,"PHASE1":4442,"PHASE2":4444,"PHASE3":4446,"PHASE4":4448,"NA":4461},{"trials":4441,"activeCount":97},[],{"trials":4443,"activeCount":97},[],{"trials":4445,"activeCount":97},[],{"trials":4447,"activeCount":97},[],{"trials":4449,"activeCount":97},[4450],{"nctId":4451,"briefTitle":4452,"status":1088,"phases":4453,"primaryCompletion":2884,"completion":4319,"start":4454,"enrollment":4455,"conditions":4456,"interventions":4458},"NCT00854581","Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia\u002FLymphoma",[88],"2007-11",13,[1116,4457],"Precancerous\u002FNonmalignant Condition",[4438,4459,4460,1139],"Interferon alfa-2b","Valproic Acid",{"trials":4462,"activeCount":97},[],{"intervention":4460,"totalTrials":142,"cells":4464},{"EARLY_PHASE1":4465,"PHASE1":4467,"PHASE2":4469,"PHASE3":4471,"PHASE4":4473,"NA":4479},{"trials":4466,"activeCount":97},[],{"trials":4468,"activeCount":97},[],{"trials":4470,"activeCount":97},[],{"trials":4472,"activeCount":97},[],{"trials":4474,"activeCount":97},[4475],{"nctId":4451,"briefTitle":4452,"status":1088,"phases":4476,"primaryCompletion":2884,"completion":4319,"start":4454,"enrollment":4455,"conditions":4477,"interventions":4478},[88],[1116,4457],[4438,4459,4460,1139],{"trials":4480,"activeCount":97},[],{"intervention":4482,"totalTrials":142,"cells":4483},"Liraglutide Pen Injector [Victoza]",{"EARLY_PHASE1":4484,"PHASE1":4486,"PHASE2":4488,"PHASE3":4490,"PHASE4":4492,"NA":4505},{"trials":4485,"activeCount":97},[],{"trials":4487,"activeCount":97},[],{"trials":4489,"activeCount":97},[],{"trials":4491,"activeCount":97},[],{"trials":4493,"activeCount":97},[4494],{"nctId":4495,"briefTitle":4496,"status":133,"phases":4497,"primaryCompletion":4498,"completion":4498,"start":4499,"enrollment":3156,"conditions":4500,"interventions":4503},"NCT03260881","Liraglutide Effects on Epicardial Fat Inflammatory Genes",[88],"2024-09-05","2018-09-01",[4501,4502],"Type2 Diabetes","Coronary Artery Disease",[4482,4504],"matching liraglutide-placebo pre-filled pens",{"trials":4506,"activeCount":97},[],{"intervention":4504,"totalTrials":142,"cells":4508},{"EARLY_PHASE1":4509,"PHASE1":4511,"PHASE2":4513,"PHASE3":4515,"PHASE4":4517,"NA":4523},{"trials":4510,"activeCount":97},[],{"trials":4512,"activeCount":97},[],{"trials":4514,"activeCount":97},[],{"trials":4516,"activeCount":97},[],{"trials":4518,"activeCount":97},[4519],{"nctId":4495,"briefTitle":4496,"status":133,"phases":4520,"primaryCompletion":4498,"completion":4498,"start":4499,"enrollment":3156,"conditions":4521,"interventions":4522},[88],[4501,4502],[4482,4504],{"trials":4524,"activeCount":97},[],{"intervention":4526,"totalTrials":142,"cells":4527},"Tetracaine drop",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4532,"PHASE3":4534,"PHASE4":4536,"NA":4547},{"trials":4529,"activeCount":97},[],{"trials":4531,"activeCount":97},[],{"trials":4533,"activeCount":97},[],{"trials":4535,"activeCount":97},[],{"trials":4537,"activeCount":97},[4538],{"nctId":4539,"briefTitle":4540,"status":1088,"phases":4541,"primaryCompletion":4542,"completion":4542,"start":2884,"enrollment":2791,"conditions":4543,"interventions":4545},"NCT01383200","Tetracaine Versus Lidocaine Gel for Anesthetic Effect and Comfort in Patients Undergoing LASIK",[88],"2011-10",[4544],"Pain",[4526,4546],"Lidocaine gel",{"trials":4548,"activeCount":97},[],{"intervention":4546,"totalTrials":142,"cells":4550},{"EARLY_PHASE1":4551,"PHASE1":4553,"PHASE2":4555,"PHASE3":4557,"PHASE4":4559,"NA":4565},{"trials":4552,"activeCount":97},[],{"trials":4554,"activeCount":97},[],{"trials":4556,"activeCount":97},[],{"trials":4558,"activeCount":97},[],{"trials":4560,"activeCount":97},[4561],{"nctId":4539,"briefTitle":4540,"status":1088,"phases":4562,"primaryCompletion":4542,"completion":4542,"start":2884,"enrollment":2791,"conditions":4563,"interventions":4564},[88],[4544],[4526,4546],{"trials":4566,"activeCount":97},[],{"intervention":4568,"totalTrials":142,"cells":4569},"Testosterone Cypionate 200 Mg\u002FML",{"EARLY_PHASE1":4570,"PHASE1":4572,"PHASE2":4574,"PHASE3":4576,"PHASE4":4578,"NA":4590},{"trials":4571,"activeCount":97},[],{"trials":4573,"activeCount":97},[],{"trials":4575,"activeCount":97},[],{"trials":4577,"activeCount":97},[],{"trials":4579,"activeCount":97},[4580],{"nctId":4581,"briefTitle":4582,"status":133,"phases":4583,"primaryCompletion":4584,"completion":4584,"start":4585,"enrollment":4586,"conditions":4587,"interventions":4588},"NCT04439799","A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections",[88],"2023-02-09","2020-08-07",81,[282],[4568,4589],"Intranasal Testosterone",{"trials":4591,"activeCount":97},[],{"intervention":4589,"totalTrials":142,"cells":4593},{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4600,"PHASE4":4602,"NA":4608},{"trials":4595,"activeCount":97},[],{"trials":4597,"activeCount":97},[],{"trials":4599,"activeCount":97},[],{"trials":4601,"activeCount":97},[],{"trials":4603,"activeCount":97},[4604],{"nctId":4581,"briefTitle":4582,"status":133,"phases":4605,"primaryCompletion":4584,"completion":4584,"start":4585,"enrollment":4586,"conditions":4606,"interventions":4607},[88],[282],[4568,4589],{"trials":4609,"activeCount":97},[],{"intervention":4611,"totalTrials":142,"cells":4612},"Lidocaine 1% Injectable Solution",{"EARLY_PHASE1":4613,"PHASE1":4615,"PHASE2":4617,"PHASE3":4619,"PHASE4":4621,"NA":4633},{"trials":4614,"activeCount":97},[],{"trials":4616,"activeCount":97},[],{"trials":4618,"activeCount":97},[],{"trials":4620,"activeCount":97},[],{"trials":4622,"activeCount":97},[4623],{"nctId":4624,"briefTitle":4625,"status":121,"phases":4626,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":97,"conditions":4629,"interventions":4631},"NCT05364099","Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries",[88],"2024-01-01","2023-11-27",[4630],"Chronic Shoulder Pain",[4611,4632],"Triamcinolone",{"trials":4634,"activeCount":97},[],{"intervention":4632,"totalTrials":142,"cells":4636},{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4641,"PHASE3":4643,"PHASE4":4645,"NA":4651},{"trials":4638,"activeCount":97},[],{"trials":4640,"activeCount":97},[],{"trials":4642,"activeCount":97},[],{"trials":4644,"activeCount":97},[],{"trials":4646,"activeCount":97},[4647],{"nctId":4624,"briefTitle":4625,"status":121,"phases":4648,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":97,"conditions":4649,"interventions":4650},[88],[4630],[4611,4632],{"trials":4652,"activeCount":97},[],{"intervention":4654,"totalTrials":142,"cells":4655},"CeraVe Hydrating Cleanser",{"EARLY_PHASE1":4656,"PHASE1":4658,"PHASE2":4660,"PHASE3":4662,"PHASE4":4664,"NA":4677},{"trials":4657,"activeCount":97},[],{"trials":4659,"activeCount":97},[],{"trials":4661,"activeCount":97},[],{"trials":4663,"activeCount":97},[],{"trials":4665,"activeCount":97},[4666],{"nctId":4667,"briefTitle":4668,"status":133,"phases":4669,"primaryCompletion":4670,"completion":4670,"start":4671,"enrollment":4672,"conditions":4673,"interventions":4675},"NCT04724967","CeraVe Diabetes Mellitus",[88],"2021-08-10","2021-03-12",528,[4674],"Diabetes Complications",[4654,4676],"CeraVe Moisturizing Cream",{"trials":4678,"activeCount":97},[],{"intervention":4676,"totalTrials":142,"cells":4680},{"EARLY_PHASE1":4681,"PHASE1":4683,"PHASE2":4685,"PHASE3":4687,"PHASE4":4689,"NA":4695},{"trials":4682,"activeCount":97},[],{"trials":4684,"activeCount":97},[],{"trials":4686,"activeCount":97},[],{"trials":4688,"activeCount":97},[],{"trials":4690,"activeCount":97},[4691],{"nctId":4667,"briefTitle":4668,"status":133,"phases":4692,"primaryCompletion":4670,"completion":4670,"start":4671,"enrollment":4672,"conditions":4693,"interventions":4694},[88],[4674],[4654,4676],{"trials":4696,"activeCount":97},[],{"intervention":4698,"totalTrials":142,"cells":4699},"Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab",{"EARLY_PHASE1":4700,"PHASE1":4702,"PHASE2":4704,"PHASE3":4706,"PHASE4":4708,"NA":4719},{"trials":4701,"activeCount":97},[],{"trials":4703,"activeCount":97},[],{"trials":4705,"activeCount":97},[],{"trials":4707,"activeCount":97},[],{"trials":4709,"activeCount":97},[4710],{"nctId":4711,"briefTitle":4712,"status":133,"phases":4713,"primaryCompletion":1360,"completion":2790,"start":4714,"enrollment":3156,"conditions":4715,"interventions":4718},"NCT01046955","Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation",[88],"2005-11",[4716,4717],"End-Stage Renal Disease","Living Donors",[4698],{"trials":4720,"activeCount":97},[],{"intervention":4722,"totalTrials":142,"cells":4723},"Tranexamic acid",{"EARLY_PHASE1":4724,"PHASE1":4726,"PHASE2":4728,"PHASE3":4730,"PHASE4":4732,"NA":4745},{"trials":4725,"activeCount":97},[],{"trials":4727,"activeCount":97},[],{"trials":4729,"activeCount":97},[],{"trials":4731,"activeCount":97},[],{"trials":4733,"activeCount":97},[4734],{"nctId":4735,"briefTitle":4736,"status":121,"phases":4737,"primaryCompletion":331,"completion":331,"start":4738,"enrollment":97,"conditions":4739,"interventions":4744},"NCT05672407","The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery",[88],"2023-09-01",[4740,4741,4742,4743],"Eyelid Diseases","Periorbital Disorder","Hemorrhage","Surgical Blood Loss",[4722],{"trials":4746,"activeCount":97},[],{"intervention":4748,"totalTrials":142,"cells":4749},"Transdermal Nicotine Patch",{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4758,"NA":4769},{"trials":4751,"activeCount":97},[],{"trials":4753,"activeCount":97},[],{"trials":4755,"activeCount":97},[],{"trials":4757,"activeCount":97},[],{"trials":4759,"activeCount":97},[4760],{"nctId":4761,"briefTitle":4762,"status":133,"phases":4763,"primaryCompletion":4764,"completion":4764,"start":4765,"enrollment":4766,"conditions":4767,"interventions":4768},"NCT02511236","Addressing Racial\u002FEthnic Tobacco Health Disparities Via Group Intervention",[88],"2019-10-23","2015-08",356,[718],[4748],{"trials":4770,"activeCount":97},[],{"intervention":4772,"totalTrials":142,"cells":4773},"0.5% hydrocortisone, silicone, vitamin E lotion",{"EARLY_PHASE1":4774,"PHASE1":4776,"PHASE2":4778,"PHASE3":4780,"PHASE4":4782,"NA":4796},{"trials":4775,"activeCount":97},[],{"trials":4777,"activeCount":97},[],{"trials":4779,"activeCount":97},[],{"trials":4781,"activeCount":97},[],{"trials":4783,"activeCount":97},[4784],{"nctId":4785,"briefTitle":4786,"status":133,"phases":4787,"primaryCompletion":4788,"completion":4788,"start":3362,"enrollment":1228,"conditions":4789,"interventions":4793},"NCT00754247","A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars",[88],"2008-02",[4790,4791,4792],"Keloid","Hypertrophic Scar","Cicatrix, Hypertrophic",[4772,4794,4795],"Onion extract gel","Cetearyl alcohol lotion",{"trials":4797,"activeCount":97},[],{"intervention":4794,"totalTrials":142,"cells":4799},{"EARLY_PHASE1":4800,"PHASE1":4802,"PHASE2":4804,"PHASE3":4806,"PHASE4":4808,"NA":4814},{"trials":4801,"activeCount":97},[],{"trials":4803,"activeCount":97},[],{"trials":4805,"activeCount":97},[],{"trials":4807,"activeCount":97},[],{"trials":4809,"activeCount":97},[4810],{"nctId":4785,"briefTitle":4786,"status":133,"phases":4811,"primaryCompletion":4788,"completion":4788,"start":3362,"enrollment":1228,"conditions":4812,"interventions":4813},[88],[4790,4791,4792],[4772,4794,4795],{"trials":4815,"activeCount":97},[],{"intervention":4795,"totalTrials":142,"cells":4817},{"EARLY_PHASE1":4818,"PHASE1":4820,"PHASE2":4822,"PHASE3":4824,"PHASE4":4826,"NA":4832},{"trials":4819,"activeCount":97},[],{"trials":4821,"activeCount":97},[],{"trials":4823,"activeCount":97},[],{"trials":4825,"activeCount":97},[],{"trials":4827,"activeCount":97},[4828],{"nctId":4785,"briefTitle":4786,"status":133,"phases":4829,"primaryCompletion":4788,"completion":4788,"start":3362,"enrollment":1228,"conditions":4830,"interventions":4831},[88],[4790,4791,4792],[4772,4794,4795],{"trials":4833,"activeCount":97},[],{"intervention":4835,"totalTrials":93,"cells":4836},"Acetazolamide",{"EARLY_PHASE1":4837,"PHASE1":4839,"PHASE2":4841,"PHASE3":4859,"PHASE4":4876,"NA":4878},{"trials":4838,"activeCount":97},[],{"trials":4840,"activeCount":97},[],{"trials":4842,"activeCount":97},[4843,4852],{"nctId":4844,"briefTitle":4845,"status":121,"phases":4846,"primaryCompletion":4847,"completion":4847,"start":4848,"enrollment":97,"conditions":4849,"interventions":4851},"NCT04351061","Acetazolamide for the Prevention of Post Operative CSF Leak",[86],"2021-11-24","2020-05-07",[4850],"Cerebrospinal Fluid Leak",[4835],{"nctId":4853,"briefTitle":4854,"status":121,"phases":4855,"primaryCompletion":123,"completion":123,"start":4856,"enrollment":97,"conditions":4857,"interventions":4858},"NCT02902133","Acetazolamide to Prevent Post Operative CSF Leak",[86],"2016-09-01",[4850],[4835],{"trials":4860,"activeCount":97},[4861],{"nctId":4862,"briefTitle":4863,"status":1088,"phases":4864,"primaryCompletion":4865,"completion":4865,"start":3425,"enrollment":4866,"conditions":4867,"interventions":4868},"NCT02390284","Stop Retinal Ganglion Cell Dysfunction Study",[87],"2024-10-04",28,[646],[4869,4870,4871,4872,4873,4874,4835,4875],"Latanoprost","Bimatoprost","Travoprost","Timolol","Dorzolamide","Brinzolamide","Methazolamide",{"trials":4877,"activeCount":97},[],{"trials":4879,"activeCount":97},[],{"intervention":4881,"totalTrials":93,"cells":4882},"Mycophenolate Mofetil",{"EARLY_PHASE1":4883,"PHASE1":4885,"PHASE2":4887,"PHASE3":4904,"PHASE4":4915,"NA":4917},{"trials":4884,"activeCount":97},[],{"trials":4886,"activeCount":97},[],{"trials":4888,"activeCount":97},[4889,4900],{"nctId":4890,"briefTitle":4891,"status":133,"phases":4892,"primaryCompletion":1571,"completion":1571,"start":4893,"enrollment":4894,"conditions":4895,"interventions":4897},"NCT00533442","Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients",[86],"2000-09",170,[4896],"Type 1 Diabetes",[4898,4881,1696,4899],"Rapamycin","Steroids",{"nctId":1684,"briefTitle":1685,"status":133,"phases":4901,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1344,"conditions":4902,"interventions":4903},[85,86],[1690,1691,1692],[1694,1695,1665,1696],{"trials":4905,"activeCount":97},[4906],{"nctId":4907,"briefTitle":4908,"status":133,"phases":4909,"completion":3166,"start":4910,"enrollment":184,"conditions":4911,"interventions":4913},"NCT00533624","Myfortic vs. Cellcept in Kidney Transplant Recipients",[86,87],"2004-12",[4912],"End Stage Renal Disease",[4914,4881],"Mycophenolate Sodium Delayed Release",{"trials":4916,"activeCount":97},[],{"trials":4918,"activeCount":97},[],{"intervention":987,"totalTrials":818,"cells":4920},{"EARLY_PHASE1":4921,"PHASE1":4923,"PHASE2":4925,"PHASE3":4927,"PHASE4":4944,"NA":4946},{"trials":4922,"activeCount":97},[],{"trials":4924,"activeCount":97},[],{"trials":4926,"activeCount":97},[],{"trials":4928,"activeCount":97},[4929,4933],{"nctId":978,"briefTitle":979,"status":133,"phases":4930,"primaryCompletion":981,"completion":981,"start":982,"enrollment":983,"conditions":4931,"interventions":4932},[87],[985],[837,987],{"nctId":4934,"briefTitle":4935,"status":1088,"phases":4936,"primaryCompletion":4937,"completion":4937,"start":4938,"enrollment":4939,"conditions":4940,"interventions":4942},"NCT00235495","Albumin in Acute Ischemic Stroke Trial",[87],"2013-02","2006-06",841,[4941],"Ischemic Stroke",[4943,987],"Albumin",{"trials":4945,"activeCount":97},[],{"trials":4947,"activeCount":97},[],{"intervention":1055,"totalTrials":818,"cells":4949},{"EARLY_PHASE1":4950,"PHASE1":4952,"PHASE2":4954,"PHASE3":4960,"PHASE4":4966,"NA":4968},{"trials":4951,"activeCount":97},[],{"trials":4953,"activeCount":97},[],{"trials":4955,"activeCount":97},[4956],{"nctId":1110,"briefTitle":1111,"status":133,"phases":4957,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":4958,"interventions":4959},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"trials":4961,"activeCount":97},[4962],{"nctId":1045,"briefTitle":1046,"status":121,"phases":4963,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":97,"conditions":4964,"interventions":4965},[87],[1051],[839,1002,1053,1054,1055,1004],{"trials":4967,"activeCount":97},[],{"trials":4969,"activeCount":97},[],{"intervention":4971,"totalTrials":142,"cells":4972},"OOC",{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4977,"PHASE3":4979,"PHASE4":4990,"NA":4992},{"trials":4974,"activeCount":97},[],{"trials":4976,"activeCount":97},[],{"trials":4978,"activeCount":97},[],{"trials":4980,"activeCount":97},[4981],{"nctId":4982,"briefTitle":4983,"status":133,"phases":4984,"primaryCompletion":4985,"completion":4985,"start":4986,"enrollment":1203,"conditions":4987,"interventions":4989},"NCT04993339","Clinical Outcomes of ACL Reconstruction Augmented by an Injectable Osteoconductive\u002FOsteoinductive Compound",[87],"2020-02-20","2016-10-24",[4988],"ACL Injury",[4971],{"trials":4991,"activeCount":97},[],{"trials":4993,"activeCount":97},[],{"intervention":4995,"totalTrials":142,"cells":4996},"Rifaximin",{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5003,"PHASE4":5015,"NA":5017},{"trials":4998,"activeCount":97},[],{"trials":5000,"activeCount":97},[],{"trials":5002,"activeCount":97},[],{"trials":5004,"activeCount":97},[5005],{"nctId":5006,"briefTitle":5007,"status":1088,"phases":5008,"primaryCompletion":5009,"completion":5009,"start":5010,"enrollment":4455,"conditions":5011,"interventions":5013},"NCT00364689","RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial",[87],"2008-07","2006-08",[5012],"Hepatic Encephalopathy",[4995,5014],"Lactulose",{"trials":5016,"activeCount":97},[],{"trials":5018,"activeCount":97},[],{"intervention":5014,"totalTrials":142,"cells":5020},{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5025,"PHASE3":5027,"PHASE4":5033,"NA":5035},{"trials":5022,"activeCount":97},[],{"trials":5024,"activeCount":97},[],{"trials":5026,"activeCount":97},[],{"trials":5028,"activeCount":97},[5029],{"nctId":5006,"briefTitle":5007,"status":1088,"phases":5030,"primaryCompletion":5009,"completion":5009,"start":5010,"enrollment":4455,"conditions":5031,"interventions":5032},[87],[5012],[4995,5014],{"trials":5034,"activeCount":97},[],{"trials":5036,"activeCount":97},[],{"intervention":5038,"totalTrials":142,"cells":5039},"N Acetyl Cysteine",{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5044,"PHASE3":5046,"PHASE4":5058,"NA":5060},{"trials":5041,"activeCount":97},[],{"trials":5043,"activeCount":97},[],{"trials":5045,"activeCount":97},[],{"trials":5047,"activeCount":97},[5048],{"nctId":5049,"briefTitle":5050,"status":1088,"phases":5051,"primaryCompletion":5052,"completion":5052,"start":5053,"enrollment":2815,"conditions":5054,"interventions":5057},"NCT03680911","NAC for Head Trauma-induced Anosmia",[87],"2020-01-07","2018-10-12",[5055,5056],"Anosmia","Head Trauma",[5038],{"trials":5059,"activeCount":97},[],{"trials":5061,"activeCount":97},[],{"intervention":5063,"totalTrials":142,"cells":5064},"Pregabalin",{"EARLY_PHASE1":5065,"PHASE1":5067,"PHASE2":5069,"PHASE3":5071,"PHASE4":5081,"NA":5083},{"trials":5066,"activeCount":97},[],{"trials":5068,"activeCount":97},[],{"trials":5070,"activeCount":97},[],{"trials":5072,"activeCount":97},[5073],{"nctId":5074,"briefTitle":5075,"status":133,"phases":5076,"primaryCompletion":5077,"completion":5077,"start":5078,"enrollment":4271,"conditions":5079,"interventions":5080},"NCT02701764","Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?",[86,87],"2018-12-01","2016-07-26",[1817],[5063],{"trials":5082,"activeCount":97},[],{"trials":5084,"activeCount":97},[],{"intervention":1518,"totalTrials":142,"cells":5086},{"EARLY_PHASE1":5087,"PHASE1":5089,"PHASE2":5091,"PHASE3":5093,"PHASE4":5099,"NA":5101},{"trials":5088,"activeCount":97},[],{"trials":5090,"activeCount":97},[],{"trials":5092,"activeCount":97},[],{"trials":5094,"activeCount":97},[5095],{"nctId":1508,"briefTitle":1509,"status":133,"phases":5096,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":5097,"interventions":5098},[87],[1515,1516],[1518,69],{"trials":5100,"activeCount":97},[],{"trials":5102,"activeCount":97},[],{"intervention":5104,"totalTrials":142,"cells":5105},"Extended release niacin",{"EARLY_PHASE1":5106,"PHASE1":5108,"PHASE2":5110,"PHASE3":5112,"PHASE4":5125,"NA":5127},{"trials":5107,"activeCount":97},[],{"trials":5109,"activeCount":97},[],{"trials":5111,"activeCount":97},[],{"trials":5113,"activeCount":97},[5114],{"nctId":5115,"briefTitle":5116,"status":1088,"phases":5117,"primaryCompletion":5118,"completion":5118,"start":5119,"enrollment":1344,"conditions":5120,"interventions":5124},"NCT00108485","Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy",[87],"2012-12","2005-04",[5121,5122,5123],"Diabetes Mellitus, Type 2","Kidney Failure, Chronic","Hyperlipidemia",[5104],{"trials":5126,"activeCount":97},[],{"trials":5128,"activeCount":97},[],{"intervention":4914,"totalTrials":142,"cells":5130},{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5137,"PHASE4":5143,"NA":5145},{"trials":5132,"activeCount":97},[],{"trials":5134,"activeCount":97},[],{"trials":5136,"activeCount":97},[],{"trials":5138,"activeCount":97},[5139],{"nctId":4907,"briefTitle":4908,"status":133,"phases":5140,"completion":3166,"start":4910,"enrollment":184,"conditions":5141,"interventions":5142},[86,87],[4912],[4914,4881],{"trials":5144,"activeCount":97},[],{"trials":5146,"activeCount":97},[],{"intervention":4869,"totalTrials":142,"cells":5148},{"EARLY_PHASE1":5149,"PHASE1":5151,"PHASE2":5153,"PHASE3":5155,"PHASE4":5161,"NA":5163},{"trials":5150,"activeCount":97},[],{"trials":5152,"activeCount":97},[],{"trials":5154,"activeCount":97},[],{"trials":5156,"activeCount":97},[5157],{"nctId":4862,"briefTitle":4863,"status":1088,"phases":5158,"primaryCompletion":4865,"completion":4865,"start":3425,"enrollment":4866,"conditions":5159,"interventions":5160},[87],[646],[4869,4870,4871,4872,4873,4874,4835,4875],{"trials":5162,"activeCount":97},[],{"trials":5164,"activeCount":97},[],{"intervention":4870,"totalTrials":142,"cells":5166},{"EARLY_PHASE1":5167,"PHASE1":5169,"PHASE2":5171,"PHASE3":5173,"PHASE4":5179,"NA":5181},{"trials":5168,"activeCount":97},[],{"trials":5170,"activeCount":97},[],{"trials":5172,"activeCount":97},[],{"trials":5174,"activeCount":97},[5175],{"nctId":4862,"briefTitle":4863,"status":1088,"phases":5176,"primaryCompletion":4865,"completion":4865,"start":3425,"enrollment":4866,"conditions":5177,"interventions":5178},[87],[646],[4869,4870,4871,4872,4873,4874,4835,4875],{"trials":5180,"activeCount":97},[],{"trials":5182,"activeCount":97},[],{"intervention":4871,"totalTrials":142,"cells":5184},{"EARLY_PHASE1":5185,"PHASE1":5187,"PHASE2":5189,"PHASE3":5191,"PHASE4":5197,"NA":5199},{"trials":5186,"activeCount":97},[],{"trials":5188,"activeCount":97},[],{"trials":5190,"activeCount":97},[],{"trials":5192,"activeCount":97},[5193],{"nctId":4862,"briefTitle":4863,"status":1088,"phases":5194,"primaryCompletion":4865,"completion":4865,"start":3425,"enrollment":4866,"conditions":5195,"interventions":5196},[87],[646],[4869,4870,4871,4872,4873,4874,4835,4875],{"trials":5198,"activeCount":97},[],{"trials":5200,"activeCount":97},[],{"intervention":4872,"totalTrials":142,"cells":5202},{"EARLY_PHASE1":5203,"PHASE1":5205,"PHASE2":5207,"PHASE3":5209,"PHASE4":5215,"NA":5217},{"trials":5204,"activeCount":97},[],{"trials":5206,"activeCount":97},[],{"trials":5208,"activeCount":97},[],{"trials":5210,"activeCount":97},[5211],{"nctId":4862,"briefTitle":4863,"status":1088,"phases":5212,"primaryCompletion":4865,"completion":4865,"start":3425,"enrollment":4866,"conditions":5213,"interventions":5214},[87],[646],[4869,4870,4871,4872,4873,4874,4835,4875],{"trials":5216,"activeCount":97},[],{"trials":5218,"activeCount":97},[],{"intervention":4873,"totalTrials":142,"cells":5220},{"EARLY_PHASE1":5221,"PHASE1":5223,"PHASE2":5225,"PHASE3":5227,"PHASE4":5233,"NA":5235},{"trials":5222,"activeCount":97},[],{"trials":5224,"activeCount":97},[],{"trials":5226,"activeCount":97},[],{"trials":5228,"activeCount":97},[5229],{"nctId":4862,"briefTitle":4863,"status":1088,"phases":5230,"primaryCompletion":4865,"completion":4865,"start":3425,"enrollment":4866,"conditions":5231,"interventions":5232},[87],[646],[4869,4870,4871,4872,4873,4874,4835,4875],{"trials":5234,"activeCount":97},[],{"trials":5236,"activeCount":97},[],{"intervention":4874,"totalTrials":142,"cells":5238},{"EARLY_PHASE1":5239,"PHASE1":5241,"PHASE2":5243,"PHASE3":5245,"PHASE4":5251,"NA":5253},{"trials":5240,"activeCount":97},[],{"trials":5242,"activeCount":97},[],{"trials":5244,"activeCount":97},[],{"trials":5246,"activeCount":97},[5247],{"nctId":4862,"briefTitle":4863,"status":1088,"phases":5248,"primaryCompletion":4865,"completion":4865,"start":3425,"enrollment":4866,"conditions":5249,"interventions":5250},[87],[646],[4869,4870,4871,4872,4873,4874,4835,4875],{"trials":5252,"activeCount":97},[],{"trials":5254,"activeCount":97},[],{"intervention":4875,"totalTrials":142,"cells":5256},{"EARLY_PHASE1":5257,"PHASE1":5259,"PHASE2":5261,"PHASE3":5263,"PHASE4":5269,"NA":5271},{"trials":5258,"activeCount":97},[],{"trials":5260,"activeCount":97},[],{"trials":5262,"activeCount":97},[],{"trials":5264,"activeCount":97},[5265],{"nctId":4862,"briefTitle":4863,"status":1088,"phases":5266,"primaryCompletion":4865,"completion":4865,"start":3425,"enrollment":4866,"conditions":5267,"interventions":5268},[87],[646],[4869,4870,4871,4872,4873,4874,4835,4875],{"trials":5270,"activeCount":97},[],{"trials":5272,"activeCount":97},[],{"intervention":5274,"totalTrials":142,"cells":5275},"Theophylline ER",{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5280,"PHASE3":5282,"PHASE4":5296,"NA":5298},{"trials":5277,"activeCount":97},[],{"trials":5279,"activeCount":97},[],{"trials":5281,"activeCount":97},[],{"trials":5283,"activeCount":97},[5284],{"nctId":5285,"briefTitle":5286,"status":133,"phases":5287,"primaryCompletion":1288,"completion":5288,"start":5289,"enrollment":137,"conditions":5290,"interventions":5295},"NCT03984188","Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD",[87],"2023-12-15","2021-02-23",[4136,5291,5292,5293,5294],"COPD Exacerbation","COPD Exacerbation Acute","Pollution Related Respiratory Disorder","Pollution; Exposure",[5274],{"trials":5297,"activeCount":97},[],{"trials":5299,"activeCount":97},[],{"intervention":5301,"totalTrials":142,"cells":5302},"Advanced therapy only without dietary intervention",{"EARLY_PHASE1":5303,"PHASE1":5305,"PHASE2":5307,"PHASE3":5309,"PHASE4":5321,"NA":5323},{"trials":5304,"activeCount":97},[],{"trials":5306,"activeCount":97},[],{"trials":5308,"activeCount":97},[],{"trials":5310,"activeCount":97},[5311],{"nctId":5312,"briefTitle":5313,"status":133,"phases":5314,"primaryCompletion":5315,"completion":5315,"start":5316,"enrollment":5317,"conditions":5318,"interventions":5320},"NCT04505410","Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis",[87],"2023-12-07","2020-09-18",32,[5319],"Ulcerative Colitis",[5301],{"trials":5322,"activeCount":97},[],{"trials":5324,"activeCount":97},[],{"intervention":5326,"totalTrials":142,"cells":5327},"Arimoclomol",{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5334,"PHASE4":5346,"NA":5348},{"trials":5329,"activeCount":97},[],{"trials":5331,"activeCount":97},[],{"trials":5333,"activeCount":97},[],{"trials":5335,"activeCount":97},[5336],{"nctId":5337,"briefTitle":5338,"status":133,"phases":5339,"primaryCompletion":5340,"completion":5341,"start":5342,"enrollment":3156,"conditions":5343,"interventions":5345},"NCT00706147","Phase II\u002FIII Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis",[86,87],"2014-12","2016-11","2009-01",[5344],"Amyotrophic Lateral Sclerosis",[5326],{"trials":5347,"activeCount":97},[],{"trials":5349,"activeCount":97},[],{"intervention":1053,"totalTrials":142,"cells":5351},{"EARLY_PHASE1":5352,"PHASE1":5354,"PHASE2":5356,"PHASE3":5358,"PHASE4":5364,"NA":5366},{"trials":5353,"activeCount":97},[],{"trials":5355,"activeCount":97},[],{"trials":5357,"activeCount":97},[],{"trials":5359,"activeCount":97},[5360],{"nctId":1045,"briefTitle":1046,"status":121,"phases":5361,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":97,"conditions":5362,"interventions":5363},[87],[1051],[839,1002,1053,1054,1055,1004],{"trials":5365,"activeCount":97},[],{"trials":5367,"activeCount":97},[],{"intervention":1054,"totalTrials":142,"cells":5369},{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5382,"NA":5384},{"trials":5371,"activeCount":97},[],{"trials":5373,"activeCount":97},[],{"trials":5375,"activeCount":97},[],{"trials":5377,"activeCount":97},[5378],{"nctId":1045,"briefTitle":1046,"status":121,"phases":5379,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":97,"conditions":5380,"interventions":5381},[87],[1051],[839,1002,1053,1054,1055,1004],{"trials":5383,"activeCount":97},[],{"trials":5385,"activeCount":97},[],{"intervention":5387,"totalTrials":142,"cells":5388},"fluconazole",{"EARLY_PHASE1":5389,"PHASE1":5391,"PHASE2":5393,"PHASE3":5395,"PHASE4":5406,"NA":5408},{"trials":5390,"activeCount":97},[],{"trials":5392,"activeCount":97},[],{"trials":5394,"activeCount":97},[],{"trials":5396,"activeCount":97},[5397],{"nctId":5398,"briefTitle":5399,"status":133,"phases":5400,"primaryCompletion":4938,"completion":5010,"start":5401,"conditions":5402,"interventions":5405},"NCT00002533","Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer",[86,87],"1993-02",[35,5403,5404],"Infection","Oral Complications",[5387],{"trials":5407,"activeCount":97},[],{"trials":5409,"activeCount":97},[],{"intervention":5411,"totalTrials":142,"cells":5412},"Testopel 75mg Drug Implant",{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5417,"PHASE3":5419,"PHASE4":5432,"NA":5434},{"trials":5414,"activeCount":97},[],{"trials":5416,"activeCount":97},[],{"trials":5418,"activeCount":97},[],{"trials":5420,"activeCount":97},[5421],{"nctId":5422,"briefTitle":5423,"status":133,"phases":5424,"primaryCompletion":5425,"completion":5425,"start":5426,"enrollment":252,"conditions":5427,"interventions":5429},"NCT04523480","Testopel ® vs. Generic Testosterone Pellets.",[87],"2022-12-20","2020-03-12",[5428],"Hypogonadism",[5411,5430,5431],"Testopel 100mg Drug Implant","Testopel 200mg Drug Implant",{"trials":5433,"activeCount":97},[],{"trials":5435,"activeCount":97},[],{"intervention":5430,"totalTrials":142,"cells":5437},{"EARLY_PHASE1":5438,"PHASE1":5440,"PHASE2":5442,"PHASE3":5444,"PHASE4":5450,"NA":5452},{"trials":5439,"activeCount":97},[],{"trials":5441,"activeCount":97},[],{"trials":5443,"activeCount":97},[],{"trials":5445,"activeCount":97},[5446],{"nctId":5422,"briefTitle":5423,"status":133,"phases":5447,"primaryCompletion":5425,"completion":5425,"start":5426,"enrollment":252,"conditions":5448,"interventions":5449},[87],[5428],[5411,5430,5431],{"trials":5451,"activeCount":97},[],{"trials":5453,"activeCount":97},[],{"intervention":5431,"totalTrials":142,"cells":5455},{"EARLY_PHASE1":5456,"PHASE1":5458,"PHASE2":5460,"PHASE3":5462,"PHASE4":5468,"NA":5470},{"trials":5457,"activeCount":97},[],{"trials":5459,"activeCount":97},[],{"trials":5461,"activeCount":97},[],{"trials":5463,"activeCount":97},[5464],{"nctId":5422,"briefTitle":5423,"status":133,"phases":5465,"primaryCompletion":5425,"completion":5425,"start":5426,"enrollment":252,"conditions":5466,"interventions":5467},[87],[5428],[5411,5430,5431],{"trials":5469,"activeCount":97},[],{"trials":5471,"activeCount":97},[],{"intervention":5473,"totalTrials":142,"cells":5474},"pioglitazone",{"EARLY_PHASE1":5475,"PHASE1":5477,"PHASE2":5479,"PHASE3":5481,"PHASE4":5491,"NA":5493},{"trials":5476,"activeCount":97},[],{"trials":5478,"activeCount":97},[],{"trials":5480,"activeCount":97},[],{"trials":5482,"activeCount":97},[5483],{"nctId":5484,"briefTitle":5485,"status":133,"phases":5486,"primaryCompletion":5487,"completion":5487,"start":5488,"enrollment":1228,"conditions":5489,"interventions":5490},"NCT01156597","Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes",[87],"2010-09","2008-04",[3582],[5473],{"trials":5492,"activeCount":97},[],{"trials":5494,"activeCount":97},[],{"intervention":4943,"totalTrials":142,"cells":5496},{"EARLY_PHASE1":5497,"PHASE1":5499,"PHASE2":5501,"PHASE3":5503,"PHASE4":5509,"NA":5511},{"trials":5498,"activeCount":97},[],{"trials":5500,"activeCount":97},[],{"trials":5502,"activeCount":97},[],{"trials":5504,"activeCount":97},[5505],{"nctId":4934,"briefTitle":4935,"status":1088,"phases":5506,"primaryCompletion":4937,"completion":4937,"start":4938,"enrollment":4939,"conditions":5507,"interventions":5508},[87],[4941],[4943,987],{"trials":5510,"activeCount":97},[],{"trials":5512,"activeCount":97},[],{"intervention":5514,"totalTrials":974,"cells":5515},"ranibizumab",{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5547,"PHASE3":5557,"PHASE4":5559,"NA":5561},{"trials":5517,"activeCount":97},[],{"trials":5519,"activeCount":97},[5520,5528,5537],{"nctId":5521,"briefTitle":5522,"status":133,"phases":5523,"primaryCompletion":4319,"completion":2747,"start":5524,"enrollment":1378,"conditions":5525,"interventions":5527},"NCT00768963","Ranibizumab for the Inhibition of Neovascularization in Pterygia",[85],"2008-10",[5526],"Pterygium",[5514,5514],{"nctId":5529,"briefTitle":5530,"status":133,"phases":5531,"primaryCompletion":5532,"completion":5533,"start":1361,"enrollment":923,"conditions":5534,"interventions":5536},"NCT00826618","Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema",[85],"2012-09","2013-09",[5535],"Uveitic Cystoid Macular Edema",[5514],{"nctId":5538,"briefTitle":5539,"status":133,"phases":5540,"primaryCompletion":5541,"completion":5542,"start":5524,"enrollment":1009,"conditions":5543,"interventions":5545},"NCT00769145","Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery",[85],"2011-08","2012-03",[5544],"Corneal Neovascularization",[5546],"Ranibizumab",{"trials":5548,"activeCount":97},[5549],{"nctId":5550,"briefTitle":5551,"status":133,"phases":5552,"primaryCompletion":1645,"completion":1645,"start":5553,"enrollment":765,"conditions":5554,"interventions":5556},"NCT00373659","An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD",[86],"2004-08",[5555],"Neovascular Age-related Macular Degeneration",[5546],{"trials":5558,"activeCount":97},[],{"trials":5560,"activeCount":97},[],{"trials":5562,"activeCount":97},[],{"intervention":1096,"totalTrials":93,"cells":5564},{"EARLY_PHASE1":5565,"PHASE1":5567,"PHASE2":5569,"PHASE3":5583,"PHASE4":5585,"NA":5587},{"trials":5566,"activeCount":97},[],{"trials":5568,"activeCount":97},[],{"trials":5570,"activeCount":97},[5571,5575,5579],{"nctId":1086,"briefTitle":1087,"status":1088,"phases":5572,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1076,"conditions":5573,"interventions":5574},[86],[255],[1095,1096,1065,1080],{"nctId":1098,"briefTitle":1099,"status":133,"phases":5576,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":5577,"interventions":5578},[86],[1105],[1095,1096,1065,1080,1107,1108],{"nctId":1152,"briefTitle":1153,"status":1088,"phases":5580,"primaryCompletion":1091,"completion":1091,"start":1155,"enrollment":1076,"conditions":5581,"interventions":5582},[86],[1157],[1159,1096,1082,1065],{"trials":5584,"activeCount":97},[],{"trials":5586,"activeCount":97},[],{"trials":5588,"activeCount":97},[],{"intervention":5590,"totalTrials":93,"cells":5591},"fenofibrate",{"EARLY_PHASE1":5592,"PHASE1":5594,"PHASE2":5596,"PHASE3":5622,"PHASE4":5624,"NA":5626},{"trials":5593,"activeCount":97},[],{"trials":5595,"activeCount":97},[],{"trials":5597,"activeCount":97},[5598,5605,5612],{"nctId":5599,"briefTitle":5600,"status":1088,"phases":5601,"primaryCompletion":5118,"completion":5118,"start":3857,"enrollment":1066,"conditions":5602,"interventions":5604},"NCT01142323","Pilot Study of Fenofibrate for PSC",[85,86],[5603],"Primary Sclerosing Cholangitis",[5590],{"nctId":5606,"briefTitle":5607,"status":121,"phases":5608,"start":1581,"enrollment":97,"conditions":5609,"interventions":5611},"NCT01141296","Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis",[86],[5610],"Primary Biliary Cirrhosis",[5590],{"nctId":5613,"briefTitle":5614,"status":1088,"phases":5615,"primaryCompletion":5616,"completion":5617,"start":5618,"enrollment":923,"conditions":5619,"interventions":5620},"NCT01965834","Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma",[86],"2016-03-21","2016-07-01","2012-11-19",[834],[5621],"Fenofibrate",{"trials":5623,"activeCount":97},[],{"trials":5625,"activeCount":97},[],{"trials":5627,"activeCount":97},[],{"intervention":2888,"totalTrials":93,"cells":5629},{"EARLY_PHASE1":5630,"PHASE1":5632,"PHASE2":5648,"PHASE3":5659,"PHASE4":5661,"NA":5663},{"trials":5631,"activeCount":97},[],{"trials":5633,"activeCount":97},[5634,5644],{"nctId":5635,"briefTitle":5636,"status":133,"phases":5637,"primaryCompletion":5638,"completion":2868,"start":1092,"enrollment":4455,"conditions":5639,"interventions":5640},"NCT00449137","Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment",[85],"2010-02",[1157],[2888,5641,5642,5643],"Fluorouracil","Leucovorin calcium","Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis",{"nctId":2881,"briefTitle":2882,"status":121,"phases":5645,"primaryCompletion":2884,"completion":2884,"start":1645,"enrollment":97,"conditions":5646,"interventions":5647},[85],[2886],[2888,836,2889,2890],{"trials":5649,"activeCount":97},[5650],{"nctId":5651,"briefTitle":5652,"status":133,"phases":5653,"primaryCompletion":1424,"completion":5654,"start":5655,"enrollment":17,"conditions":5656,"interventions":5657},"NCT00006021","Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma",[85,86],"2007-03","2000-06",[2886],[5658],"arsenic trioxide",{"trials":5660,"activeCount":97},[],{"trials":5662,"activeCount":97},[],{"trials":5664,"activeCount":97},[],{"intervention":1120,"totalTrials":93,"cells":5666},{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5671,"PHASE3":5685,"PHASE4":5687,"NA":5689},{"trials":5668,"activeCount":97},[],{"trials":5670,"activeCount":97},[],{"trials":5672,"activeCount":97},[5673,5677,5681],{"nctId":1110,"briefTitle":1111,"status":133,"phases":5674,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":5675,"interventions":5676},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1141,"briefTitle":1142,"status":133,"phases":5678,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":5679,"interventions":5680},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"nctId":1614,"briefTitle":1615,"status":1088,"phases":5682,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":818,"conditions":5683,"interventions":5684},[86],[1621,1622,1623,1624],[1626,1118,1120,1210,943],{"trials":5686,"activeCount":97},[],{"trials":5688,"activeCount":97},[],{"trials":5690,"activeCount":97},[],{"intervention":1123,"totalTrials":93,"cells":5692},{"EARLY_PHASE1":5693,"PHASE1":5695,"PHASE2":5697,"PHASE3":5711,"PHASE4":5713,"NA":5715},{"trials":5694,"activeCount":97},[],{"trials":5696,"activeCount":97},[],{"trials":5698,"activeCount":97},[5699,5703,5707],{"nctId":1110,"briefTitle":1111,"status":133,"phases":5700,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":5701,"interventions":5702},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1141,"briefTitle":1142,"status":133,"phases":5704,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":5705,"interventions":5706},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"nctId":1568,"briefTitle":1569,"status":1088,"phases":5708,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":5709,"interventions":5710},[86],[1116],[1118,944,945,1576,1123],{"trials":5712,"activeCount":97},[],{"trials":5714,"activeCount":97},[],{"trials":5716,"activeCount":97},[],{"intervention":2764,"totalTrials":818,"cells":5718},{"EARLY_PHASE1":5719,"PHASE1":5721,"PHASE2":5727,"PHASE3":5733,"PHASE4":5735,"NA":5737},{"trials":5720,"activeCount":97},[],{"trials":5722,"activeCount":97},[5723],{"nctId":5635,"briefTitle":5636,"status":133,"phases":5724,"primaryCompletion":5638,"completion":2868,"start":1092,"enrollment":4455,"conditions":5725,"interventions":5726},[85],[1157],[2888,5641,5642,5643],{"trials":5728,"activeCount":97},[5729],{"nctId":2754,"briefTitle":2755,"status":133,"phases":5730,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":5731,"interventions":5732},[85,86],[2761,35],[2763,2731,2764,2765],{"trials":5734,"activeCount":97},[],{"trials":5736,"activeCount":97},[],{"trials":5738,"activeCount":97},[],{"intervention":1125,"totalTrials":818,"cells":5740},{"EARLY_PHASE1":5741,"PHASE1":5743,"PHASE2":5745,"PHASE3":5761,"PHASE4":5763,"NA":5765},{"trials":5742,"activeCount":97},[],{"trials":5744,"activeCount":97},[],{"trials":5746,"activeCount":97},[5747,5757],{"nctId":5748,"briefTitle":5749,"status":1088,"phases":5750,"primaryCompletion":4318,"completion":4318,"start":5751,"enrollment":17,"conditions":5752,"interventions":5753},"NCT00503984","A Phase I\u002FII Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients",[85,86],"2007-05",[19,4544],[5754,1095,1576,5755,5756,1125],"Azacitidine","GADD45α methylation and expression analysis","Pegfilgrastim",{"nctId":1110,"briefTitle":1111,"status":133,"phases":5758,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":5759,"interventions":5760},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"trials":5762,"activeCount":97},[],{"trials":5764,"activeCount":97},[],{"trials":5766,"activeCount":97},[],{"intervention":1649,"totalTrials":818,"cells":5768},{"EARLY_PHASE1":5769,"PHASE1":5771,"PHASE2":5773,"PHASE3":5785,"PHASE4":5787,"NA":5789},{"trials":5770,"activeCount":97},[],{"trials":5772,"activeCount":97},[],{"trials":5774,"activeCount":97},[5775,5779],{"nctId":1642,"briefTitle":1643,"status":133,"phases":5776,"primaryCompletion":1423,"completion":1423,"start":1645,"enrollment":1228,"conditions":5777,"interventions":5778},[86],[25],[1648,1170,1649],{"nctId":5780,"briefTitle":5781,"status":133,"phases":5782,"primaryCompletion":5118,"completion":5118,"start":1361,"enrollment":20,"conditions":5783,"interventions":5784},"NCT00691054","Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy",[86],[1426],[1649],{"trials":5786,"activeCount":97},[],{"trials":5788,"activeCount":97},[],{"trials":5790,"activeCount":97},[],{"intervention":1122,"totalTrials":818,"cells":5792},{"EARLY_PHASE1":5793,"PHASE1":5795,"PHASE2":5797,"PHASE3":5813,"PHASE4":5815,"NA":5817},{"trials":5794,"activeCount":97},[],{"trials":5796,"activeCount":97},[],{"trials":5798,"activeCount":97},[5799,5809],{"nctId":5800,"briefTitle":5801,"status":133,"phases":5802,"primaryCompletion":5803,"completion":5803,"start":5804,"enrollment":818,"conditions":5805,"interventions":5808},"NCT02507336","Long-Term Followup and\u002For Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165",[86],"2023-08-02","2015-11-24",[5806,5807],"Mantle Cell Lymphoma","Non-Hodgkin's Lymphoma",[1122],{"nctId":1110,"briefTitle":1111,"status":133,"phases":5810,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":5811,"interventions":5812},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"trials":5814,"activeCount":97},[],{"trials":5816,"activeCount":97},[],{"trials":5818,"activeCount":97},[],{"intervention":1696,"totalTrials":818,"cells":5820},{"EARLY_PHASE1":5821,"PHASE1":5823,"PHASE2":5825,"PHASE3":5835,"PHASE4":5837,"NA":5839},{"trials":5822,"activeCount":97},[],{"trials":5824,"activeCount":97},[],{"trials":5826,"activeCount":97},[5827,5831],{"nctId":4890,"briefTitle":4891,"status":133,"phases":5828,"primaryCompletion":1571,"completion":1571,"start":4893,"enrollment":4894,"conditions":5829,"interventions":5830},[86],[4896],[4898,4881,1696,4899],{"nctId":1684,"briefTitle":1685,"status":133,"phases":5832,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1344,"conditions":5833,"interventions":5834},[85,86],[1690,1691,1692],[1694,1695,1665,1696],{"trials":5836,"activeCount":97},[],{"trials":5838,"activeCount":97},[],{"trials":5840,"activeCount":97},[],{"intervention":1407,"totalTrials":818,"cells":5842},{"EARLY_PHASE1":5843,"PHASE1":5845,"PHASE2":5847,"PHASE3":5857,"PHASE4":5859,"NA":5861},{"trials":5844,"activeCount":97},[],{"trials":5846,"activeCount":97},[],{"trials":5848,"activeCount":97},[5849,5853],{"nctId":1397,"briefTitle":1398,"status":1088,"phases":5850,"primaryCompletion":1400,"completion":1400,"start":1401,"enrollment":1344,"conditions":5851,"interventions":5852},[85,86],[1403,1404,1405],[1170,1080,1407],{"nctId":2786,"briefTitle":2787,"status":133,"phases":5854,"primaryCompletion":2789,"completion":2789,"start":2790,"enrollment":2791,"conditions":5855,"interventions":5856},[86],[2793],[1210,1220,1407],{"trials":5858,"activeCount":97},[],{"trials":5860,"activeCount":97},[],{"trials":5862,"activeCount":97},[],{"intervention":1124,"totalTrials":818,"cells":5864},{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5869,"PHASE3":5879,"PHASE4":5881,"NA":5883},{"trials":5866,"activeCount":97},[],{"trials":5868,"activeCount":97},[],{"trials":5870,"activeCount":97},[5871,5875],{"nctId":1110,"briefTitle":1111,"status":133,"phases":5872,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":5873,"interventions":5874},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1141,"briefTitle":1142,"status":133,"phases":5876,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":5877,"interventions":5878},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"trials":5880,"activeCount":97},[],{"trials":5882,"activeCount":97},[],{"trials":5884,"activeCount":97},[],{"intervention":5886,"totalTrials":818,"cells":5887},"Autologous Platelet Rich Plasma",{"EARLY_PHASE1":5888,"PHASE1":5890,"PHASE2":5892,"PHASE3":5916,"PHASE4":5918,"NA":5920},{"trials":5889,"activeCount":97},[],{"trials":5891,"activeCount":97},[],{"trials":5893,"activeCount":97},[5894,5905],{"nctId":5895,"briefTitle":5896,"status":133,"phases":5897,"primaryCompletion":5898,"completion":5899,"start":5900,"enrollment":5901,"conditions":5902,"interventions":5904},"NCT04396795","Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.",[86],"2023-01-23","2023-04-18","2020-05-21",61,[5903],"Erectile Dysfunction",[5886],{"nctId":5906,"briefTitle":5907,"status":133,"phases":5908,"primaryCompletion":5909,"completion":5909,"start":5910,"enrollment":5911,"conditions":5912,"interventions":5915},"NCT04512287","PRP for Treatment of Peyronie's Disease",[86],"2025-08-11","2021-03-29",65,[810,5913,5914,812],"Sexual Dysfunction, Physiological","Sexual Dysfunction Male",[5886],{"trials":5917,"activeCount":97},[],{"trials":5919,"activeCount":97},[],{"trials":5921,"activeCount":97},[],{"intervention":5923,"totalTrials":818,"cells":5924},"Recombinant methionyl human leptin",{"EARLY_PHASE1":5925,"PHASE1":5927,"PHASE2":5929,"PHASE3":5948,"PHASE4":5950,"NA":5952},{"trials":5926,"activeCount":97},[],{"trials":5928,"activeCount":97},[],{"trials":5930,"activeCount":97},[5931,5940],{"nctId":5932,"briefTitle":5933,"status":133,"phases":5934,"primaryCompletion":5935,"completion":5935,"start":1092,"enrollment":142,"conditions":5936,"interventions":5939},"NCT00659828","Effects of Leptin Replacement in Children",[86],"2010-04-16",[27,5937,5938],"Metabolic Syndrome","Diabetes",[5923],{"nctId":5941,"briefTitle":5942,"status":133,"phases":5943,"primaryCompletion":5944,"completion":5944,"start":5945,"enrollment":93,"conditions":5946,"interventions":5947},"NCT00657605","Effects of Human Leptin Replacement",[86],"2010-05-04","2001-06",[27,5937,5938],[5923],{"trials":5949,"activeCount":97},[],{"trials":5951,"activeCount":97},[],{"trials":5953,"activeCount":97},[],{"intervention":2763,"totalTrials":142,"cells":5955},{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5960,"PHASE3":5966,"PHASE4":5968,"NA":5970},{"trials":5957,"activeCount":97},[],{"trials":5959,"activeCount":97},[],{"trials":5961,"activeCount":97},[5962],{"nctId":2754,"briefTitle":2755,"status":133,"phases":5963,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":5964,"interventions":5965},[85,86],[2761,35],[2763,2731,2764,2765],{"trials":5967,"activeCount":97},[],{"trials":5969,"activeCount":97},[],{"trials":5971,"activeCount":97},[],{"intervention":5973,"totalTrials":142,"cells":5974},"Lucentis",{"EARLY_PHASE1":5975,"PHASE1":5977,"PHASE2":5979,"PHASE3":5988,"PHASE4":5990,"NA":5992},{"trials":5976,"activeCount":97},[],{"trials":5978,"activeCount":97},[],{"trials":5980,"activeCount":97},[5981],{"nctId":5982,"briefTitle":5983,"status":133,"phases":5984,"completion":1360,"start":5553,"enrollment":765,"conditions":5985,"interventions":5987},"NCT00344227","Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)",[86],[5986],"Neovascular Age-Related Macular Degeneration",[5973],{"trials":5989,"activeCount":97},[],{"trials":5991,"activeCount":97},[],{"trials":5993,"activeCount":97},[],{"intervention":5995,"totalTrials":142,"cells":5996},"Ampyra first, then Placebo",{"EARLY_PHASE1":5997,"PHASE1":5999,"PHASE2":6001,"PHASE3":6011,"PHASE4":6013,"NA":6015},{"trials":5998,"activeCount":97},[],{"trials":6000,"activeCount":97},[],{"trials":6002,"activeCount":97},[6003],{"nctId":6004,"briefTitle":6005,"status":133,"phases":6006,"primaryCompletion":1400,"completion":1400,"start":6007,"enrollment":17,"conditions":6008,"interventions":6010},"NCT01491022","A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease",[85,86],"2012-07",[6009],"Parkinson's Disease",[5995],{"trials":6012,"activeCount":97},[],{"trials":6014,"activeCount":97},[],{"trials":6016,"activeCount":97},[],{"intervention":6018,"totalTrials":142,"cells":6019},"Autologous human mesenchymal cells",{"EARLY_PHASE1":6020,"PHASE1":6022,"PHASE2":6024,"PHASE3":6036,"PHASE4":6038,"NA":6040},{"trials":6021,"activeCount":97},[],{"trials":6023,"activeCount":97},[],{"trials":6025,"activeCount":97},[6026],{"nctId":6027,"briefTitle":6028,"status":133,"phases":6029,"primaryCompletion":6030,"completion":5533,"start":2927,"enrollment":5911,"conditions":6031,"interventions":6034},"NCT00768066","The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)",[85,86],"2012-08",[6032,6033],"Stem Cell Transplantation","Ventricular Dysfunction, Left",[6018,6035],"Autologous human bone marrow cells",{"trials":6037,"activeCount":97},[],{"trials":6039,"activeCount":97},[],{"trials":6041,"activeCount":97},[],{"intervention":6035,"totalTrials":142,"cells":6043},{"EARLY_PHASE1":6044,"PHASE1":6046,"PHASE2":6048,"PHASE3":6054,"PHASE4":6056,"NA":6058},{"trials":6045,"activeCount":97},[],{"trials":6047,"activeCount":97},[],{"trials":6049,"activeCount":97},[6050],{"nctId":6027,"briefTitle":6028,"status":133,"phases":6051,"primaryCompletion":6030,"completion":5533,"start":2927,"enrollment":5911,"conditions":6052,"interventions":6053},[85,86],[6032,6033],[6018,6035],{"trials":6055,"activeCount":97},[],{"trials":6057,"activeCount":97},[],{"trials":6059,"activeCount":97},[],{"intervention":6061,"totalTrials":142,"cells":6062},"Gelfoam slurry",{"EARLY_PHASE1":6063,"PHASE1":6065,"PHASE2":6067,"PHASE3":6077,"PHASE4":6079,"NA":6081},{"trials":6064,"activeCount":97},[],{"trials":6066,"activeCount":97},[],{"trials":6068,"activeCount":97},[6069],{"nctId":6070,"briefTitle":6071,"status":121,"phases":6072,"primaryCompletion":6073,"completion":6073,"start":5077,"enrollment":97,"conditions":6074,"interventions":6076},"NCT03669003","Gelfoam to Prevent Pneumothorax After Lung Biopsy",[86],"2019-12-01",[6075],"Pneumothorax Iatrogenic Postprocedural",[6061],{"trials":6078,"activeCount":97},[],{"trials":6080,"activeCount":97},[],{"trials":6082,"activeCount":97},[],{"intervention":6084,"totalTrials":142,"cells":6085},"Souvenaid",{"EARLY_PHASE1":6086,"PHASE1":6088,"PHASE2":6090,"PHASE3":6102,"PHASE4":6104,"NA":6106},{"trials":6087,"activeCount":97},[],{"trials":6089,"activeCount":97},[],{"trials":6091,"activeCount":97},[6092],{"nctId":6093,"briefTitle":6094,"status":133,"phases":6095,"primaryCompletion":6096,"completion":6096,"start":6097,"enrollment":6098,"conditions":6099,"interventions":6101},"NCT04147624","Reducing the Effects of Aging on Cognition With Therapeutic Intervention of an Oral Nutrient (REACTION): A Pilot Trial",[86],"2022-12-02","2021-06-04",67,[6100],"Cognitive Decline",[6084],{"trials":6103,"activeCount":97},[],{"trials":6105,"activeCount":97},[],{"trials":6107,"activeCount":97},[],{"intervention":6109,"totalTrials":142,"cells":6110},"Porfimer Sodium",{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6124,"PHASE4":6126,"NA":6128},{"trials":6112,"activeCount":97},[],{"trials":6114,"activeCount":97},[],{"trials":6116,"activeCount":97},[6117],{"nctId":6118,"briefTitle":6119,"status":133,"phases":6120,"primaryCompletion":1401,"completion":1387,"start":6121,"enrollment":2929,"conditions":6122,"interventions":6123},"NCT00453336","Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract",[86],"2003-06",[35,4457],[6109],{"trials":6125,"activeCount":97},[],{"trials":6127,"activeCount":97},[],{"trials":6129,"activeCount":97},[],{"intervention":6131,"totalTrials":142,"cells":6132},"Ibritumomab Tiuxetan",{"EARLY_PHASE1":6133,"PHASE1":6135,"PHASE2":6137,"PHASE3":6145,"PHASE4":6147,"NA":6149},{"trials":6134,"activeCount":97},[],{"trials":6136,"activeCount":97},[],{"trials":6138,"activeCount":97},[6139],{"nctId":6140,"briefTitle":6141,"status":133,"phases":6142,"primaryCompletion":2746,"completion":2746,"start":3166,"enrollment":23,"conditions":6143,"interventions":6144},"NCT00453102","Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma",[86],[1624],[1118,6131],{"trials":6146,"activeCount":97},[],{"trials":6148,"activeCount":97},[],{"trials":6150,"activeCount":97},[],{"intervention":6152,"totalTrials":142,"cells":6153},"Auto-hMSCs",{"EARLY_PHASE1":6154,"PHASE1":6156,"PHASE2":6158,"PHASE3":6167,"PHASE4":6169,"NA":6171},{"trials":6155,"activeCount":97},[],{"trials":6157,"activeCount":97},[],{"trials":6159,"activeCount":97},[6160],{"nctId":6161,"briefTitle":6162,"status":133,"phases":6163,"primaryCompletion":1581,"completion":4015,"start":1091,"enrollment":1485,"conditions":6164,"interventions":6165},"NCT01087996","The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)",[85,86],[6032],[6152,6166],"Allo-hMSCs",{"trials":6168,"activeCount":97},[],{"trials":6170,"activeCount":97},[],{"trials":6172,"activeCount":97},[],{"intervention":6166,"totalTrials":142,"cells":6174},{"EARLY_PHASE1":6175,"PHASE1":6177,"PHASE2":6179,"PHASE3":6185,"PHASE4":6187,"NA":6189},{"trials":6176,"activeCount":97},[],{"trials":6178,"activeCount":97},[],{"trials":6180,"activeCount":97},[6181],{"nctId":6161,"briefTitle":6162,"status":133,"phases":6182,"primaryCompletion":1581,"completion":4015,"start":1091,"enrollment":1485,"conditions":6183,"interventions":6184},[85,86],[6032],[6152,6166],{"trials":6186,"activeCount":97},[],{"trials":6188,"activeCount":97},[],{"trials":6190,"activeCount":97},[],{"intervention":5754,"totalTrials":142,"cells":6192},{"EARLY_PHASE1":6193,"PHASE1":6195,"PHASE2":6197,"PHASE3":6203,"PHASE4":6205,"NA":6207},{"trials":6194,"activeCount":97},[],{"trials":6196,"activeCount":97},[],{"trials":6198,"activeCount":97},[6199],{"nctId":5748,"briefTitle":5749,"status":1088,"phases":6200,"primaryCompletion":4318,"completion":4318,"start":5751,"enrollment":17,"conditions":6201,"interventions":6202},[85,86],[19,4544],[5754,1095,1576,5755,5756,1125],{"trials":6204,"activeCount":97},[],{"trials":6206,"activeCount":97},[],{"trials":6208,"activeCount":97},[],{"intervention":5755,"totalTrials":142,"cells":6210},{"EARLY_PHASE1":6211,"PHASE1":6213,"PHASE2":6215,"PHASE3":6221,"PHASE4":6223,"NA":6225},{"trials":6212,"activeCount":97},[],{"trials":6214,"activeCount":97},[],{"trials":6216,"activeCount":97},[6217],{"nctId":5748,"briefTitle":5749,"status":1088,"phases":6218,"primaryCompletion":4318,"completion":4318,"start":5751,"enrollment":17,"conditions":6219,"interventions":6220},[85,86],[19,4544],[5754,1095,1576,5755,5756,1125],{"trials":6222,"activeCount":97},[],{"trials":6224,"activeCount":97},[],{"trials":6226,"activeCount":97},[],{"intervention":5756,"totalTrials":142,"cells":6228},{"EARLY_PHASE1":6229,"PHASE1":6231,"PHASE2":6233,"PHASE3":6239,"PHASE4":6241,"NA":6243},{"trials":6230,"activeCount":97},[],{"trials":6232,"activeCount":97},[],{"trials":6234,"activeCount":97},[6235],{"nctId":5748,"briefTitle":5749,"status":1088,"phases":6236,"primaryCompletion":4318,"completion":4318,"start":5751,"enrollment":17,"conditions":6237,"interventions":6238},[85,86],[19,4544],[5754,1095,1576,5755,5756,1125],{"trials":6240,"activeCount":97},[],{"trials":6242,"activeCount":97},[],{"trials":6244,"activeCount":97},[],{"intervention":6246,"totalTrials":142,"cells":6247},"vinorelbine ditartrate",{"EARLY_PHASE1":6248,"PHASE1":6250,"PHASE2":6252,"PHASE3":6262,"PHASE4":6264,"NA":6266},{"trials":6249,"activeCount":97},[],{"trials":6251,"activeCount":97},[],{"trials":6253,"activeCount":97},[6254],{"nctId":6255,"briefTitle":6256,"status":121,"phases":6257,"primaryCompletion":4015,"completion":4015,"start":6258,"enrollment":97,"conditions":6259,"interventions":6260},"NCT00881387","Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment",[86],"2009-02",[1116],[6261,1381,6246],"rituximab",{"trials":6263,"activeCount":97},[],{"trials":6265,"activeCount":97},[],{"trials":6267,"activeCount":97},[],{"intervention":6269,"totalTrials":142,"cells":6270},"Sucrase",{"EARLY_PHASE1":6271,"PHASE1":6273,"PHASE2":6275,"PHASE3":6286,"PHASE4":6288,"NA":6290},{"trials":6272,"activeCount":97},[],{"trials":6274,"activeCount":97},[],{"trials":6276,"activeCount":97},[6277],{"nctId":6278,"briefTitle":6279,"status":1088,"phases":6280,"primaryCompletion":6281,"completion":6281,"start":6282,"enrollment":93,"conditions":6283,"interventions":6285},"NCT04604275","Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure",[86],"2024-09-01","2022-01-31",[6284],"Short Gut Syndrome",[6269],{"trials":6287,"activeCount":97},[],{"trials":6289,"activeCount":97},[],{"trials":6291,"activeCount":97},[],{"intervention":6293,"totalTrials":142,"cells":6294},"Fluticasone \u002Fsalmeterol",{"EARLY_PHASE1":6295,"PHASE1":6297,"PHASE2":6299,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6296,"activeCount":97},[],{"trials":6298,"activeCount":97},[],{"trials":6300,"activeCount":97},[6301],{"nctId":6302,"briefTitle":6303,"status":121,"phases":6304,"primaryCompletion":3814,"completion":3814,"start":3857,"enrollment":97,"conditions":6305,"interventions":6306},"NCT01209715","Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD",[86],[4136],[6293],{"trials":6308,"activeCount":97},[],{"trials":6310,"activeCount":97},[],{"trials":6312,"activeCount":97},[],{"intervention":6314,"totalTrials":142,"cells":6315},"Belinostat",{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6336,"PHASE4":6338,"NA":6340},{"trials":6317,"activeCount":97},[],{"trials":6319,"activeCount":97},[],{"trials":6321,"activeCount":97},[6322],{"nctId":6323,"briefTitle":6324,"status":133,"phases":6325,"primaryCompletion":6326,"completion":6327,"start":6328,"enrollment":4018,"conditions":6329,"interventions":6332},"NCT02737046","Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma",[86],"2024-12-31","2025-12-31","2016-12-12",[6330,6331],"Adult T-cell Leukemia-Lymphoma","ATLL",[6314,1139,6333,6334,6335],"Interferon-Alfa-2b","Pegylated Interferon-Alfa-2b","Lymphodepleting Therapy",{"trials":6337,"activeCount":97},[],{"trials":6339,"activeCount":97},[],{"trials":6341,"activeCount":97},[],{"intervention":6333,"totalTrials":142,"cells":6343},{"EARLY_PHASE1":6344,"PHASE1":6346,"PHASE2":6348,"PHASE3":6354,"PHASE4":6356,"NA":6358},{"trials":6345,"activeCount":97},[],{"trials":6347,"activeCount":97},[],{"trials":6349,"activeCount":97},[6350],{"nctId":6323,"briefTitle":6324,"status":133,"phases":6351,"primaryCompletion":6326,"completion":6327,"start":6328,"enrollment":4018,"conditions":6352,"interventions":6353},[86],[6330,6331],[6314,1139,6333,6334,6335],{"trials":6355,"activeCount":97},[],{"trials":6357,"activeCount":97},[],{"trials":6359,"activeCount":97},[],{"intervention":6334,"totalTrials":142,"cells":6361},{"EARLY_PHASE1":6362,"PHASE1":6364,"PHASE2":6366,"PHASE3":6372,"PHASE4":6374,"NA":6376},{"trials":6363,"activeCount":97},[],{"trials":6365,"activeCount":97},[],{"trials":6367,"activeCount":97},[6368],{"nctId":6323,"briefTitle":6324,"status":133,"phases":6369,"primaryCompletion":6326,"completion":6327,"start":6328,"enrollment":4018,"conditions":6370,"interventions":6371},[86],[6330,6331],[6314,1139,6333,6334,6335],{"trials":6373,"activeCount":97},[],{"trials":6375,"activeCount":97},[],{"trials":6377,"activeCount":97},[],{"intervention":6335,"totalTrials":142,"cells":6379},{"EARLY_PHASE1":6380,"PHASE1":6382,"PHASE2":6384,"PHASE3":6390,"PHASE4":6392,"NA":6394},{"trials":6381,"activeCount":97},[],{"trials":6383,"activeCount":97},[],{"trials":6385,"activeCount":97},[6386],{"nctId":6323,"briefTitle":6324,"status":133,"phases":6387,"primaryCompletion":6326,"completion":6327,"start":6328,"enrollment":4018,"conditions":6388,"interventions":6389},[86],[6330,6331],[6314,1139,6333,6334,6335],{"trials":6391,"activeCount":97},[],{"trials":6393,"activeCount":97},[],{"trials":6395,"activeCount":97},[],{"intervention":6397,"totalTrials":142,"cells":6398},"Amniotic Membrane Placement",{"EARLY_PHASE1":6399,"PHASE1":6401,"PHASE2":6403,"PHASE3":6413,"PHASE4":6415,"NA":6417},{"trials":6400,"activeCount":97},[],{"trials":6402,"activeCount":97},[],{"trials":6404,"activeCount":97},[6405],{"nctId":6406,"briefTitle":6407,"status":1088,"phases":6408,"primaryCompletion":6409,"completion":6409,"start":6410,"enrollment":306,"conditions":6411,"interventions":6412},"NCT02710422","Miami Membrane for Potency (MMEP) Trial",[86],"2019-01-22","2016-05-17",[19],[6397],{"trials":6414,"activeCount":97},[],{"trials":6416,"activeCount":97},[],{"trials":6418,"activeCount":97},[],{"intervention":1648,"totalTrials":142,"cells":6420},{"EARLY_PHASE1":6421,"PHASE1":6423,"PHASE2":6425,"PHASE3":6431,"PHASE4":6433,"NA":6435},{"trials":6422,"activeCount":97},[],{"trials":6424,"activeCount":97},[],{"trials":6426,"activeCount":97},[6427],{"nctId":1642,"briefTitle":1643,"status":133,"phases":6428,"primaryCompletion":1423,"completion":1423,"start":1645,"enrollment":1228,"conditions":6429,"interventions":6430},[86],[25],[1648,1170,1649],{"trials":6432,"activeCount":97},[],{"trials":6434,"activeCount":97},[],{"trials":6436,"activeCount":97},[],{"intervention":6438,"totalTrials":142,"cells":6439},"Dostarlimab",{"EARLY_PHASE1":6440,"PHASE1":6442,"PHASE2":6444,"PHASE3":6455,"PHASE4":6457,"NA":6459},{"trials":6441,"activeCount":97},[],{"trials":6443,"activeCount":97},[],{"trials":6445,"activeCount":97},[6446],{"nctId":6447,"briefTitle":6448,"status":121,"phases":6449,"primaryCompletion":619,"completion":6450,"start":6451,"enrollment":97,"conditions":6452,"interventions":6454},"NCT05405192","Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia",[86],"2028-12-01","2023-03-01",[6453],"Gestational Trophoblastic Neoplasia",[6438],{"trials":6456,"activeCount":97},[],{"trials":6458,"activeCount":97},[],{"trials":6460,"activeCount":97},[],{"intervention":1107,"totalTrials":142,"cells":6462},{"EARLY_PHASE1":6463,"PHASE1":6465,"PHASE2":6467,"PHASE3":6473,"PHASE4":6475,"NA":6477},{"trials":6464,"activeCount":97},[],{"trials":6466,"activeCount":97},[],{"trials":6468,"activeCount":97},[6469],{"nctId":1098,"briefTitle":1099,"status":133,"phases":6470,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":6471,"interventions":6472},[86],[1105],[1095,1096,1065,1080,1107,1108],{"trials":6474,"activeCount":97},[],{"trials":6476,"activeCount":97},[],{"trials":6478,"activeCount":97},[],{"intervention":1108,"totalTrials":142,"cells":6480},{"EARLY_PHASE1":6481,"PHASE1":6483,"PHASE2":6485,"PHASE3":6491,"PHASE4":6493,"NA":6495},{"trials":6482,"activeCount":97},[],{"trials":6484,"activeCount":97},[],{"trials":6486,"activeCount":97},[6487],{"nctId":1098,"briefTitle":1099,"status":133,"phases":6488,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":6489,"interventions":6490},[86],[1105],[1095,1096,1065,1080,1107,1108],{"trials":6492,"activeCount":97},[],{"trials":6494,"activeCount":97},[],{"trials":6496,"activeCount":97},[],{"intervention":4898,"totalTrials":142,"cells":6498},{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6509,"PHASE4":6511,"NA":6513},{"trials":6500,"activeCount":97},[],{"trials":6502,"activeCount":97},[],{"trials":6504,"activeCount":97},[6505],{"nctId":4890,"briefTitle":4891,"status":133,"phases":6506,"primaryCompletion":1571,"completion":1571,"start":4893,"enrollment":4894,"conditions":6507,"interventions":6508},[86],[4896],[4898,4881,1696,4899],{"trials":6510,"activeCount":97},[],{"trials":6512,"activeCount":97},[],{"trials":6514,"activeCount":97},[],{"intervention":4899,"totalTrials":142,"cells":6516},{"EARLY_PHASE1":6517,"PHASE1":6519,"PHASE2":6521,"PHASE3":6527,"PHASE4":6529,"NA":6531},{"trials":6518,"activeCount":97},[],{"trials":6520,"activeCount":97},[],{"trials":6522,"activeCount":97},[6523],{"nctId":4890,"briefTitle":4891,"status":133,"phases":6524,"primaryCompletion":1571,"completion":1571,"start":4893,"enrollment":4894,"conditions":6525,"interventions":6526},[86],[4896],[4898,4881,1696,4899],{"trials":6528,"activeCount":97},[],{"trials":6530,"activeCount":97},[],{"trials":6532,"activeCount":97},[],{"intervention":6534,"totalTrials":142,"cells":6535},"trastuzumab, docetaxel and carboplatin in dose dense regimen",{"EARLY_PHASE1":6536,"PHASE1":6538,"PHASE2":6540,"PHASE3":6548,"PHASE4":6550,"NA":6552},{"trials":6537,"activeCount":97},[],{"trials":6539,"activeCount":97},[],{"trials":6541,"activeCount":97},[6542],{"nctId":6543,"briefTitle":6544,"status":133,"phases":6545,"primaryCompletion":1376,"completion":1361,"start":1377,"enrollment":937,"conditions":6546,"interventions":6547},"NCT00232479","Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer",[86],[25],[6534],{"trials":6549,"activeCount":97},[],{"trials":6551,"activeCount":97},[],{"trials":6553,"activeCount":97},[],{"intervention":6555,"totalTrials":142,"cells":6556},"Polypodium leucotomos",{"EARLY_PHASE1":6557,"PHASE1":6559,"PHASE2":6561,"PHASE3":6572,"PHASE4":6574,"NA":6576},{"trials":6558,"activeCount":97},[],{"trials":6560,"activeCount":97},[],{"trials":6562,"activeCount":97},[6563],{"nctId":6564,"briefTitle":6565,"status":133,"phases":6566,"primaryCompletion":6567,"completion":6567,"start":1422,"enrollment":1378,"conditions":6568,"interventions":6571},"NCT00520910","Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers",[86],"2009-05",[6569,6570],"Aging","Skin Abnormalities",[6555],{"trials":6573,"activeCount":97},[],{"trials":6575,"activeCount":97},[],{"trials":6577,"activeCount":97},[],{"intervention":6579,"totalTrials":142,"cells":6580},"Ursolic Acid",{"EARLY_PHASE1":6581,"PHASE1":6583,"PHASE2":6585,"PHASE3":6600,"PHASE4":6602,"NA":6604},{"trials":6582,"activeCount":97},[],{"trials":6584,"activeCount":97},[],{"trials":6586,"activeCount":97},[6587],{"nctId":6588,"briefTitle":6589,"status":133,"phases":6590,"primaryCompletion":6591,"completion":6591,"start":6592,"enrollment":1378,"conditions":6593,"interventions":6599},"NCT05776862","Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)",[86],"2025-01-29","2023-03-27",[29,6594,6595,6596,6597,6598],"Tetraplegia","Paraplegia","Muscle Loss","Atrophy, Muscular","Insulin Resistance",[6579],{"trials":6601,"activeCount":97},[],{"trials":6603,"activeCount":97},[],{"trials":6605,"activeCount":97},[],{"intervention":6607,"totalTrials":142,"cells":6608},"Trastuzumab Emtansine",{"EARLY_PHASE1":6609,"PHASE1":6611,"PHASE2":6613,"PHASE3":6622,"PHASE4":6624,"NA":6626},{"trials":6610,"activeCount":97},[],{"trials":6612,"activeCount":97},[],{"trials":6614,"activeCount":97},[6615],{"nctId":6616,"briefTitle":6617,"status":1088,"phases":6618,"primaryCompletion":3904,"completion":3904,"start":6619,"enrollment":818,"conditions":6620,"interventions":6621},"NCT02658084","Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer",[85,86],"2017-04-12",[25,1861],[2812,6607],{"trials":6623,"activeCount":97},[],{"trials":6625,"activeCount":97},[],{"trials":6627,"activeCount":97},[],{"intervention":1126,"totalTrials":142,"cells":6629},{"EARLY_PHASE1":6630,"PHASE1":6632,"PHASE2":6634,"PHASE3":6640,"PHASE4":6642,"NA":6644},{"trials":6631,"activeCount":97},[],{"trials":6633,"activeCount":97},[],{"trials":6635,"activeCount":97},[6636],{"nctId":1110,"briefTitle":1111,"status":133,"phases":6637,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":6638,"interventions":6639},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"trials":6641,"activeCount":97},[],{"trials":6643,"activeCount":97},[],{"trials":6645,"activeCount":97},[],{"intervention":1138,"totalTrials":142,"cells":6647},{"EARLY_PHASE1":6648,"PHASE1":6650,"PHASE2":6652,"PHASE3":6658,"PHASE4":6660,"NA":6662},{"trials":6649,"activeCount":97},[],{"trials":6651,"activeCount":97},[],{"trials":6653,"activeCount":97},[6654],{"nctId":1128,"briefTitle":1129,"status":1088,"phases":6655,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":923,"conditions":6656,"interventions":6657},[86],[1134,1135,1136],[945,1121,1065,1138,1139,1118],{"trials":6659,"activeCount":97},[],{"trials":6661,"activeCount":97},[],{"trials":6663,"activeCount":97},[],{"intervention":6665,"totalTrials":142,"cells":6666},"Kuvan",{"EARLY_PHASE1":6667,"PHASE1":6669,"PHASE2":6671,"PHASE3":6682,"PHASE4":6684,"NA":6686},{"trials":6668,"activeCount":97},[],{"trials":6670,"activeCount":97},[],{"trials":6672,"activeCount":97},[6673],{"nctId":6674,"briefTitle":6675,"status":133,"phases":6676,"primaryCompletion":6677,"completion":6677,"start":2790,"enrollment":6678,"conditions":6679,"interventions":6681},"NCT00841100","Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response",[86],"2011-07-19",21,[6680],"Phenylketonuria",[6665],{"trials":6683,"activeCount":97},[],{"trials":6685,"activeCount":97},[],{"trials":6687,"activeCount":97},[],{"intervention":1150,"totalTrials":142,"cells":6689},{"EARLY_PHASE1":6690,"PHASE1":6692,"PHASE2":6694,"PHASE3":6700,"PHASE4":6702,"NA":6704},{"trials":6691,"activeCount":97},[],{"trials":6693,"activeCount":97},[],{"trials":6695,"activeCount":97},[6696],{"nctId":1141,"briefTitle":1142,"status":133,"phases":6697,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":6698,"interventions":6699},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"trials":6701,"activeCount":97},[],{"trials":6703,"activeCount":97},[],{"trials":6705,"activeCount":97},[],{"intervention":6707,"totalTrials":142,"cells":6708},"L-Histidine",{"EARLY_PHASE1":6709,"PHASE1":6711,"PHASE2":6713,"PHASE3":6724,"PHASE4":6726,"NA":6728},{"trials":6710,"activeCount":97},[],{"trials":6712,"activeCount":97},[],{"trials":6714,"activeCount":97},[6715],{"nctId":6716,"briefTitle":6717,"status":121,"phases":6718,"primaryCompletion":6719,"completion":6719,"start":6720,"enrollment":97,"conditions":6721,"interventions":6722},"NCT04764383","Histaminergic Basis of Fatigue in Multiple Sclerosis",[86],"2022-10-30","2022-01-01",[852],[6707,6723],"Lodosyn",{"trials":6725,"activeCount":97},[],{"trials":6727,"activeCount":97},[],{"trials":6729,"activeCount":97},[],{"intervention":6723,"totalTrials":142,"cells":6731},{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6736,"PHASE3":6742,"PHASE4":6744,"NA":6746},{"trials":6733,"activeCount":97},[],{"trials":6735,"activeCount":97},[],{"trials":6737,"activeCount":97},[6738],{"nctId":6716,"briefTitle":6717,"status":121,"phases":6739,"primaryCompletion":6719,"completion":6719,"start":6720,"enrollment":97,"conditions":6740,"interventions":6741},[86],[852],[6707,6723],{"trials":6743,"activeCount":97},[],{"trials":6745,"activeCount":97},[],{"trials":6747,"activeCount":97},[],{"intervention":6749,"totalTrials":142,"cells":6750},"ADI-PEG-20",{"EARLY_PHASE1":6751,"PHASE1":6753,"PHASE2":6755,"PHASE3":6766,"PHASE4":6768,"NA":6770},{"trials":6752,"activeCount":97},[],{"trials":6754,"activeCount":97},[],{"trials":6756,"activeCount":97},[6757],{"nctId":6758,"briefTitle":6759,"status":133,"phases":6760,"primaryCompletion":6761,"completion":3813,"start":6762,"enrollment":3156,"conditions":6763,"interventions":6765},"NCT00450372","Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery",[86],"2011-01","2004-06",[6764],"Melanoma (Skin)",[6749],{"trials":6767,"activeCount":97},[],{"trials":6769,"activeCount":97},[],{"trials":6771,"activeCount":97},[],{"intervention":6773,"totalTrials":142,"cells":6774},"irinotecan hydrochloride",{"EARLY_PHASE1":6775,"PHASE1":6777,"PHASE2":6779,"PHASE3":6789,"PHASE4":6791,"NA":6793},{"trials":6776,"activeCount":97},[],{"trials":6778,"activeCount":97},[],{"trials":6780,"activeCount":97},[6781],{"nctId":6782,"briefTitle":6783,"status":133,"phases":6784,"primaryCompletion":5751,"completion":6785,"start":6786,"enrollment":5317,"conditions":6787,"interventions":6788},"NCT00449020","Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer",[86],"2008-01","2004-01",[1390],[1210,1095,6773],{"trials":6790,"activeCount":97},[],{"trials":6792,"activeCount":97},[],{"trials":6794,"activeCount":97},[],{"intervention":6796,"totalTrials":142,"cells":6797},"Islet Transplantation and Bone Marrow",{"EARLY_PHASE1":6798,"PHASE1":6800,"PHASE2":6802,"PHASE3":6812,"PHASE4":6814,"NA":6816},{"trials":6799,"activeCount":97},[],{"trials":6801,"activeCount":97},[],{"trials":6803,"activeCount":97},[6804],{"nctId":6805,"briefTitle":6806,"status":1088,"phases":6807,"primaryCompletion":2868,"completion":2868,"start":6808,"enrollment":93,"conditions":6809,"interventions":6811},"NCT00315614","Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus",[86],"2000-12",[6810],"Type 1 Diabetes Mellitus",[6796],{"trials":6813,"activeCount":97},[],{"trials":6815,"activeCount":97},[],{"trials":6817,"activeCount":97},[],{"intervention":6819,"totalTrials":142,"cells":6820},"Losartan",{"EARLY_PHASE1":6821,"PHASE1":6823,"PHASE2":6825,"PHASE3":6837,"PHASE4":6839,"NA":6841},{"trials":6822,"activeCount":97},[],{"trials":6824,"activeCount":97},[],{"trials":6826,"activeCount":97},[6827],{"nctId":6828,"briefTitle":6829,"status":1088,"phases":6830,"primaryCompletion":6831,"completion":6832,"start":6833,"enrollment":2815,"conditions":6834,"interventions":6836},"NCT03206788","Losartan and Inflammation in Cystic Fibrosis",[86],"2019-10-24","2019-12-30","2017-11-11",[6835],"Cystic Fibrosis",[6819],{"trials":6838,"activeCount":97},[],{"trials":6840,"activeCount":97},[],{"trials":6842,"activeCount":97},[],{"intervention":2780,"totalTrials":142,"cells":6844},{"EARLY_PHASE1":6845,"PHASE1":6847,"PHASE2":6849,"PHASE3":6855,"PHASE4":6857,"NA":6859},{"trials":6846,"activeCount":97},[],{"trials":6848,"activeCount":97},[],{"trials":6850,"activeCount":97},[6851],{"nctId":2771,"briefTitle":2772,"status":133,"phases":6852,"primaryCompletion":2774,"completion":2774,"start":2775,"conditions":6853,"interventions":6854},[86],[2777],[2731,2779,2780],{"trials":6856,"activeCount":97},[],{"trials":6858,"activeCount":97},[],{"trials":6860,"activeCount":97},[],{"intervention":3368,"totalTrials":142,"cells":6862},{"EARLY_PHASE1":6863,"PHASE1":6865,"PHASE2":6867,"PHASE3":6873,"PHASE4":6875,"NA":6877},{"trials":6864,"activeCount":97},[],{"trials":6866,"activeCount":97},[],{"trials":6868,"activeCount":97},[6869],{"nctId":3359,"briefTitle":3360,"status":133,"phases":6870,"primaryCompletion":136,"completion":136,"start":3362,"enrollment":3363,"conditions":6871,"interventions":6872},[85,86],[3365,3366],[3350,3368],{"trials":6874,"activeCount":97},[],{"trials":6876,"activeCount":97},[],{"trials":6878,"activeCount":97},[],{"intervention":1626,"totalTrials":142,"cells":6880},{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6885,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6882,"activeCount":97},[],{"trials":6884,"activeCount":97},[],{"trials":6886,"activeCount":97},[6887],{"nctId":1614,"briefTitle":1615,"status":1088,"phases":6888,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":818,"conditions":6889,"interventions":6890},[86],[1621,1622,1623,1624],[1626,1118,1120,1210,943],{"trials":6892,"activeCount":97},[],{"trials":6894,"activeCount":97},[],{"trials":6896,"activeCount":97},[],{"intervention":6898,"totalTrials":142,"cells":6899},"Dietary Sources",{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6916,"PHASE4":6918,"NA":6920},{"trials":6901,"activeCount":97},[],{"trials":6903,"activeCount":97},[],{"trials":6905,"activeCount":97},[6906],{"nctId":6907,"briefTitle":6908,"status":121,"phases":6909,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":97,"conditions":6913,"interventions":6915},"NCT02827747","The Role of Antioxidant Supplementation in Keratoconus Patients",[86],"2022-07","2023-03","2021-08-01",[6914],"Keratoconus",[6898],{"trials":6917,"activeCount":97},[],{"trials":6919,"activeCount":97},[],{"trials":6921,"activeCount":97},[],{"intervention":6923,"totalTrials":142,"cells":6924},"Autologous Platelet-Rich Plasma",{"EARLY_PHASE1":6925,"PHASE1":6927,"PHASE2":6929,"PHASE3":6940,"PHASE4":6942,"NA":6944},{"trials":6926,"activeCount":97},[],{"trials":6928,"activeCount":97},[],{"trials":6930,"activeCount":97},[6931],{"nctId":6932,"briefTitle":6933,"status":1088,"phases":6934,"primaryCompletion":6935,"completion":6935,"start":6936,"enrollment":818,"conditions":6937,"interventions":6939},"NCT05525572","Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM)",[85,86],"2024-08-02","2024-02-12",[6938],"Erectile Dysfunction With Diabetes Mellitus",[6923],{"trials":6941,"activeCount":97},[],{"trials":6943,"activeCount":97},[],{"trials":6945,"activeCount":97},[],{"intervention":6947,"totalTrials":142,"cells":6948},"Allogeneic B7.1\u002FHLA-A1",{"EARLY_PHASE1":6949,"PHASE1":6951,"PHASE2":6953,"PHASE3":6961,"PHASE4":6963,"NA":6965},{"trials":6950,"activeCount":97},[],{"trials":6952,"activeCount":97},[],{"trials":6954,"activeCount":97},[6955],{"nctId":6956,"briefTitle":6957,"status":1088,"phases":6958,"primaryCompletion":1101,"completion":1101,"start":5342,"enrollment":142,"conditions":6959,"interventions":6960},"NCT00534209","Vaccine Therapy in Patients With Stages IIIB\u002FIV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy",[85,86],[1390],[6947],{"trials":6962,"activeCount":97},[],{"trials":6964,"activeCount":97},[],{"trials":6966,"activeCount":97},[],{"intervention":6968,"totalTrials":142,"cells":6969},"Roflumilast Placebo",{"EARLY_PHASE1":6970,"PHASE1":6972,"PHASE2":6974,"PHASE3":6983,"PHASE4":6985,"NA":6987},{"trials":6971,"activeCount":97},[],{"trials":6973,"activeCount":97},[],{"trials":6975,"activeCount":97},[6976],{"nctId":6977,"briefTitle":6978,"status":133,"phases":6979,"primaryCompletion":1113,"completion":1113,"start":4937,"enrollment":2791,"conditions":6980,"interventions":6981},"NCT02097992","Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD",[85,86],[4136],[6968,6982],"Roflumilast",{"trials":6984,"activeCount":97},[],{"trials":6986,"activeCount":97},[],{"trials":6988,"activeCount":97},[],{"intervention":6982,"totalTrials":142,"cells":6990},{"EARLY_PHASE1":6991,"PHASE1":6993,"PHASE2":6995,"PHASE3":7001,"PHASE4":7003,"NA":7005},{"trials":6992,"activeCount":97},[],{"trials":6994,"activeCount":97},[],{"trials":6996,"activeCount":97},[6997],{"nctId":6977,"briefTitle":6978,"status":133,"phases":6998,"primaryCompletion":1113,"completion":1113,"start":4937,"enrollment":2791,"conditions":6999,"interventions":7000},[85,86],[4136],[6968,6982],{"trials":7002,"activeCount":97},[],{"trials":7004,"activeCount":97},[],{"trials":7006,"activeCount":97},[],{"intervention":7008,"totalTrials":142,"cells":7009},"Cemiplimab-Rwlc",{"EARLY_PHASE1":7010,"PHASE1":7012,"PHASE2":7014,"PHASE3":7028,"PHASE4":7030,"NA":7032},{"trials":7011,"activeCount":97},[],{"trials":7013,"activeCount":97},[],{"trials":7015,"activeCount":97},[7016],{"nctId":7017,"briefTitle":7018,"status":121,"phases":7019,"primaryCompletion":7020,"completion":7020,"start":6910,"enrollment":97,"conditions":7021,"interventions":7027},"NCT04831450","Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)",[86],"2022-07-15",[7022,7023,7024,7025,7026],"Head and Neck Squamous Cell Carcinoma","HNSCC","Squamous Cell Carcinoma of the Larynx","Squamous Cell Carcinoma of the Oral Cavity","Squamous Cell Carcinoma of Hypopharynx",[7008],{"trials":7029,"activeCount":97},[],{"trials":7031,"activeCount":97},[],{"trials":7033,"activeCount":97},[],{"intervention":7035,"totalTrials":142,"cells":7036},"Liftactiv B3",{"EARLY_PHASE1":7037,"PHASE1":7039,"PHASE2":7041,"PHASE3":7054,"PHASE4":7056,"NA":7058},{"trials":7038,"activeCount":97},[],{"trials":7040,"activeCount":97},[],{"trials":7042,"activeCount":97},[7043],{"nctId":7044,"briefTitle":7045,"status":1088,"phases":7046,"primaryCompletion":7047,"completion":7048,"start":7049,"enrollment":4455,"conditions":7050,"interventions":7053},"NCT05327361","LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)",[86],"2023-01-17","2023-03-06","2022-03-22",[7051,7052],"Acne","Post Inflammatory Hyperpigmentation",[7035],{"trials":7055,"activeCount":97},[],{"trials":7057,"activeCount":97},[],{"trials":7059,"activeCount":97},[],{"intervention":7061,"totalTrials":142,"cells":7062},"Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting",{"EARLY_PHASE1":7063,"PHASE1":7065,"PHASE2":7067,"PHASE3":7079,"PHASE4":7081,"NA":7083},{"trials":7064,"activeCount":97},[],{"trials":7066,"activeCount":97},[],{"trials":7068,"activeCount":97},[7069],{"nctId":7070,"briefTitle":7071,"status":133,"phases":7072,"primaryCompletion":7073,"completion":7073,"start":7074,"enrollment":137,"conditions":7075,"interventions":7077},"NCT05319860","Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)",[86],"2024-04-15","2022-08-01",[7076],"Chemotherapy-induced Nausea and Vomiting",[7061,7078],"Aromatherapy Care",{"trials":7080,"activeCount":97},[],{"trials":7082,"activeCount":97},[],{"trials":7084,"activeCount":97},[],{"intervention":7078,"totalTrials":142,"cells":7086},{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7091,"PHASE3":7097,"PHASE4":7099,"NA":7101},{"trials":7088,"activeCount":97},[],{"trials":7090,"activeCount":97},[],{"trials":7092,"activeCount":97},[7093],{"nctId":7070,"briefTitle":7071,"status":133,"phases":7094,"primaryCompletion":7073,"completion":7073,"start":7074,"enrollment":137,"conditions":7095,"interventions":7096},[86],[7076],[7061,7078],{"trials":7098,"activeCount":97},[],{"trials":7100,"activeCount":97},[],{"trials":7102,"activeCount":97},[],{"intervention":1041,"totalTrials":142,"cells":7104},{"EARLY_PHASE1":7105,"PHASE1":7107,"PHASE2":7109,"PHASE3":7115,"PHASE4":7117,"NA":7119},{"trials":7106,"activeCount":97},[],{"trials":7108,"activeCount":97},[],{"trials":7110,"activeCount":97},[7111],{"nctId":1033,"briefTitle":1034,"status":133,"phases":7112,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":30,"conditions":7113,"interventions":7114},[85,86],[1039],[839,1041],{"trials":7116,"activeCount":97},[],{"trials":7118,"activeCount":97},[],{"trials":7120,"activeCount":97},[],{"intervention":7122,"totalTrials":142,"cells":7123},"Naltrexone hydrochloride",{"EARLY_PHASE1":7124,"PHASE1":7126,"PHASE2":7128,"PHASE3":7140,"PHASE4":7142,"NA":7144},{"trials":7125,"activeCount":97},[],{"trials":7127,"activeCount":97},[],{"trials":7129,"activeCount":97},[7130],{"nctId":7131,"briefTitle":7132,"status":133,"phases":7133,"primaryCompletion":7134,"completion":7135,"start":1424,"enrollment":7136,"conditions":7137,"interventions":7139},"NCT00302133","Optimizing Pharmacotherapy for Bipolar Alcoholics",[85,86],"2013-04","2013-07",88,[3365,7138],"Alcohol Dependence",[7122],{"trials":7141,"activeCount":97},[],{"trials":7143,"activeCount":97},[],{"trials":7145,"activeCount":97},[],{"intervention":7147,"totalTrials":142,"cells":7148},"Erbitux",{"EARLY_PHASE1":7149,"PHASE1":7151,"PHASE2":7153,"PHASE3":7166,"PHASE4":7168,"NA":7170},{"trials":7150,"activeCount":97},[],{"trials":7152,"activeCount":97},[],{"trials":7154,"activeCount":97},[7155],{"nctId":7156,"briefTitle":7157,"status":1088,"phases":7158,"primaryCompletion":7159,"completion":7159,"start":7160,"enrollment":1009,"conditions":7161,"interventions":7164},"NCT01794845","Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma",[86],"2016-06-07","2013-06-03",[7162,35,7163],"Squamous Cell Carcinoma","Recurrent Disease",[7147,7165],"Taxotere",{"trials":7167,"activeCount":97},[],{"trials":7169,"activeCount":97},[],{"trials":7171,"activeCount":97},[],{"intervention":7165,"totalTrials":142,"cells":7173},{"EARLY_PHASE1":7174,"PHASE1":7176,"PHASE2":7178,"PHASE3":7184,"PHASE4":7186,"NA":7188},{"trials":7175,"activeCount":97},[],{"trials":7177,"activeCount":97},[],{"trials":7179,"activeCount":97},[7180],{"nctId":7156,"briefTitle":7157,"status":1088,"phases":7181,"primaryCompletion":7159,"completion":7159,"start":7160,"enrollment":1009,"conditions":7182,"interventions":7183},[86],[7162,35,7163],[7147,7165],{"trials":7185,"activeCount":97},[],{"trials":7187,"activeCount":97},[],{"trials":7189,"activeCount":97},[],{"intervention":1586,"totalTrials":142,"cells":7191},{"EARLY_PHASE1":7192,"PHASE1":7194,"PHASE2":7196,"PHASE3":7202,"PHASE4":7204,"NA":7206},{"trials":7193,"activeCount":97},[],{"trials":7195,"activeCount":97},[],{"trials":7197,"activeCount":97},[7198],{"nctId":1578,"briefTitle":1579,"status":133,"phases":7199,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":7200,"interventions":7201},[86],[25],[944,1095,945,1586],{"trials":7203,"activeCount":97},[],{"trials":7205,"activeCount":97},[],{"trials":7207,"activeCount":97},[],{"intervention":7209,"totalTrials":142,"cells":7210},"Albuterol",{"EARLY_PHASE1":7211,"PHASE1":7213,"PHASE2":7215,"PHASE3":7226,"PHASE4":7228,"NA":7230},{"trials":7212,"activeCount":97},[],{"trials":7214,"activeCount":97},[],{"trials":7216,"activeCount":97},[7217],{"nctId":7218,"briefTitle":7219,"status":133,"phases":7220,"primaryCompletion":7221,"completion":7221,"start":7222,"enrollment":1378,"conditions":7223,"interventions":7225},"NCT03270332","Effect of Inhaled Albuterol in Pulmonary Hypertension",[86],"2020-07-02","2017-10-05",[7224],"Pulmonary Hypertension",[7209],{"trials":7227,"activeCount":97},[],{"trials":7229,"activeCount":97},[],{"trials":7231,"activeCount":97},[],{"intervention":7233,"totalTrials":142,"cells":7234},"Platelet Rich Plasma",{"EARLY_PHASE1":7235,"PHASE1":7237,"PHASE2":7248,"PHASE3":7250,"PHASE4":7252,"NA":7254},{"trials":7236,"activeCount":97},[],{"trials":7238,"activeCount":97},[7239],{"nctId":7240,"briefTitle":7241,"status":133,"phases":7242,"primaryCompletion":7243,"completion":7243,"start":7244,"enrollment":7245,"conditions":7246,"interventions":7247},"NCT05048667","Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction",[85],"2025-03-14","2022-06-27",59,[5903],[7233],{"trials":7249,"activeCount":97},[],{"trials":7251,"activeCount":97},[],{"trials":7253,"activeCount":97},[],{"trials":7255,"activeCount":97},[],{"intervention":7257,"totalTrials":142,"cells":7258},"Tranylcypromine",{"EARLY_PHASE1":7259,"PHASE1":7261,"PHASE2":7276,"PHASE3":7278,"PHASE4":7280,"NA":7282},{"trials":7260,"activeCount":97},[],{"trials":7262,"activeCount":97},[7263],{"nctId":7264,"briefTitle":7265,"status":133,"phases":7266,"primaryCompletion":7267,"completion":7268,"start":7269,"enrollment":30,"conditions":7270,"interventions":7274},"NCT02273102","Study of TCP-ATRA for Adult Patients With AML and MDS",[85],"2018-11-08","2020-07-01","2015-03-02",[7271,7272,7273],"Acute Myelogenous Leukemia","Myelodysplastic Syndromes","Leukemia",[7257,7275],"Tretinoin",{"trials":7277,"activeCount":97},[],{"trials":7279,"activeCount":97},[],{"trials":7281,"activeCount":97},[],{"trials":7283,"activeCount":97},[],{"intervention":7275,"totalTrials":142,"cells":7285},{"EARLY_PHASE1":7286,"PHASE1":7288,"PHASE2":7294,"PHASE3":7296,"PHASE4":7298,"NA":7300},{"trials":7287,"activeCount":97},[],{"trials":7289,"activeCount":97},[7290],{"nctId":7264,"briefTitle":7265,"status":133,"phases":7291,"primaryCompletion":7267,"completion":7268,"start":7269,"enrollment":30,"conditions":7292,"interventions":7293},[85],[7271,7272,7273],[7257,7275],{"trials":7295,"activeCount":97},[],{"trials":7297,"activeCount":97},[],{"trials":7299,"activeCount":97},[],{"trials":7301,"activeCount":97},[],{"intervention":2732,"totalTrials":142,"cells":7303},{"EARLY_PHASE1":7304,"PHASE1":7306,"PHASE2":7312,"PHASE3":7314,"PHASE4":7316,"NA":7318},{"trials":7305,"activeCount":97},[],{"trials":7307,"activeCount":97},[7308],{"nctId":2725,"briefTitle":2726,"status":133,"phases":7309,"primaryCompletion":2728,"completion":2728,"start":1114,"enrollment":142,"conditions":7310,"interventions":7311},[85],[35],[2731,2732,2733],{"trials":7313,"activeCount":97},[],{"trials":7315,"activeCount":97},[],{"trials":7317,"activeCount":97},[],{"trials":7319,"activeCount":97},[],{"intervention":2733,"totalTrials":142,"cells":7321},{"EARLY_PHASE1":7322,"PHASE1":7324,"PHASE2":7330,"PHASE3":7332,"PHASE4":7334,"NA":7336},{"trials":7323,"activeCount":97},[],{"trials":7325,"activeCount":97},[7326],{"nctId":2725,"briefTitle":2726,"status":133,"phases":7327,"primaryCompletion":2728,"completion":2728,"start":1114,"enrollment":142,"conditions":7328,"interventions":7329},[85],[35],[2731,2732,2733],{"trials":7331,"activeCount":97},[],{"trials":7333,"activeCount":97},[],{"trials":7335,"activeCount":97},[],{"trials":7337,"activeCount":97},[],{"intervention":1539,"totalTrials":142,"cells":7339},{"EARLY_PHASE1":7340,"PHASE1":7342,"PHASE2":7348,"PHASE3":7350,"PHASE4":7352,"NA":7354},{"trials":7341,"activeCount":97},[],{"trials":7343,"activeCount":97},[7344],{"nctId":1530,"briefTitle":1531,"status":121,"phases":7345,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":97,"conditions":7346,"interventions":7347},[85],[1537],[1539,945,1540],{"trials":7349,"activeCount":97},[],{"trials":7351,"activeCount":97},[],{"trials":7353,"activeCount":97},[],{"trials":7355,"activeCount":97},[],{"intervention":1540,"totalTrials":142,"cells":7357},{"EARLY_PHASE1":7358,"PHASE1":7360,"PHASE2":7366,"PHASE3":7368,"PHASE4":7370,"NA":7372},{"trials":7359,"activeCount":97},[],{"trials":7361,"activeCount":97},[7362],{"nctId":1530,"briefTitle":1531,"status":121,"phases":7363,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":97,"conditions":7364,"interventions":7365},[85],[1537],[1539,945,1540],{"trials":7367,"activeCount":97},[],{"trials":7369,"activeCount":97},[],{"trials":7371,"activeCount":97},[],{"trials":7373,"activeCount":97},[],{"intervention":7375,"totalTrials":142,"cells":7376},"Ad100-gp96Ig-HLA A1",{"EARLY_PHASE1":7377,"PHASE1":7379,"PHASE2":7388,"PHASE3":7390,"PHASE4":7392,"NA":7394},{"trials":7378,"activeCount":97},[],{"trials":7380,"activeCount":97},[7381],{"nctId":7382,"briefTitle":7383,"status":133,"phases":7384,"primaryCompletion":6030,"completion":6030,"start":5751,"enrollment":7385,"conditions":7386,"interventions":7387},"NCT00503568","Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy",[85],19,[1390],[7375],{"trials":7389,"activeCount":97},[],{"trials":7391,"activeCount":97},[],{"trials":7393,"activeCount":97},[],{"trials":7395,"activeCount":97},[],{"intervention":7397,"totalTrials":142,"cells":7398},"celecoxib",{"EARLY_PHASE1":7399,"PHASE1":7401,"PHASE2":7411,"PHASE3":7413,"PHASE4":7415,"NA":7417},{"trials":7400,"activeCount":97},[],{"trials":7402,"activeCount":97},[7403],{"nctId":7404,"briefTitle":7405,"status":133,"phases":7406,"primaryCompletion":6567,"completion":6567,"start":7407,"enrollment":93,"conditions":7408,"interventions":7410},"NCT00450736","Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery",[85],"2004-03",[7409,2777],"Childhood Malignant Fibrous Histiocytoma of Bone",[7397],{"trials":7412,"activeCount":97},[],{"trials":7414,"activeCount":97},[],{"trials":7416,"activeCount":97},[],{"trials":7418,"activeCount":97},[],{"intervention":5643,"totalTrials":142,"cells":7420},{"EARLY_PHASE1":7421,"PHASE1":7423,"PHASE2":7429,"PHASE3":7431,"PHASE4":7433,"NA":7435},{"trials":7422,"activeCount":97},[],{"trials":7424,"activeCount":97},[7425],{"nctId":5635,"briefTitle":5636,"status":133,"phases":7426,"primaryCompletion":5638,"completion":2868,"start":1092,"enrollment":4455,"conditions":7427,"interventions":7428},[85],[1157],[2888,5641,5642,5643],{"trials":7430,"activeCount":97},[],{"trials":7432,"activeCount":97},[],{"trials":7434,"activeCount":97},[],{"trials":7436,"activeCount":97},[],{"intervention":7438,"totalTrials":142,"cells":7439},"Pyridostigmine",{"EARLY_PHASE1":7440,"PHASE1":7442,"PHASE2":7453,"PHASE3":7455,"PHASE4":7457,"NA":7459},{"trials":7441,"activeCount":97},[],{"trials":7443,"activeCount":97},[7444],{"nctId":7445,"briefTitle":7446,"status":133,"phases":7447,"primaryCompletion":7448,"completion":7448,"start":7449,"enrollment":33,"conditions":7450,"interventions":7452},"NCT03063515","AchE Inhibitor and Insulin",[85],"2018-12-14","2017-04-19",[7451],"Diabetes Mellitus",[7438],{"trials":7454,"activeCount":97},[],{"trials":7456,"activeCount":97},[],{"trials":7458,"activeCount":97},[],{"trials":7460,"activeCount":97},[],{"intervention":7462,"totalTrials":142,"cells":7463},"Imiquimod, 5% cream",{"EARLY_PHASE1":7464,"PHASE1":7466,"PHASE2":7475,"PHASE3":7477,"PHASE4":7479,"NA":7481},{"trials":7465,"activeCount":97},[],{"trials":7467,"activeCount":97},[7468],{"nctId":7469,"briefTitle":7470,"status":133,"phases":7471,"primaryCompletion":7472,"completion":7472,"start":4788,"enrollment":93,"conditions":7473,"interventions":7474},"NCT00638651","Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal",[85],"2014-08",[3994],[7462],{"trials":7476,"activeCount":97},[],{"trials":7478,"activeCount":97},[],{"trials":7480,"activeCount":97},[],{"trials":7482,"activeCount":97},[],{"intervention":7484,"totalTrials":142,"cells":7485},"OpenBiome Fecal Microbiota Transplantation retention enema",{"EARLY_PHASE1":7486,"PHASE1":7488,"PHASE2":7499,"PHASE3":7501,"PHASE4":7503,"NA":7505},{"trials":7487,"activeCount":97},[],{"trials":7489,"activeCount":97},[7490],{"nctId":7491,"briefTitle":7492,"status":121,"phases":7493,"primaryCompletion":7494,"completion":7495,"start":3332,"enrollment":97,"conditions":7496,"interventions":7498},"NCT02816437","FMT for MDRO Colonization in Solid Organ Transplant",[85],"2022-10","2022-12",[7497],"Infection Due to Resistant Organism",[7484],{"trials":7500,"activeCount":97},[],{"trials":7502,"activeCount":97},[],{"trials":7504,"activeCount":97},[],{"trials":7506,"activeCount":97},[],{"intervention":7508,"totalTrials":142,"cells":7509},"Collagenase ointment",{"EARLY_PHASE1":7510,"PHASE1":7512,"PHASE2":7523,"PHASE3":7525,"PHASE4":7527,"NA":7529},{"trials":7511,"activeCount":97},[],{"trials":7513,"activeCount":97},[7514],{"nctId":7515,"briefTitle":7516,"status":133,"phases":7517,"primaryCompletion":4318,"completion":4318,"start":7518,"enrollment":974,"conditions":7519,"interventions":7522},"NCT02131961","EZCast-DFU Study With Portal for Application of Topical Medications",[85],"2014-10",[7520,7521],"Foot Ulcer","Diabetic Foot",[7508],{"trials":7524,"activeCount":97},[],{"trials":7526,"activeCount":97},[],{"trials":7528,"activeCount":97},[],{"trials":7530,"activeCount":97},[],{"intervention":7532,"totalTrials":142,"cells":7533},"Carbidopa",{"EARLY_PHASE1":7534,"PHASE1":7536,"PHASE2":7545,"PHASE3":7547,"PHASE4":7549,"NA":7551},{"trials":7535,"activeCount":97},[],{"trials":7537,"activeCount":97},[7538],{"nctId":7539,"briefTitle":7540,"status":133,"phases":7541,"primaryCompletion":4585,"completion":4585,"start":7542,"enrollment":23,"conditions":7543,"interventions":7544},"NCT03266965","Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach",[85],"2018-03-23",[852],[7532],{"trials":7546,"activeCount":97},[],{"trials":7548,"activeCount":97},[],{"trials":7550,"activeCount":97},[],{"trials":7552,"activeCount":97},[],{"intervention":2750,"totalTrials":142,"cells":7554},{"EARLY_PHASE1":7555,"PHASE1":7557,"PHASE2":7563,"PHASE3":7565,"PHASE4":7567,"NA":7569},{"trials":7556,"activeCount":97},[],{"trials":7558,"activeCount":97},[7559],{"nctId":2743,"briefTitle":2744,"status":133,"phases":7560,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":1066,"conditions":7561,"interventions":7562},[85],[1218],[2750,1220],{"trials":7564,"activeCount":97},[],{"trials":7566,"activeCount":97},[],{"trials":7568,"activeCount":97},[],{"trials":7570,"activeCount":97},[],{"intervention":7572,"totalTrials":142,"cells":7573},"vytorin",{"EARLY_PHASE1":7574,"PHASE1":7576,"PHASE2":7587,"PHASE3":7589,"PHASE4":7591,"NA":7593},{"trials":7575,"activeCount":97},[],{"trials":7577,"activeCount":97},[7578],{"nctId":7579,"briefTitle":7580,"status":133,"phases":7581,"primaryCompletion":7582,"completion":7582,"start":7583,"enrollment":1103,"conditions":7584,"interventions":7586},"NCT01520077","Vytorin in the Treatment of Alopecia Areata",[85],"2015-01","2011-07",[7585],"Alopecia Areata",[7572],{"trials":7588,"activeCount":97},[],{"trials":7590,"activeCount":97},[],{"trials":7592,"activeCount":97},[],{"trials":7594,"activeCount":97},[],{"intervention":2890,"totalTrials":142,"cells":7596},{"EARLY_PHASE1":7597,"PHASE1":7599,"PHASE2":7605,"PHASE3":7607,"PHASE4":7609,"NA":7611},{"trials":7598,"activeCount":97},[],{"trials":7600,"activeCount":97},[7601],{"nctId":2881,"briefTitle":2882,"status":121,"phases":7602,"primaryCompletion":2884,"completion":2884,"start":1645,"enrollment":97,"conditions":7603,"interventions":7604},[85],[2886],[2888,836,2889,2890],{"trials":7606,"activeCount":97},[],{"trials":7608,"activeCount":97},[],{"trials":7610,"activeCount":97},[],{"trials":7612,"activeCount":97},[],{"intervention":7614,"totalTrials":142,"cells":7615},"FMP-30",{"EARLY_PHASE1":7616,"PHASE1":7618,"PHASE2":7628,"PHASE3":7630,"PHASE4":7632,"NA":7634},{"trials":7617,"activeCount":97},[],{"trials":7619,"activeCount":97},[7620],{"nctId":7621,"briefTitle":7622,"status":133,"phases":7623,"primaryCompletion":3477,"completion":3477,"start":7624,"enrollment":1378,"conditions":7625,"interventions":7627},"NCT03926286","Fecal Microbial Transplant (FMT) for Sjogrens Syndrome",[85],"2019-04-15",[7626],"Sjogren's Syndrome",[7614],{"trials":7629,"activeCount":97},[],{"trials":7631,"activeCount":97},[],{"trials":7633,"activeCount":97},[],{"trials":7635,"activeCount":97},[],{"intervention":7637,"totalTrials":142,"cells":7638},"propranolol",{"EARLY_PHASE1":7639,"PHASE1":7641,"PHASE2":7652,"PHASE3":7654,"PHASE4":7656,"NA":7658},{"trials":7640,"activeCount":97},[],{"trials":7642,"activeCount":97},[7643],{"nctId":7644,"briefTitle":7645,"status":1088,"phases":7646,"primaryCompletion":7647,"completion":7648,"start":2928,"enrollment":1344,"conditions":7649,"interventions":7651},"NCT02012777","Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease",[85],"2012-11","2013-04-03",[7650],"Sickle Cell Disease",[7637],{"trials":7653,"activeCount":97},[],{"trials":7655,"activeCount":97},[],{"trials":7657,"activeCount":97},[],{"trials":7659,"activeCount":97},[],{"intervention":7661,"totalTrials":142,"cells":7662},"Tetracaine 0.5%",{"EARLY_PHASE1":7663,"PHASE1":7676,"PHASE2":7678,"PHASE3":7680,"PHASE4":7682,"NA":7684},{"trials":7664,"activeCount":97},[7665],{"nctId":7666,"briefTitle":7667,"status":121,"phases":7668,"primaryCompletion":7669,"completion":7670,"start":7671,"enrollment":97,"conditions":7672,"interventions":7674},"NCT02955524","Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma",[84],"2020-06","2020-12","2018-03",[7673],"Hemodynamic Instability",[7661,7675],"Lidocaine hydrochloride ophthalmic gel 3.5%",{"trials":7677,"activeCount":97},[],{"trials":7679,"activeCount":97},[],{"trials":7681,"activeCount":97},[],{"trials":7683,"activeCount":97},[],{"trials":7685,"activeCount":97},[],{"intervention":7675,"totalTrials":142,"cells":7687},{"EARLY_PHASE1":7688,"PHASE1":7694,"PHASE2":7696,"PHASE3":7698,"PHASE4":7700,"NA":7702},{"trials":7689,"activeCount":97},[7690],{"nctId":7666,"briefTitle":7667,"status":121,"phases":7691,"primaryCompletion":7669,"completion":7670,"start":7671,"enrollment":97,"conditions":7692,"interventions":7693},[84],[7673],[7661,7675],{"trials":7695,"activeCount":97},[],{"trials":7697,"activeCount":97},[],{"trials":7699,"activeCount":97},[],{"trials":7701,"activeCount":97},[],{"trials":7703,"activeCount":97},[],{"intervention":7705,"totalTrials":142,"cells":7706},"Tono-pen XL Applanation tonometer + Ocu-film +",{"EARLY_PHASE1":7707,"PHASE1":7718,"PHASE2":7720,"PHASE3":7722,"PHASE4":7724,"NA":7726},{"trials":7708,"activeCount":97},[7709],{"nctId":7710,"briefTitle":7711,"status":133,"phases":7712,"primaryCompletion":7713,"completion":7713,"start":4245,"enrollment":252,"conditions":7714,"interventions":7717},"NCT01925391","The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops",[84],"2014-05",[646,7715,7716],"Intraocular Pressure","Anesthesia",[7705],{"trials":7719,"activeCount":97},[],{"trials":7721,"activeCount":97},[],{"trials":7723,"activeCount":97},[],{"trials":7725,"activeCount":97},[],{"trials":7727,"activeCount":97},[],{"intervention":7729,"totalTrials":142,"cells":7730},"Vorinostat",{"EARLY_PHASE1":7731,"PHASE1":7741,"PHASE2":7743,"PHASE3":7745,"PHASE4":7747,"NA":7749},{"trials":7732,"activeCount":97},[7733],{"nctId":7734,"briefTitle":7735,"status":121,"phases":7736,"primaryCompletion":7737,"completion":7737,"start":7738,"enrollment":97,"conditions":7739,"interventions":7740},"NCT03022565","Vorinostat in Patients With Class 2 High Risk Uveal Melanoma",[84],"2020-01-29","2020-01",[2587],[7729],{"trials":7742,"activeCount":97},[],{"trials":7744,"activeCount":97},[],{"trials":7746,"activeCount":97},[],{"trials":7748,"activeCount":97},[],{"trials":7750,"activeCount":97},[],{"intervention":7752,"totalTrials":142,"cells":7753},"AZ6244",{"EARLY_PHASE1":7754,"PHASE1":7763,"PHASE2":7765,"PHASE3":7767,"PHASE4":7769,"NA":7771},{"trials":7755,"activeCount":97},[7756],{"nctId":7757,"briefTitle":7758,"status":133,"phases":7759,"primaryCompletion":7760,"completion":7760,"start":2869,"enrollment":974,"conditions":7761,"interventions":7762},"NCT01313039","Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative\u002FLow Breast Cancer",[84],"2014-04",[25],[7752],{"trials":7764,"activeCount":97},[],{"trials":7766,"activeCount":97},[],{"trials":7768,"activeCount":97},[],{"trials":7770,"activeCount":97},[],{"trials":7772,"activeCount":97},[],{"intervention":7774,"totalTrials":142,"cells":7775},"Povidone-iodine 5% solution",{"EARLY_PHASE1":7776,"PHASE1":7788,"PHASE2":7790,"PHASE3":7792,"PHASE4":7794,"NA":7796},{"trials":7777,"activeCount":97},[7778],{"nctId":7779,"briefTitle":7780,"status":133,"phases":7781,"primaryCompletion":7782,"completion":7782,"start":5077,"enrollment":6678,"conditions":7783,"interventions":7785},"NCT02990013","AvenovaTM as a Sterile Skin Preparation Agent",[84],"2019-12-20",[7784],"Cleaning Product Causing Toxic Effect",[7774,7786,7787],"4% chlorhexidine","Isopropyl alcohol",{"trials":7789,"activeCount":97},[],{"trials":7791,"activeCount":97},[],{"trials":7793,"activeCount":97},[],{"trials":7795,"activeCount":97},[],{"trials":7797,"activeCount":97},[],{"intervention":7786,"totalTrials":142,"cells":7799},{"EARLY_PHASE1":7800,"PHASE1":7806,"PHASE2":7808,"PHASE3":7810,"PHASE4":7812,"NA":7814},{"trials":7801,"activeCount":97},[7802],{"nctId":7779,"briefTitle":7780,"status":133,"phases":7803,"primaryCompletion":7782,"completion":7782,"start":5077,"enrollment":6678,"conditions":7804,"interventions":7805},[84],[7784],[7774,7786,7787],{"trials":7807,"activeCount":97},[],{"trials":7809,"activeCount":97},[],{"trials":7811,"activeCount":97},[],{"trials":7813,"activeCount":97},[],{"trials":7815,"activeCount":97},[],{"intervention":7787,"totalTrials":142,"cells":7817},{"EARLY_PHASE1":7818,"PHASE1":7824,"PHASE2":7826,"PHASE3":7828,"PHASE4":7830,"NA":7832},{"trials":7819,"activeCount":97},[7820],{"nctId":7779,"briefTitle":7780,"status":133,"phases":7821,"primaryCompletion":7782,"completion":7782,"start":5077,"enrollment":6678,"conditions":7822,"interventions":7823},[84],[7784],[7774,7786,7787],{"trials":7825,"activeCount":97},[],{"trials":7827,"activeCount":97},[],{"trials":7829,"activeCount":97},[],{"trials":7831,"activeCount":97},[],{"trials":7833,"activeCount":97},[],{"intervention":7835,"totalTrials":142,"cells":7836},"vedolizumab",{"EARLY_PHASE1":7837,"PHASE1":7848,"PHASE2":7850,"PHASE3":7852,"PHASE4":7854,"NA":7856},{"trials":7838,"activeCount":97},[7839],{"nctId":7840,"briefTitle":7841,"status":133,"phases":7842,"primaryCompletion":112,"completion":7843,"start":3905,"enrollment":7844,"conditions":7845,"interventions":7846},"NCT02953275","Synergistic Effect of Vedolizumab and Pentoxifylline",[84],"2019-06-13",37,[308],[7835,7847],"Pentoxifylline",{"trials":7849,"activeCount":97},[],{"trials":7851,"activeCount":97},[],{"trials":7853,"activeCount":97},[],{"trials":7855,"activeCount":97},[],{"trials":7857,"activeCount":97},[],{"intervention":7847,"totalTrials":142,"cells":7859},{"EARLY_PHASE1":7860,"PHASE1":7866,"PHASE2":7868,"PHASE3":7870,"PHASE4":7872,"NA":7874},{"trials":7861,"activeCount":97},[7862],{"nctId":7840,"briefTitle":7841,"status":133,"phases":7863,"primaryCompletion":112,"completion":7843,"start":3905,"enrollment":7844,"conditions":7864,"interventions":7865},[84],[308],[7835,7847],{"trials":7867,"activeCount":97},[],{"trials":7869,"activeCount":97},[],{"trials":7871,"activeCount":97},[],{"trials":7873,"activeCount":97},[],{"trials":7875,"activeCount":97},[],{"intervention":7877,"totalTrials":142,"cells":7878},"N-acetyl cysteine",{"EARLY_PHASE1":7879,"PHASE1":7888,"PHASE2":7890,"PHASE3":7892,"PHASE4":7894,"NA":7896},{"trials":7880,"activeCount":97},[7881],{"nctId":7882,"briefTitle":7883,"status":133,"phases":7884,"primaryCompletion":7885,"completion":7885,"start":1400,"enrollment":1103,"conditions":7886,"interventions":7887},"NCT02481609","NAC Trial for Anosmia",[84],"2017-12-01",[5055],[7877],{"trials":7889,"activeCount":97},[],{"trials":7891,"activeCount":97},[],{"trials":7893,"activeCount":97},[],{"trials":7895,"activeCount":97},[],{"trials":7897,"activeCount":97},[],{"intervention":1095,"totalTrials":1344,"cells":7899},{"EARLY_PHASE1":7900,"PHASE1":7902,"PHASE2":7914,"PHASE3":7949,"PHASE4":7951,"NA":7953},{"trials":7901,"activeCount":97},[],{"trials":7903,"activeCount":97},[7904],{"nctId":7905,"briefTitle":7906,"status":121,"phases":7907,"primaryCompletion":7908,"start":7713,"enrollment":97,"conditions":7909,"interventions":7913},"NCT02083536","LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma",[85],"2019-05",[334,7910,7911,7912],"Ovarian Carcinoma","Recurrent Ovarian Cancer","Recurrent Ovarian Carcinoma",[1095],{"trials":7915,"activeCount":97},[7916,7920,7924,7928,7937,7941,7945],{"nctId":1086,"briefTitle":1087,"status":1088,"phases":7917,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1076,"conditions":7918,"interventions":7919},[86],[255],[1095,1096,1065,1080],{"nctId":5748,"briefTitle":5749,"status":1088,"phases":7921,"primaryCompletion":4318,"completion":4318,"start":5751,"enrollment":17,"conditions":7922,"interventions":7923},[85,86],[19,4544],[5754,1095,1576,5755,5756,1125],{"nctId":1098,"briefTitle":1099,"status":133,"phases":7925,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":7926,"interventions":7927},[86],[1105],[1095,1096,1065,1080,1107,1108],{"nctId":7929,"briefTitle":7930,"status":121,"phases":7931,"primaryCompletion":7932,"completion":7932,"start":7933,"enrollment":97,"conditions":7934,"interventions":7935},"NCT00452920","Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer",[85,86],"2009-06","2003-09",[1218],[7936],"docetaxel",{"nctId":6782,"briefTitle":6783,"status":133,"phases":7938,"primaryCompletion":5751,"completion":6785,"start":6786,"enrollment":5317,"conditions":7939,"interventions":7940},[86],[1390],[1210,1095,6773],{"nctId":2924,"briefTitle":2925,"status":133,"phases":7942,"primaryCompletion":2927,"completion":2928,"start":1546,"enrollment":2929,"conditions":7943,"interventions":7944},[86],[1426],[1081,1095],{"nctId":1578,"briefTitle":1579,"status":133,"phases":7946,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":7947,"interventions":7948},[86],[25],[944,1095,945,1586],{"trials":7950,"activeCount":97},[],{"trials":7952,"activeCount":97},[],{"trials":7954,"activeCount":97},[7955],{"nctId":2802,"briefTitle":2803,"status":133,"phases":7956,"primaryCompletion":2805,"start":2806,"enrollment":923,"conditions":7957,"interventions":7958},[89],[1390,2808,2809],[1220,1210,1209,2811,2812,1095,2813],{"intervention":1118,"totalTrials":1066,"cells":7960},{"EARLY_PHASE1":7961,"PHASE1":7963,"PHASE2":7965,"PHASE3":7995,"PHASE4":7997,"NA":7999},{"trials":7962,"activeCount":97},[],{"trials":7964,"activeCount":97},[],{"trials":7966,"activeCount":97},[7967,7971,7975,7979,7983,7987,7991],{"nctId":6140,"briefTitle":6141,"status":133,"phases":7968,"primaryCompletion":2746,"completion":2746,"start":3166,"enrollment":23,"conditions":7969,"interventions":7970},[86],[1624],[1118,6131],{"nctId":6255,"briefTitle":6256,"status":121,"phases":7972,"primaryCompletion":4015,"completion":4015,"start":6258,"enrollment":97,"conditions":7973,"interventions":7974},[86],[1116],[6261,1381,6246],{"nctId":1110,"briefTitle":1111,"status":133,"phases":7976,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":7977,"interventions":7978},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1128,"briefTitle":1129,"status":1088,"phases":7980,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":923,"conditions":7981,"interventions":7982},[86],[1134,1135,1136],[945,1121,1065,1138,1139,1118],{"nctId":1141,"briefTitle":1142,"status":133,"phases":7984,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":7985,"interventions":7986},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"nctId":1614,"briefTitle":1615,"status":1088,"phases":7988,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":818,"conditions":7989,"interventions":7990},[86],[1621,1622,1623,1624],[1626,1118,1120,1210,943],{"nctId":1568,"briefTitle":1569,"status":1088,"phases":7992,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":7993,"interventions":7994},[86],[1116],[1118,944,945,1576,1123],{"trials":7996,"activeCount":97},[],{"trials":7998,"activeCount":97},[],{"trials":8000,"activeCount":97},[8001],{"nctId":2865,"briefTitle":2866,"status":1088,"phases":8002,"primaryCompletion":2868,"completion":2869,"start":2870,"enrollment":93,"conditions":8003,"interventions":8004},[89],[1116,2872,1624],[1118,836,944,1576],{"intervention":1210,"totalTrials":923,"cells":8006},{"EARLY_PHASE1":8007,"PHASE1":8009,"PHASE2":8011,"PHASE3":8033,"PHASE4":8035,"NA":8037},{"trials":8008,"activeCount":97},[],{"trials":8010,"activeCount":97},[],{"trials":8012,"activeCount":97},[8013,8017,8021,8025,8029],{"nctId":6782,"briefTitle":6783,"status":133,"phases":8014,"primaryCompletion":5751,"completion":6785,"start":6786,"enrollment":5317,"conditions":8015,"interventions":8016},[86],[1390],[1210,1095,6773],{"nctId":1197,"briefTitle":1198,"status":1088,"phases":8018,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":8019,"interventions":8020},[86],[1205,1206,1207],[1179,1209,1210],{"nctId":1614,"briefTitle":1615,"status":1088,"phases":8022,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":818,"conditions":8023,"interventions":8024},[86],[1621,1622,1623,1624],[1626,1118,1120,1210,943],{"nctId":1212,"briefTitle":1213,"status":1088,"phases":8026,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":30,"conditions":8027,"interventions":8028},[86],[1218],[1179,1209,1220,1210,1159],{"nctId":2786,"briefTitle":2787,"status":133,"phases":8030,"primaryCompletion":2789,"completion":2789,"start":2790,"enrollment":2791,"conditions":8031,"interventions":8032},[86],[2793],[1210,1220,1407],{"trials":8034,"activeCount":97},[],{"trials":8036,"activeCount":97},[],{"trials":8038,"activeCount":97},[8039],{"nctId":2802,"briefTitle":2803,"status":133,"phases":8040,"primaryCompletion":2805,"start":2806,"enrollment":923,"conditions":8041,"interventions":8042},[89],[1390,2808,2809],[1220,1210,1209,2811,2812,1095,2813],{"intervention":1381,"totalTrials":974,"cells":8044},{"EARLY_PHASE1":8045,"PHASE1":8047,"PHASE2":8049,"PHASE3":8063,"PHASE4":8065,"NA":8067},{"trials":8046,"activeCount":97},[],{"trials":8048,"activeCount":97},[],{"trials":8050,"activeCount":97},[8051,8055,8059],{"nctId":1372,"briefTitle":1373,"status":1088,"phases":8052,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":8053,"interventions":8054},[86],[1157],[1381,1366],{"nctId":6255,"briefTitle":6256,"status":121,"phases":8056,"primaryCompletion":4015,"completion":4015,"start":6258,"enrollment":97,"conditions":8057,"interventions":8058},[86],[1116],[6261,1381,6246],{"nctId":1383,"briefTitle":1384,"status":133,"phases":8060,"primaryCompletion":1386,"completion":1387,"start":1388,"enrollment":1228,"conditions":8061,"interventions":8062},[86],[1390],[1381,1366],{"trials":8064,"activeCount":97},[],{"trials":8066,"activeCount":97},[],{"trials":8068,"activeCount":97},[8069],{"nctId":1419,"briefTitle":1420,"status":133,"phases":8070,"primaryCompletion":1422,"completion":1423,"start":1424,"enrollment":983,"conditions":8071,"interventions":8072},[89],[1426],[1428,1429,1080],{"intervention":1209,"totalTrials":974,"cells":8074},{"EARLY_PHASE1":8075,"PHASE1":8077,"PHASE2":8079,"PHASE3":8093,"PHASE4":8095,"NA":8097},{"trials":8076,"activeCount":97},[],{"trials":8078,"activeCount":97},[],{"trials":8080,"activeCount":97},[8081,8085,8089],{"nctId":2754,"briefTitle":2755,"status":133,"phases":8082,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":8083,"interventions":8084},[85,86],[2761,35],[2763,2731,2764,2765],{"nctId":1197,"briefTitle":1198,"status":1088,"phases":8086,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":8087,"interventions":8088},[86],[1205,1206,1207],[1179,1209,1210],{"nctId":1212,"briefTitle":1213,"status":1088,"phases":8090,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":30,"conditions":8091,"interventions":8092},[86],[1218],[1179,1209,1220,1210,1159],{"trials":8094,"activeCount":97},[],{"trials":8096,"activeCount":97},[],{"trials":8098,"activeCount":97},[8099],{"nctId":2802,"briefTitle":2803,"status":133,"phases":8100,"primaryCompletion":2805,"start":2806,"enrollment":923,"conditions":8101,"interventions":8102},[89],[1390,2808,2809],[1220,1210,1209,2811,2812,1095,2813],{"intervention":1121,"totalTrials":974,"cells":8104},{"EARLY_PHASE1":8105,"PHASE1":8107,"PHASE2":8109,"PHASE3":8123,"PHASE4":8125,"NA":8127},{"trials":8106,"activeCount":97},[],{"trials":8108,"activeCount":97},[],{"trials":8110,"activeCount":97},[8111,8115,8119],{"nctId":1110,"briefTitle":1111,"status":133,"phases":8112,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":8113,"interventions":8114},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1128,"briefTitle":1129,"status":1088,"phases":8116,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":923,"conditions":8117,"interventions":8118},[86],[1134,1135,1136],[945,1121,1065,1138,1139,1118],{"nctId":1141,"briefTitle":1142,"status":133,"phases":8120,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":8121,"interventions":8122},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"trials":8124,"activeCount":97},[],{"trials":8126,"activeCount":97},[],{"trials":8128,"activeCount":97},[8129],{"nctId":2850,"briefTitle":2851,"status":121,"phases":8130,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":8131,"interventions":8132},[89],[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],{"intervention":1576,"totalTrials":974,"cells":8134},{"EARLY_PHASE1":8135,"PHASE1":8137,"PHASE2":8139,"PHASE3":8149,"PHASE4":8151,"NA":8153},{"trials":8136,"activeCount":97},[],{"trials":8138,"activeCount":97},[],{"trials":8140,"activeCount":97},[8141,8145],{"nctId":5748,"briefTitle":5749,"status":1088,"phases":8142,"primaryCompletion":4318,"completion":4318,"start":5751,"enrollment":17,"conditions":8143,"interventions":8144},[85,86],[19,4544],[5754,1095,1576,5755,5756,1125],{"nctId":1568,"briefTitle":1569,"status":1088,"phases":8146,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":8147,"interventions":8148},[86],[1116],[1118,944,945,1576,1123],{"trials":8150,"activeCount":97},[],{"trials":8152,"activeCount":97},[],{"trials":8154,"activeCount":97},[8155,8159],{"nctId":2850,"briefTitle":2851,"status":121,"phases":8156,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":8157,"interventions":8158},[89],[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],{"nctId":2865,"briefTitle":2866,"status":1088,"phases":8160,"primaryCompletion":2868,"completion":2869,"start":2870,"enrollment":93,"conditions":8161,"interventions":8162},[89],[1116,2872,1624],[1118,836,944,1576],{"intervention":1139,"totalTrials":974,"cells":8164},{"EARLY_PHASE1":8165,"PHASE1":8167,"PHASE2":8169,"PHASE3":8179,"PHASE4":8181,"NA":8187},{"trials":8166,"activeCount":97},[],{"trials":8168,"activeCount":97},[],{"trials":8170,"activeCount":97},[8171,8175],{"nctId":6323,"briefTitle":6324,"status":133,"phases":8172,"primaryCompletion":6326,"completion":6327,"start":6328,"enrollment":4018,"conditions":8173,"interventions":8174},[86],[6330,6331],[6314,1139,6333,6334,6335],{"nctId":1128,"briefTitle":1129,"status":1088,"phases":8176,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":923,"conditions":8177,"interventions":8178},[86],[1134,1135,1136],[945,1121,1065,1138,1139,1118],{"trials":8180,"activeCount":97},[],{"trials":8182,"activeCount":97},[8183],{"nctId":4451,"briefTitle":4452,"status":1088,"phases":8184,"primaryCompletion":2884,"completion":4319,"start":4454,"enrollment":4455,"conditions":8185,"interventions":8186},[88],[1116,4457],[4438,4459,4460,1139],{"trials":8188,"activeCount":97},[8189],{"nctId":8190,"briefTitle":8191,"status":133,"phases":8192,"conditions":8193,"interventions":8195},"NCT00002270","A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection",[89],[4044,8194],"Leukoencephalopathy, Progressive Multifocal",[4459,1139],{"intervention":1119,"totalTrials":93,"cells":8197},{"EARLY_PHASE1":8198,"PHASE1":8200,"PHASE2":8202,"PHASE3":8212,"PHASE4":8214,"NA":8216},{"trials":8199,"activeCount":97},[],{"trials":8201,"activeCount":97},[],{"trials":8203,"activeCount":97},[8204,8208],{"nctId":1110,"briefTitle":1111,"status":133,"phases":8205,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":17,"conditions":8206,"interventions":8207},[86],[1116],[1118,944,1119,945,943,1120,1065,1121,1122,1123,1124,1125,1126,1055],{"nctId":1141,"briefTitle":1142,"status":133,"phases":8209,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1076,"conditions":8210,"interventions":8211},[86],[1148],[1150,1118,944,1119,945,943,1120,1065,1124,1121,1123],{"trials":8213,"activeCount":97},[],{"trials":8215,"activeCount":97},[],{"trials":8217,"activeCount":97},[8218],{"nctId":2850,"briefTitle":2851,"status":121,"phases":8219,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":8220,"interventions":8221},[89],[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],{"intervention":8223,"totalTrials":818,"cells":8224},"Fluticasone",{"EARLY_PHASE1":8225,"PHASE1":8227,"PHASE2":8229,"PHASE3":8231,"PHASE4":8233,"NA":8235},{"trials":8226,"activeCount":97},[],{"trials":8228,"activeCount":97},[],{"trials":8230,"activeCount":97},[],{"trials":8232,"activeCount":97},[],{"trials":8234,"activeCount":97},[],{"trials":8236,"activeCount":97},[8237,8245],{"nctId":8238,"briefTitle":8239,"status":133,"phases":8240,"primaryCompletion":1090,"completion":5487,"start":8241,"enrollment":5317,"conditions":8242,"interventions":8244},"NCT01216735","Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers",[89],"2008-09",[8243],"Tobacco Abuse Smoke",[8223],{"nctId":8246,"briefTitle":8247,"status":133,"phases":8248,"primaryCompletion":1090,"completion":8249,"start":5751,"enrollment":8250,"conditions":8251,"interventions":8252},"NCT01231230","Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway",[89],"2010-08",14,[767],[8253,8254,8255],"fluticasone","Salmeterol","fluticasone\u002Fsalmeterol",{"intervention":2779,"totalTrials":818,"cells":8257},{"EARLY_PHASE1":8258,"PHASE1":8260,"PHASE2":8262,"PHASE3":8268,"PHASE4":8270,"NA":8272},{"trials":8259,"activeCount":97},[],{"trials":8261,"activeCount":97},[],{"trials":8263,"activeCount":97},[8264],{"nctId":2771,"briefTitle":2772,"status":133,"phases":8265,"primaryCompletion":2774,"completion":2774,"start":2775,"conditions":8266,"interventions":8267},[86],[2777],[2731,2779,2780],{"trials":8269,"activeCount":97},[],{"trials":8271,"activeCount":97},[],{"trials":8273,"activeCount":97},[8274],{"nctId":2850,"briefTitle":2851,"status":121,"phases":8275,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":8276,"interventions":8277},[89],[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],{"intervention":2859,"totalTrials":818,"cells":8279},{"EARLY_PHASE1":8280,"PHASE1":8282,"PHASE2":8288,"PHASE3":8290,"PHASE4":8292,"NA":8294},{"trials":8281,"activeCount":97},[],{"trials":8283,"activeCount":97},[8284],{"nctId":5635,"briefTitle":5636,"status":133,"phases":8285,"primaryCompletion":5638,"completion":2868,"start":1092,"enrollment":4455,"conditions":8286,"interventions":8287},[85],[1157],[2888,5641,5642,5643],{"trials":8289,"activeCount":97},[],{"trials":8291,"activeCount":97},[],{"trials":8293,"activeCount":97},[],{"trials":8295,"activeCount":97},[8296],{"nctId":2850,"briefTitle":2851,"status":121,"phases":8297,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":8298,"interventions":8299},[89],[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],{"intervention":4459,"totalTrials":818,"cells":8301},{"EARLY_PHASE1":8302,"PHASE1":8304,"PHASE2":8306,"PHASE3":8308,"PHASE4":8310,"NA":8316},{"trials":8303,"activeCount":97},[],{"trials":8305,"activeCount":97},[],{"trials":8307,"activeCount":97},[],{"trials":8309,"activeCount":97},[],{"trials":8311,"activeCount":97},[8312],{"nctId":4451,"briefTitle":4452,"status":1088,"phases":8313,"primaryCompletion":2884,"completion":4319,"start":4454,"enrollment":4455,"conditions":8314,"interventions":8315},[88],[1116,4457],[4438,4459,4460,1139],{"trials":8317,"activeCount":97},[8318],{"nctId":8190,"briefTitle":8191,"status":133,"phases":8319,"conditions":8320,"interventions":8321},[89],[4044,8194],[4459,1139],{"intervention":2812,"totalTrials":818,"cells":8323},{"EARLY_PHASE1":8324,"PHASE1":8326,"PHASE2":8328,"PHASE3":8334,"PHASE4":8336,"NA":8338},{"trials":8325,"activeCount":97},[],{"trials":8327,"activeCount":97},[],{"trials":8329,"activeCount":97},[8330],{"nctId":6616,"briefTitle":6617,"status":1088,"phases":8331,"primaryCompletion":3904,"completion":3904,"start":6619,"enrollment":818,"conditions":8332,"interventions":8333},[85,86],[25,1861],[2812,6607],{"trials":8335,"activeCount":97},[],{"trials":8337,"activeCount":97},[],{"trials":8339,"activeCount":97},[8340],{"nctId":2802,"briefTitle":2803,"status":133,"phases":8341,"primaryCompletion":2805,"start":2806,"enrollment":923,"conditions":8342,"interventions":8343},[89],[1390,2808,2809],[1220,1210,1209,2811,2812,1095,2813],{"intervention":2889,"totalTrials":818,"cells":8345},{"EARLY_PHASE1":8346,"PHASE1":8348,"PHASE2":8354,"PHASE3":8356,"PHASE4":8358,"NA":8360},{"trials":8347,"activeCount":97},[],{"trials":8349,"activeCount":97},[8350],{"nctId":2881,"briefTitle":2882,"status":121,"phases":8351,"primaryCompletion":2884,"completion":2884,"start":1645,"enrollment":97,"conditions":8352,"interventions":8353},[85],[2886],[2888,836,2889,2890],{"trials":8355,"activeCount":97},[],{"trials":8357,"activeCount":97},[],{"trials":8359,"activeCount":97},[],{"trials":8361,"activeCount":97},[8362],{"nctId":8363,"briefTitle":8364,"status":133,"phases":8365,"primaryCompletion":8366,"completion":8366,"start":2927,"enrollment":818,"conditions":8367,"interventions":8370},"NCT02007863","Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia",[89],"2014-06",[7273,8368,8369,7271],"Myelodysplasia","Acute Lymphocytic Leukemia",[8371,8372,2889],"Fludarabine","Busulfan",{"intervention":1428,"totalTrials":142,"cells":8374},{"EARLY_PHASE1":8375,"PHASE1":8377,"PHASE2":8379,"PHASE3":8381,"PHASE4":8383,"NA":8385},{"trials":8376,"activeCount":97},[],{"trials":8378,"activeCount":97},[],{"trials":8380,"activeCount":97},[],{"trials":8382,"activeCount":97},[],{"trials":8384,"activeCount":97},[],{"trials":8386,"activeCount":97},[8387],{"nctId":1419,"briefTitle":1420,"status":133,"phases":8388,"primaryCompletion":1422,"completion":1423,"start":1424,"enrollment":983,"conditions":8389,"interventions":8390},[89],[1426],[1428,1429,1080],{"intervention":8392,"totalTrials":142,"cells":8393},"Budesonide 360ug",{"EARLY_PHASE1":8394,"PHASE1":8396,"PHASE2":8398,"PHASE3":8400,"PHASE4":8402,"NA":8404},{"trials":8395,"activeCount":97},[],{"trials":8397,"activeCount":97},[],{"trials":8399,"activeCount":97},[],{"trials":8401,"activeCount":97},[],{"trials":8403,"activeCount":97},[],{"trials":8405,"activeCount":97},[8406],{"nctId":8407,"briefTitle":8408,"status":133,"phases":8409,"primaryCompletion":6030,"completion":6030,"start":5009,"enrollment":20,"conditions":8410,"interventions":8411},"NCT01219738","Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide",[89],[767],[8392,8412,8413,8414],"Budesonide 720ug","Budesonide 1440ug","Budesonide720ug 4 times",{"intervention":8412,"totalTrials":142,"cells":8416},{"EARLY_PHASE1":8417,"PHASE1":8419,"PHASE2":8421,"PHASE3":8423,"PHASE4":8425,"NA":8427},{"trials":8418,"activeCount":97},[],{"trials":8420,"activeCount":97},[],{"trials":8422,"activeCount":97},[],{"trials":8424,"activeCount":97},[],{"trials":8426,"activeCount":97},[],{"trials":8428,"activeCount":97},[8429],{"nctId":8407,"briefTitle":8408,"status":133,"phases":8430,"primaryCompletion":6030,"completion":6030,"start":5009,"enrollment":20,"conditions":8431,"interventions":8432},[89],[767],[8392,8412,8413,8414],{"intervention":8413,"totalTrials":142,"cells":8434},{"EARLY_PHASE1":8435,"PHASE1":8437,"PHASE2":8439,"PHASE3":8441,"PHASE4":8443,"NA":8445},{"trials":8436,"activeCount":97},[],{"trials":8438,"activeCount":97},[],{"trials":8440,"activeCount":97},[],{"trials":8442,"activeCount":97},[],{"trials":8444,"activeCount":97},[],{"trials":8446,"activeCount":97},[8447],{"nctId":8407,"briefTitle":8408,"status":133,"phases":8448,"primaryCompletion":6030,"completion":6030,"start":5009,"enrollment":20,"conditions":8449,"interventions":8450},[89],[767],[8392,8412,8413,8414],{"intervention":8414,"totalTrials":142,"cells":8452},{"EARLY_PHASE1":8453,"PHASE1":8455,"PHASE2":8457,"PHASE3":8459,"PHASE4":8461,"NA":8463},{"trials":8454,"activeCount":97},[],{"trials":8456,"activeCount":97},[],{"trials":8458,"activeCount":97},[],{"trials":8460,"activeCount":97},[],{"trials":8462,"activeCount":97},[],{"trials":8464,"activeCount":97},[8465],{"nctId":8407,"briefTitle":8408,"status":133,"phases":8466,"primaryCompletion":6030,"completion":6030,"start":5009,"enrollment":20,"conditions":8467,"interventions":8468},[89],[767],[8392,8412,8413,8414],{"intervention":8470,"totalTrials":142,"cells":8471},"Washed RBC",{"EARLY_PHASE1":8472,"PHASE1":8474,"PHASE2":8476,"PHASE3":8478,"PHASE4":8480,"NA":8482},{"trials":8473,"activeCount":97},[],{"trials":8475,"activeCount":97},[],{"trials":8477,"activeCount":97},[],{"trials":8479,"activeCount":97},[],{"trials":8481,"activeCount":97},[],{"trials":8483,"activeCount":97},[8484],{"nctId":8485,"briefTitle":8486,"status":133,"phases":8487,"primaryCompletion":7760,"completion":8488,"start":8489,"enrollment":8490,"conditions":8491,"interventions":8493},"NCT01185600","Microparticles in Stored RBC as Potential Mediators of Transfusion Complications",[89],"2015-05","2010-07",177,[8492],"Coronary Artery Bypass",[8470,8494],"Unwashed RBC",{"intervention":8494,"totalTrials":142,"cells":8496},{"EARLY_PHASE1":8497,"PHASE1":8499,"PHASE2":8501,"PHASE3":8503,"PHASE4":8505,"NA":8507},{"trials":8498,"activeCount":97},[],{"trials":8500,"activeCount":97},[],{"trials":8502,"activeCount":97},[],{"trials":8504,"activeCount":97},[],{"trials":8506,"activeCount":97},[],{"trials":8508,"activeCount":97},[8509],{"nctId":8485,"briefTitle":8486,"status":133,"phases":8510,"primaryCompletion":7760,"completion":8488,"start":8489,"enrollment":8490,"conditions":8511,"interventions":8512},[89],[8492],[8470,8494],{"intervention":8514,"totalTrials":142,"cells":8515},"latanoprost 0.005%",{"EARLY_PHASE1":8516,"PHASE1":8518,"PHASE2":8520,"PHASE3":8522,"PHASE4":8524,"NA":8526},{"trials":8517,"activeCount":97},[],{"trials":8519,"activeCount":97},[],{"trials":8521,"activeCount":97},[],{"trials":8523,"activeCount":97},[],{"trials":8525,"activeCount":97},[],{"trials":8527,"activeCount":97},[8528],{"nctId":8529,"briefTitle":8530,"status":133,"phases":8531,"primaryCompletion":1090,"completion":1090,"start":3166,"enrollment":8532,"conditions":8533,"interventions":8534},"NCT01042665","Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo",[],82,[646],[8514],{"intervention":2856,"totalTrials":142,"cells":8536},{"EARLY_PHASE1":8537,"PHASE1":8539,"PHASE2":8541,"PHASE3":8543,"PHASE4":8545,"NA":8547},{"trials":8538,"activeCount":97},[],{"trials":8540,"activeCount":97},[],{"trials":8542,"activeCount":97},[],{"trials":8544,"activeCount":97},[],{"trials":8546,"activeCount":97},[],{"trials":8548,"activeCount":97},[8549],{"nctId":2850,"briefTitle":2851,"status":121,"phases":8550,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":8551,"interventions":8552},[89],[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],{"intervention":2862,"totalTrials":142,"cells":8554},{"EARLY_PHASE1":8555,"PHASE1":8557,"PHASE2":8559,"PHASE3":8561,"PHASE4":8563,"NA":8565},{"trials":8556,"activeCount":97},[],{"trials":8558,"activeCount":97},[],{"trials":8560,"activeCount":97},[],{"trials":8562,"activeCount":97},[],{"trials":8564,"activeCount":97},[],{"trials":8566,"activeCount":97},[8567],{"nctId":2850,"briefTitle":2851,"status":121,"phases":8568,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":8569,"interventions":8570},[89],[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],{"intervention":2863,"totalTrials":142,"cells":8572},{"EARLY_PHASE1":8573,"PHASE1":8575,"PHASE2":8577,"PHASE3":8579,"PHASE4":8581,"NA":8583},{"trials":8574,"activeCount":97},[],{"trials":8576,"activeCount":97},[],{"trials":8578,"activeCount":97},[],{"trials":8580,"activeCount":97},[],{"trials":8582,"activeCount":97},[],{"trials":8584,"activeCount":97},[8585],{"nctId":2850,"briefTitle":2851,"status":121,"phases":8586,"primaryCompletion":1361,"start":2853,"enrollment":97,"conditions":8587,"interventions":8588},[89],[1116],[2856,2857,2858,2779,2859,2860,2861,2862,2863],{"intervention":2811,"totalTrials":142,"cells":8590},{"EARLY_PHASE1":8591,"PHASE1":8593,"PHASE2":8595,"PHASE3":8597,"PHASE4":8599,"NA":8601},{"trials":8592,"activeCount":97},[],{"trials":8594,"activeCount":97},[],{"trials":8596,"activeCount":97},[],{"trials":8598,"activeCount":97},[],{"trials":8600,"activeCount":97},[],{"trials":8602,"activeCount":97},[8603],{"nctId":2802,"briefTitle":2803,"status":133,"phases":8604,"primaryCompletion":2805,"start":2806,"enrollment":923,"conditions":8605,"interventions":8606},[89],[1390,2808,2809],[1220,1210,1209,2811,2812,1095,2813],{"intervention":2813,"totalTrials":142,"cells":8608},{"EARLY_PHASE1":8609,"PHASE1":8611,"PHASE2":8613,"PHASE3":8615,"PHASE4":8617,"NA":8619},{"trials":8610,"activeCount":97},[],{"trials":8612,"activeCount":97},[],{"trials":8614,"activeCount":97},[],{"trials":8616,"activeCount":97},[],{"trials":8618,"activeCount":97},[],{"trials":8620,"activeCount":97},[8621],{"nctId":2802,"briefTitle":2803,"status":133,"phases":8622,"primaryCompletion":2805,"start":2806,"enrollment":923,"conditions":8623,"interventions":8624},[89],[1390,2808,2809],[1220,1210,1209,2811,2812,1095,2813],{"intervention":8626,"totalTrials":142,"cells":8627},"mometasone 400 mcg",{"EARLY_PHASE1":8628,"PHASE1":8630,"PHASE2":8632,"PHASE3":8634,"PHASE4":8636,"NA":8638},{"trials":8629,"activeCount":97},[],{"trials":8631,"activeCount":97},[],{"trials":8633,"activeCount":97},[],{"trials":8635,"activeCount":97},[],{"trials":8637,"activeCount":97},[],{"trials":8639,"activeCount":97},[8640],{"nctId":8641,"briefTitle":8642,"status":133,"phases":8643,"primaryCompletion":4937,"completion":4937,"start":3857,"enrollment":17,"conditions":8644,"interventions":8645},"NCT01210170","Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma",[89],[767],[8626,8646],"mometasone 200 mcg",{"intervention":8646,"totalTrials":142,"cells":8648},{"EARLY_PHASE1":8649,"PHASE1":8651,"PHASE2":8653,"PHASE3":8655,"PHASE4":8657,"NA":8659},{"trials":8650,"activeCount":97},[],{"trials":8652,"activeCount":97},[],{"trials":8654,"activeCount":97},[],{"trials":8656,"activeCount":97},[],{"trials":8658,"activeCount":97},[],{"trials":8660,"activeCount":97},[8661],{"nctId":8641,"briefTitle":8642,"status":133,"phases":8662,"primaryCompletion":4937,"completion":4937,"start":3857,"enrollment":17,"conditions":8663,"interventions":8664},[89],[767],[8626,8646],{"intervention":8666,"totalTrials":142,"cells":8667},"1-34 parathyroid",{"EARLY_PHASE1":8668,"PHASE1":8670,"PHASE2":8672,"PHASE3":8674,"PHASE4":8676,"NA":8678},{"trials":8669,"activeCount":97},[],{"trials":8671,"activeCount":97},[],{"trials":8673,"activeCount":97},[],{"trials":8675,"activeCount":97},[],{"trials":8677,"activeCount":97},[],{"trials":8679,"activeCount":97},[8680],{"nctId":8681,"briefTitle":8682,"status":133,"phases":8683,"primaryCompletion":2884,"completion":2884,"start":6258,"enrollment":1203,"conditions":8684,"interventions":8686},"NCT00856726","Racial Differences in Phosphorus Metabolism",[89],[8685],"Control",[8666],{"intervention":8688,"totalTrials":142,"cells":8689},"Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days",{"EARLY_PHASE1":8690,"PHASE1":8692,"PHASE2":8694,"PHASE3":8696,"PHASE4":8698,"NA":8700},{"trials":8691,"activeCount":97},[],{"trials":8693,"activeCount":97},[],{"trials":8695,"activeCount":97},[],{"trials":8697,"activeCount":97},[],{"trials":8699,"activeCount":97},[],{"trials":8701,"activeCount":97},[8702],{"nctId":8703,"briefTitle":8704,"status":133,"phases":8705,"primaryCompletion":3814,"completion":3814,"start":2806,"enrollment":23,"conditions":8706,"interventions":8707},"NCT01201759","Effects of Salsalate on Prandial-Induced Vascular Inflammation After Spinal Cord Injury (SCI)",[89],[22],[8688],{"intervention":8254,"totalTrials":142,"cells":8709},{"EARLY_PHASE1":8710,"PHASE1":8712,"PHASE2":8714,"PHASE3":8716,"PHASE4":8718,"NA":8720},{"trials":8711,"activeCount":97},[],{"trials":8713,"activeCount":97},[],{"trials":8715,"activeCount":97},[],{"trials":8717,"activeCount":97},[],{"trials":8719,"activeCount":97},[],{"trials":8721,"activeCount":97},[8722],{"nctId":8246,"briefTitle":8247,"status":133,"phases":8723,"primaryCompletion":1090,"completion":8249,"start":5751,"enrollment":8250,"conditions":8724,"interventions":8725},[89],[767],[8253,8254,8255],{"intervention":8255,"totalTrials":142,"cells":8727},{"EARLY_PHASE1":8728,"PHASE1":8730,"PHASE2":8732,"PHASE3":8734,"PHASE4":8736,"NA":8738},{"trials":8729,"activeCount":97},[],{"trials":8731,"activeCount":97},[],{"trials":8733,"activeCount":97},[],{"trials":8735,"activeCount":97},[],{"trials":8737,"activeCount":97},[],{"trials":8739,"activeCount":97},[8740],{"nctId":8246,"briefTitle":8247,"status":133,"phases":8741,"primaryCompletion":1090,"completion":8249,"start":5751,"enrollment":8250,"conditions":8742,"interventions":8743},[89],[767],[8253,8254,8255],{"intervention":8371,"totalTrials":142,"cells":8745},{"EARLY_PHASE1":8746,"PHASE1":8748,"PHASE2":8750,"PHASE3":8752,"PHASE4":8754,"NA":8756},{"trials":8747,"activeCount":97},[],{"trials":8749,"activeCount":97},[],{"trials":8751,"activeCount":97},[],{"trials":8753,"activeCount":97},[],{"trials":8755,"activeCount":97},[],{"trials":8757,"activeCount":97},[8758],{"nctId":8363,"briefTitle":8364,"status":133,"phases":8759,"primaryCompletion":8366,"completion":8366,"start":2927,"enrollment":818,"conditions":8760,"interventions":8761},[89],[7273,8368,8369,7271],[8371,8372,2889],{"intervention":8372,"totalTrials":142,"cells":8763},{"EARLY_PHASE1":8764,"PHASE1":8766,"PHASE2":8768,"PHASE3":8770,"PHASE4":8772,"NA":8774},{"trials":8765,"activeCount":97},[],{"trials":8767,"activeCount":97},[],{"trials":8769,"activeCount":97},[],{"trials":8771,"activeCount":97},[],{"trials":8773,"activeCount":97},[],{"trials":8775,"activeCount":97},[8776],{"nctId":8363,"briefTitle":8364,"status":133,"phases":8777,"primaryCompletion":8366,"completion":8366,"start":2927,"enrollment":818,"conditions":8778,"interventions":8779},[89],[7273,8368,8369,7271],[8371,8372,2889],{"intervention":8781,"totalTrials":142,"cells":8782},"Sputum",{"EARLY_PHASE1":8783,"PHASE1":8785,"PHASE2":8787,"PHASE3":8789,"PHASE4":8791,"NA":8793},{"trials":8784,"activeCount":97},[],{"trials":8786,"activeCount":97},[],{"trials":8788,"activeCount":97},[],{"trials":8790,"activeCount":97},[],{"trials":8792,"activeCount":97},[],{"trials":8794,"activeCount":97},[8795],{"nctId":8796,"briefTitle":8797,"status":133,"phases":8798,"primaryCompletion":2965,"completion":2965,"start":1091,"enrollment":8799,"conditions":8800,"interventions":8802},"NCT02198079","A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida",[],85,[6835,8801],"Pediatrics",[8781],{"intervention":8804,"totalTrials":142,"cells":8805},"Fluticasone propionate",{"EARLY_PHASE1":8806,"PHASE1":8808,"PHASE2":8810,"PHASE3":8812,"PHASE4":8814,"NA":8816},{"trials":8807,"activeCount":97},[],{"trials":8809,"activeCount":97},[],{"trials":8811,"activeCount":97},[],{"trials":8813,"activeCount":97},[],{"trials":8815,"activeCount":97},[],{"trials":8817,"activeCount":97},[8818],{"nctId":8819,"briefTitle":8820,"status":133,"phases":8821,"primaryCompletion":4318,"completion":8822,"start":7134,"enrollment":1485,"conditions":8823,"interventions":8824},"NCT02141633","Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment",[89],"2015-12",[3308],[8804],{"intervention":8826,"totalTrials":142,"cells":8827},"Hextend",{"EARLY_PHASE1":8828,"PHASE1":8830,"PHASE2":8832,"PHASE3":8834,"PHASE4":8836,"NA":8838},{"trials":8829,"activeCount":97},[],{"trials":8831,"activeCount":97},[],{"trials":8833,"activeCount":97},[],{"trials":8835,"activeCount":97},[],{"trials":8837,"activeCount":97},[],{"trials":8839,"activeCount":97},[8840],{"nctId":8841,"briefTitle":8842,"status":133,"phases":8843,"primaryCompletion":8844,"completion":8844,"start":2927,"enrollment":8845,"conditions":8846,"interventions":8847},"NCT00983281","Use of Hextend in Trauma",[],"2009-09",1714,[1488],[8826],{"intervention":8849,"totalTrials":142,"cells":8850},"arginine vasopressin",{"EARLY_PHASE1":8851,"PHASE1":8853,"PHASE2":8855,"PHASE3":8857,"PHASE4":8859,"NA":8861},{"trials":8852,"activeCount":97},[],{"trials":8854,"activeCount":97},[],{"trials":8856,"activeCount":97},[],{"trials":8858,"activeCount":97},[],{"trials":8860,"activeCount":97},[],{"trials":8862,"activeCount":97},[8863],{"nctId":8864,"briefTitle":8865,"status":133,"phases":8866,"primaryCompletion":8867,"completion":8867,"start":8241,"enrollment":3107,"conditions":8868,"interventions":8869},"NCT00795366","Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients",[89],"2014-09",[2625],[8849,8870],"Standard catecholamine",{"intervention":8870,"totalTrials":142,"cells":8872},{"EARLY_PHASE1":8873,"PHASE1":8875,"PHASE2":8877,"PHASE3":8879,"PHASE4":8881,"NA":8883},{"trials":8874,"activeCount":97},[],{"trials":8876,"activeCount":97},[],{"trials":8878,"activeCount":97},[],{"trials":8880,"activeCount":97},[],{"trials":8882,"activeCount":97},[],{"trials":8884,"activeCount":97},[8885],{"nctId":8864,"briefTitle":8865,"status":133,"phases":8886,"primaryCompletion":8867,"completion":8867,"start":8241,"enrollment":3107,"conditions":8887,"interventions":8888},[89],[2625],[8849,8870],{"intervention":8890,"totalTrials":142,"cells":8891},"Isosulfan blue",{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8896,"PHASE3":8898,"PHASE4":8900,"NA":8902},{"trials":8893,"activeCount":97},[],{"trials":8895,"activeCount":97},[],{"trials":8897,"activeCount":97},[],{"trials":8899,"activeCount":97},[],{"trials":8901,"activeCount":97},[],{"trials":8903,"activeCount":97},[8904],{"nctId":8905,"briefTitle":8906,"status":133,"phases":8907,"primaryCompletion":6761,"completion":1423,"start":8908,"enrollment":3306,"conditions":8909,"interventions":8910},"NCT00450723","Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer",[89],"2004-05",[25],[8890],{"intervention":8912,"totalTrials":142,"cells":8913},"Opioids delivered through PCA",{"EARLY_PHASE1":8914,"PHASE1":8916,"PHASE2":8918,"PHASE3":8920,"PHASE4":8922,"NA":8924},{"trials":8915,"activeCount":97},[],{"trials":8917,"activeCount":97},[],{"trials":8919,"activeCount":97},[],{"trials":8921,"activeCount":97},[],{"trials":8923,"activeCount":97},[],{"trials":8925,"activeCount":97},[8926],{"nctId":8927,"briefTitle":8928,"status":121,"phases":8929,"primaryCompletion":8930,"completion":8930,"start":8931,"enrollment":97,"conditions":8932,"interventions":8936},"NCT03076710","Post-Operative Pain Management Following Spine Surgery",[],"2022-03","2017-07-31",[8933,8934,8935],"Pain Management","Analgesia","Anesthetic",[8912,8937],"EXPAREL® infiltration",{"intervention":8937,"totalTrials":142,"cells":8939},{"EARLY_PHASE1":8940,"PHASE1":8942,"PHASE2":8944,"PHASE3":8946,"PHASE4":8948,"NA":8950},{"trials":8941,"activeCount":97},[],{"trials":8943,"activeCount":97},[],{"trials":8945,"activeCount":97},[],{"trials":8947,"activeCount":97},[],{"trials":8949,"activeCount":97},[],{"trials":8951,"activeCount":97},[8952],{"nctId":8927,"briefTitle":8928,"status":121,"phases":8953,"primaryCompletion":8930,"completion":8930,"start":8931,"enrollment":97,"conditions":8954,"interventions":8955},[],[8933,8934,8935],[8912,8937],{"intervention":8957,"totalTrials":142,"cells":8958},"Caffeine citrate",{"EARLY_PHASE1":8959,"PHASE1":8961,"PHASE2":8963,"PHASE3":8965,"PHASE4":8967,"NA":8969},{"trials":8960,"activeCount":97},[],{"trials":8962,"activeCount":97},[],{"trials":8964,"activeCount":97},[],{"trials":8966,"activeCount":97},[],{"trials":8968,"activeCount":97},[],{"trials":8970,"activeCount":97},[8971],{"nctId":8972,"briefTitle":8973,"status":1088,"phases":8974,"primaryCompletion":8975,"completion":8975,"start":5118,"enrollment":8976,"conditions":8977,"interventions":8981},"NCT01751724","Caffeine to Reduce Mechanical Ventilation in Preterm Infants",[89],"2016-01",87,[8978,8979,8980],"Prematurity","Apnea","Respiratory Failure",[8957],{"intervention":8983,"totalTrials":142,"cells":8984},"Early ibuprofen",{"EARLY_PHASE1":8985,"PHASE1":8987,"PHASE2":8989,"PHASE3":8991,"PHASE4":8993,"NA":8995},{"trials":8986,"activeCount":97},[],{"trials":8988,"activeCount":97},[],{"trials":8990,"activeCount":97},[],{"trials":8992,"activeCount":97},[],{"trials":8994,"activeCount":97},[],{"trials":8996,"activeCount":97},[8997],{"nctId":8998,"briefTitle":8999,"status":1088,"phases":9000,"primaryCompletion":8249,"completion":2869,"start":4454,"enrollment":9001,"conditions":9002,"interventions":9004},"NCT00802685","Timing of PDA Closure and Respiratory Outcome in Premature Infants",[89],105,[9003],"Patent Ductus Arteriosus",[8983],{"intervention":9006,"totalTrials":142,"cells":9007},"Blood spot specimens will be drawn",{"EARLY_PHASE1":9008,"PHASE1":9010,"PHASE2":9012,"PHASE3":9014,"PHASE4":9016,"NA":9018},{"trials":9009,"activeCount":97},[],{"trials":9011,"activeCount":97},[],{"trials":9013,"activeCount":97},[],{"trials":9015,"activeCount":97},[],{"trials":9017,"activeCount":97},[],{"trials":9019,"activeCount":97},[9020],{"nctId":9021,"briefTitle":9022,"status":1088,"phases":9023,"primaryCompletion":1401,"completion":1401,"start":8241,"enrollment":9024,"conditions":9025,"interventions":9027},"NCT00675753","Three Interacting Single Nucleotide Polymorphisms (SNPs) and the Risk of Preterm Birth in Black Families",[],258,[9026],"Premature Birth",[9006],{"intervention":9029,"totalTrials":142,"cells":9030},"Allogeneic human mesenchymal stem cells",{"EARLY_PHASE1":9031,"PHASE1":9033,"PHASE2":9035,"PHASE3":9037,"PHASE4":9039,"NA":9041},{"trials":9032,"activeCount":97},[],{"trials":9034,"activeCount":97},[],{"trials":9036,"activeCount":97},[],{"trials":9038,"activeCount":97},[],{"trials":9040,"activeCount":97},[],{"trials":9042,"activeCount":97},[9043],{"nctId":9044,"briefTitle":9045,"status":9046,"phases":9047,"conditions":9048,"interventions":9054},"NCT05522569","Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)","NO_LONGER_AVAILABLE",[],[9049,9050,9051,9052,9053],"Acute Ischemic Stroke","Mesenchymal Stem Cells","Stroke, Acute","Stroke\u002FBrain Attack","Stroke, Ischemic",[9029],{"intervention":9056,"totalTrials":142,"cells":9057},"5%povidone iodine ophthalmic solution",{"EARLY_PHASE1":9058,"PHASE1":9060,"PHASE2":9062,"PHASE3":9064,"PHASE4":9066,"NA":9068},{"trials":9059,"activeCount":97},[],{"trials":9061,"activeCount":97},[],{"trials":9063,"activeCount":97},[],{"trials":9065,"activeCount":97},[],{"trials":9067,"activeCount":97},[],{"trials":9069,"activeCount":97},[9070],{"nctId":9071,"briefTitle":9072,"status":133,"phases":9073,"primaryCompletion":8975,"completion":1484,"start":1113,"enrollment":5911,"conditions":9074,"interventions":9076},"NCT02424357","Suture Contamination Rate in Adjustable Suture Strabismus Surgery",[89],[9075],"Suture Strabismus Surgery",[9056,9077],"routine post-operative ophthalmic ointment",{"intervention":9077,"totalTrials":142,"cells":9079},{"EARLY_PHASE1":9080,"PHASE1":9082,"PHASE2":9084,"PHASE3":9086,"PHASE4":9088,"NA":9090},{"trials":9081,"activeCount":97},[],{"trials":9083,"activeCount":97},[],{"trials":9085,"activeCount":97},[],{"trials":9087,"activeCount":97},[],{"trials":9089,"activeCount":97},[],{"trials":9091,"activeCount":97},[9092],{"nctId":9071,"briefTitle":9072,"status":133,"phases":9093,"primaryCompletion":8975,"completion":1484,"start":1113,"enrollment":5911,"conditions":9094,"interventions":9095},[89],[9075],[9056,9077],{"intervention":9097,"totalTrials":142,"cells":9098},"Bimatoprost Suspension",{"EARLY_PHASE1":9099,"PHASE1":9101,"PHASE2":9103,"PHASE3":9105,"PHASE4":9107,"NA":9109},{"trials":9100,"activeCount":97},[],{"trials":9102,"activeCount":97},[],{"trials":9104,"activeCount":97},[],{"trials":9106,"activeCount":97},[],{"trials":9108,"activeCount":97},[],{"trials":9110,"activeCount":97},[9111],{"nctId":9112,"briefTitle":9113,"status":133,"phases":9114,"primaryCompletion":5009,"completion":5009,"start":4788,"enrollment":6678,"conditions":9115,"interventions":9117},"NCT00773136","Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes",[89],[9116],"Hypertrichosis",[9097]]